AUTHOR INDEX

(Page numbers marked with an asterisk refer to abstracts)

A

Abelmann, Walter H. See CALABRESI and ABELMANN 1257

Ahrens, Edward H., Jr. See HELLMAN, ROSENFELD, INSULL, and AHRENS *898

Aisen, Philip A. See JAFFÉ, LOWY, VANDERHOFF, AISEN, and LONDON 1498

Alessandri, Hernán. See KATZ, DUCCI, and ALESSANDRI 1370

Alexander, James K., Mise, Junichi, Dennis, Edward W., and Hershberger, Robert L. Cardiorespiratory effects of epinephrine inhalation in normal subjects and patients with chronic pulmonary emphysema *869

Allen, David W., and Schroeder, W. A. A comparison of the phenylalanine content of the hemoglobin of normal and phenylketonuric individuals: Determination by ion exchange chromatography 1343

Altman, K. I., Tabechian, H., Young, L. E., Izzo, M. J., Murphy, M., and Roberts, G. Abnormalities of carbohydrate metabolism of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria *869

Anderson, Joseph T., Lawler, Adrian, and Keys, Ancel. Weight gain from simple overeating. II. Serum lipids and blood volume 81

Anderson, S. A. See HILLEMAN, HODGES, WARFIELD, and ANDERSON 1072

Andersson, M. See HIGGINSON, KEELEY, ANDERSSON, and WALKER 1723

Andres, Reubin, Cader, Gordon, Goldman, Peter, and Zierler, Kenneth L. Net potassium movement between resting muscle and plasma in man in the basal state and during the night 723

—. See ZIERLER and ANDRES 730

Appelboom, Johannes, and Brodsky, William A. Isoosmotic level of freezing point depression in boiled tissues *869

Apt, Leonard, Pollycove, Myron, and Ross, Joseph F. Idiopathic pulmonary hemosiderosis. A study of the anemia and iron distribution using radioiron and radiochromium 1150

—. See CHODOS, ROSS, APT, POLLYCOVE, and HALKETT 314

Arai, Y. See ELRICK, ARAI, and YEARWOOD-DRAYTON *887

Arney, Glen K. See MERONEY, ARNEY, SEGAR, and BALCH 825

Arroyave, Guillermo. See BURCH, ARROYAVE, SCHWARTZ, PADILLA, BÉHAR, VITERI, and SCRIMSHAW 1579

Ashenbrucker, Helen. See ATHENS, MAUER, ASHENBRUCKER, and CARTWRIGHT *870

Asper, Samuel P., Jr. See PROUT, WEAVER, SCOTT, and ASPER *921

Athens, J. W., Mauer, A. M., Ashenbrucker, Helen, and Cartwright, G. E. Labelling of leukocytes *in vivo* with DFP^{32} *870

Atkinson, Michael, Kramer, Philip, Wyman, Stanley M., and Ingelfinger, Franz J. The dynamics of swallowing. I. Normal pharyngeal mechanisms 581

—. See KRAMER, ATKINSON, WYMAN, and INGELFINGER 589

Austen, F. K., Rubini, M. E., Meroney, W. H., and Wolff, J. Salicylates and thyroid function *870

Axelrod, D. Robert. Relationship of calcium and citric acid to hyperventilation in man *870

Axelrod, Julius. See SCHMID, AXELROD, HAMMAKER, and ROSENTHAL *927

B

Bader, Mortimer E., Bader, Richard A., and Selikoff, Irving J. Pulmonary function in asbestosis of the lungs; an "alveolar-capillary block" syndrome *871

Bader, Richard A. See BADER, BADER, and SELIKOFF *871

Baker, William H. See DOW, BAKER, and STANBURY *884

—. See HENNEMAN and BAKER *899

Balch, Henry H. See MERONEY, ARNEY, SEGAR, and BALCH 825

Baldini, Mario. Physiology of anemia in "hypersplenism" *871

Baldwin, David S., Biggs, Albert W., and Hulet, William H. Exaggerated natriuresis in essential hypertension *871

Ball, Wilmot C., Jr. See DAVIS, PECHET, BALL, and GOODKIND 689

Ballon, Jonathan D. See WESSLER, BALLON, and KATZ *935

Bally, Peter, and Numa, Shosaku. The relationship of the pituitary to hyperlipemia of induced nephrosis in rats *872

Band, Raymond I. See CALLAWAY, BAND, and FINESINGER *877

Bang, Frederick B. See LUTTRELL and BANG *912

Barker, E. S., Singer, R. B., Elkinton, J. R., and Clark, J. K. The renal response in man to acute experimental respiratory alkalosis and acidosis 515

—, and **Clark, John K.** An attempt to apply the "cell separation theory" to renal hemodynamic and metabolic measurements in intact man *872

Barnes, Benjamin A., Gordon, Esther B., and Cope, Oliver. Skeletal muscle analyses in health and in certain metabolic disorders. I. The method of analysis and the values in normal muscle 1239

Barrow, Emily M. See HOUGIE, BARROW, and GRAHAM 485

—. See GRAHAM, BARROW, and HOUGIE 497

Bartter, Frederic C., and Fourman, Paul. A non-renal effect of adrenal cortical steroids upon potassium metabolism *872

Bates, Richard C. See HESS, COBURN, BATES, and MURPHY 449

Bauman, Arthur. See ROTHSCHILD, BAUMAN, YALOW, and BERSON 422

Baxter, James H., Goodman, Howard C., and Havel, Richard J. Hyperlipidemia of nephrosis *873

Bayles, Theodore B. See FREIREICH, ROSS, BAYLES, EMERSON, and FINCH 1043

Bearn, A. G., Yü, T. F., and Gutman, A. B. Renal function in Wilson's disease 1107

AUTHOR INDEX

(Page numbers marked with an asterisk refer to abstracts)

A

Abelmann, Walter H. See CALABRESI and ABELMANN 1257

Ahrens, Edward H., Jr. See HELLMAN, ROSENFELD, INSULL, and AHRENS *898

Aisen, Philip A. See JAFFÉ, LOWY, VANDERHOFF, AISEN, and LONDON 1498

Alessandri, Hernán. See KATZ, DUCCI, and ALESSANDRI 1370

Alexander, James K., Mise, Junichi, Dennis, Edward W., and Hershberger, Robert L. Cardiorespiratory effects of epinephrine inhalation in normal subjects and patients with chronic pulmonary emphysema *869

Allen, David W., and Schroeder, W. A. A comparison of the phenylalanine content of the hemoglobin of normal and phenylketonuric individuals: Determination by ion exchange chromatography 1343

Altman, K. I., Tabechian, H., Young, L. E., Izzo, M. J., Murphy, M., and Roberts, G. Abnormalities of carbohydrate metabolism of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria *869

Anderson, Joseph T., Lawler, Adrian, and Keys, Ancel. Weight gain from simple overeating. II. Serum lipids and blood volume 81

Anderson, S. A. See HILLEMAN, HODGES, WARFIELD, and ANDERSON 1072

Andersson, M. See HIGGINSON, KEELEY, ANDERSSON, and WALKER 1723

Andres, Reubin, Cader, Gordon, Goldman, Peter, and Zierler, Kenneth L. Net potassium movement between resting muscle and plasma in man in the basal state and during the night 723

—. See ZIERLER and ANDRES 730

Appelboom, Johannes, and Brodsky, William A. Isoosmotic level of freezing point depression in boiled tissues *869

Apt, Leonard, Pollycove, Myron, and Ross, Joseph F. Idiopathic pulmonary hemosiderosis. A study of the anemia and iron distribution using radioiron and radiochromium 1150

—. See CHODOS, ROSS, APT, POLLYCOVE, and HALKETT 314

Arai, Y. See ELRICK, ARAI, and YEARWOOD-DRAYTON *887

Arney, Glen K. See MERONEY, ARNEY, SEGAR, and BALCH 825

Arroyave, Guillermo. See BURCH, ARROYAVE, SCHWARTZ, PADILLA, BÉHAR, VITERI, and SCRIMSHAW 1579

Ashenbrucker, Helen. See ATHENS, MAUER, ASHENBRUCKER, and CARTWRIGHT *870

Asper, Samuel P., Jr. See PROUT, WEAVER, SCOTT, and ASPER *921

Athens, J. W., Mauer, A. M., Ashenbrucker, Helen, and Cartwright, G. E. Labelling of leukocytes *in vivo* with DFP^{32} *870

Atkinson, Michael, Kramer, Philip, Wyman, Stanley M., and Ingelfinger, Franz J. The dynamics of swallowing. I. Normal pharyngeal mechanisms 581

—. See KRAMER, ATKINSON, WYMAN, and INGELFINGER 589

Austen, F. K., Rubini, M. E., Meroney, W. H., and Wolff, J. Salicylates and thyroid function *870

Axelrod, D. Robert. Relationship of calcium and citric acid to hyperventilation in man *870

Axelrod, Julius. See SCHMID, AXELROD, HAMMAKER, and ROSENTHAL *927

B

Bader, Mortimer E., Bader, Richard A., and Selikoff, Irving J. Pulmonary function in asbestosis of the lungs; an "alveolar-capillary block" syndrome *871

Bader, Richard A. See BADER, BADER, and SELIKOFF *871

Baker, William H. See DOW, BAKER, and STANBURY *884

—. See HENNEMAN and BAKER *899

Balch, Henry H. See MERONEY, ARNEY, SEGAR, and BALCH 825

Baldini, Mario. Physiology of anemia in "hypersplenism" *871

Baldwin, David S., Biggs, Albert W., and Hulet, William H. Exaggerated natriuresis in essential hypertension *871

Ball, Wilmot C., Jr. See DAVIS, PECHET, BALL, and GOODKIND 689

Ballon, Jonathan D. See WESSLER, BALLON, and KATZ *935

Bally, Peter, and Numa, Shosaku. The relationship of the pituitary to hyperlipemia of induced nephrosis in rats *872

Band, Raymond I. See CALLAWAY, BAND, and FINESINGER *877

Bang, Frederick B. See LUTTRELL and BANG *912

Barker, E. S., Singer, R. B., Elkinton, J. R., and Clark, J. K. The renal response in man to acute experimental respiratory alkalosis and acidosis 515

—, and **Clark, John K.** An attempt to apply the "cell separation theory" to renal hemodynamic and metabolic measurements in intact man *872

Barnes, Benjamin A., Gordon, Esther B., and Cope, Oliver. Skeletal muscle analyses in health and in certain metabolic disorders. I. The method of analysis and the values in normal muscle 1239

Barrow, Emily M. See HOUGIE, BARROW, and GRAHAM 485

—. See GRAHAM, BARROW, and HOUGIE 497

Bartter, Frederic C., and Fourman, Paul. A non-renal effect of adrenal cortical steroids upon potassium metabolism *872

Bates, Richard C. See HESS, COBURN, BATES, and MURPHY 449

Bauman, Arthur. See ROTHSCHILD, BAUMAN, YALOW, and BERSON 422

Baxter, James H., Goodman, Howard C., and Havel, Richard J. Hyperlipidemia of nephrosis *873

Bayles, Theodore B. See FREIREICH, ROSS, BAYLES, EMERSON, and FINCH 1043

Bearn, A. G., Yü, T. F., and Gutman, A. B. Renal function in Wilson's disease 1107

Beck, J. C., McGarry, E. E., Dyrenfurth, I., and Venning, E. H. The metabolic effects of human and monkey growth hormone in man *873
Bedell, George N. See CULBERTSON, ECKSTEIN, KIRKENDALL, and BEDELL 1537
Béhar, Moisés. See BURCH, ARROYAVE, SCHWARTZ, PADILLA, BÉHAR, VITERI, and SCRIMSHAW 1579
Benjamin, Alvin D. See LATHEM and BENJAMIN 89
Berg, Margaret. See HOGNESS, LEE, BERG, and WILLIAMS 803
Bergenstal, D. M. See HERTZ, BERGENSTAL, LUBS, and JACKSON *899
Berglund, Erik. See BORST, BERGLUND, and MCGREGOR 669
—. See BORST, BERGLUND, WHITTENBERGER, MEAD, MCGREGOR, and COLLIER 1708
Berkowitz, Mordecai E. See BERNFELD, BERKOWITZ, and DONAHUE 1363
Berliner, Robert W., and **Davidson, Douglas G.** Production of hypertonic urine in the absence of pituitary antidiuretic hormone 1416
—. See DAVIDSON, LEVINSKY, and BERLINER *882
Bernard, Harvey R. See BRICKER, BERNARD, and STOKES *876
Berne, Robert M., Blackmon, John R., and **Gardner, Thomas H.** Hypoxemia and coronary blood flow 1101
Bernfeld, Peter, Berkowitz, Mordecai E., and **Donahue, Virginia M.** A simple nephelometric method for the determination of human serum beta-lipoprotein 1363
Berns, Aline W. See BUKANTZ and BERNS *877
Berry, Edward R., and **Chanutin, Alfred.** Electrophoretic studies of red cell extracts of stored blood 225
Berson, Solomon A., and **Yalow, Rosalyn S.** Ethanol fractionation of plasma and electrophoretic identification of insulin-binding antibody 642
—, and **Yalow, Rosalyn S.** Kinetics of reaction between insulin and insulin-binding antibody *873
—. See YALOW and BERSON 44
—. See ROTHSCHILD, BAUMAN, YALOW, and BERSON 422
—. See YALOW and BERSON 648
Bertinchamps, Albert, Kenis, Y., and **Tagnon, Henry J.** The effect of the administration of HN_3 on the utilization of plasma iron in humans *874
Bertles, John F. Sodium transport across the surface membrane of red blood cells in hereditary spherocytosis 816
Bertrand, Jean. See MIGEON, BERTRAND, and WALL 1350
Bessman, S. P., and **Stauffer, J. C.** Factors affecting the appearance of ammonia in the gastric juice *874
Best, Maurice M. See DUNCAN AND BEST *885
Bethune, John E., Nelson, Don H., and **Thorn, George W.** Plasma adrenocorticotrophic hormone in Addison's disease and its modification by the administration of adrenal steroids 1701
Beutler, Ernest, Robson, Melba, and **Buttenwieser, Ellen.** The mechanism of glutathione destruction and protection in drug-sensitive and non-sensitive erythrocytes. *In vitro* studies 617
—. Iron enzymes in iron deficiency: Cytochrome C *874
Bierman, Edwin L. See DOLE, BIERMAN, and ROBERTS *884
Bierman, H. R., Kelly, K. H., Byron, R. L., Jr., Rattunde, H., and **Cordes, F.** Stimulation of the bone marrow: A clinical study in man *875
Biggs, Albert W. See BALDWIN, BIGGS, and HULET *871
Birkenfeld, L. W. See O'MEARA, BIRKENFELD, GOTCH, and EDELMAN 784
—. See EDELMAN, LEIBMAN, O'MEARA, and BIRKENFELD *886
Bishop, Jonathan S. See MARKS and BISHOP 254
Blackmon, John R. See BERNE, BLACKMON, and GARDNER 1101
Blakemore, W. S. See OGILVIE, FORSTER, BLAKEMORE, and MORTON 1
—. See LUDWIG, BLAKEMORE, and DRABKIN *912
—. See KUO, SCHNABEL, BLAKEMORE, and WHEREAT 1035
Bloom, Walter L. See FOWLER and BLOOM *889
—. See FLEMING and BLOOM 1233
Bluhm, M. M. See MULDOWNEY, CROOKS, and BLUHM 1375
Blythe, W. B. See RUBINI, BLYTHE, and MERONEY *926
Bocanegra, Manuel. See MARKLEY, BOCANEGRA, MORALES, and CHIAPPORI 303
Bodenlos, Leonard J. See WALSER and BODENLOS *933
Bollet, Alfred Jay. The hexosamine content of the serum globulins in normal and pathological sera 51
—, **Seraydarian, Maria W.,** and **Turner, Rachel E.** Serum acid mucopolysaccarides *875
—, **Seraydarian, Maria W.,** and **Simpson, William F.** Acid mucopolysaccharides in normal serum 1328
Bond, Victor P. See CRONKITE, BOND, ROBERTSON, and PAGLIA *881
Bondurant, Stuart, Hickam, John B., and **Isley, Joseph K.** Pulmonary and circulatory effects of acute pulmonary vascular engorgement in normal subjects 59
Bondy, Philip K. See SCHEUER and BONDY 67
Bone, Mary. See BRAUDE, BONE, WAGGONER, and HATTEN *876
Bonting, Sjoerd L. See POLLAK, NETTLES, PIRANI, KARK, and BONTING *920
Borgström, B., Dahlqvist, A., Lundh, G., and **Sjövall, J.** Studies of intestinal digestion and absorption in the human 1521
Borst, Hans G., Berglund, Erik, and **McGregor, Maurice.** The effects of pharmacologic agents on the pulmonary circulation in the dog. Studies on epinephrine, nor-epinephrine, 5-hydroxy-tryptamine, acetylcholine, histamine, and aminophylline 669
—, **Berglund, Erik, Whittenberger, James L., Mead, Jere, McGregor, Maurice,** and **Collier, Clarence.** The effect of pulmonary vascular pressures on the mechanical properties of the lungs of anesthetized dogs 1708
Borun, E. Raymond, Figueroa, William G., and **Perry, Seymour M.** The distribution of Fe^{59} tagged human erythrocytes in centrifuged specimens as a function of cell age 676
Bothwell, T., Noyes, W. D., and **Finch, C. A.** The handling of erythrocyte iron by the reticulo-endothelial cell *875
Bove, Joseph R. See EBAUGH, BOVE, and STEMLER *886
Bozer, John M. See GORLIN, BOZER, and VESTER *895

Bozicevich, J. See WAALKES, WEISSBACH, BOZICEVICH, and UDENFRIEND 1115
Bradley, Matthew H. See KORY, WATSON, BRADLEY, and PETERS *907
Bradley, S. E. See COMBES, PREEDY, WHEELER, HAYS, and BRADLEY 860
Brandfonbrener, Martin. See SILVERSTONE, BRANDFONBRENER, SHOCK, and YIENGST 504
Branscome, William. See LEVITIN, BRANSCOME, and EPSTEIN *910
Braude, A. I., Bone, Mary, Waggoner, Billie, and **Hatten, Betty.** Type specific antibody response to M-protein of nephritogenic streptococci in glomerulonephritis *876
—. See SMITH, BRAUDE, and CAREY 695
Braunwald, E., Welch, G. H., Jr., Sarnoff, S. J., and **Morrow, A. G.** Hemodynamic effects of quantified mitral regurgitant flow *876
Braverman, Nancy. See DANCIS, BRAVERMAN, and LIND 398
Brenner, Robert. See HOLLAND, BRENNER, ROCK, and DANIELSON *901
Bricker, Neal S., Bernard, Harvey R., and **Stokes, James M.** Unilateral renal disease in dogs: Method of induction and serial bilateral renal function studies *876
Brill, Norman Q. See RASMUSSEN, MARSH, and BRILL *922
Brin, Myron. See WOLFE and BRIN *936
Brittingham, T. E., and **Chaplin, H., Jr.** Sensitivity to buffy coat—A cause of "non-specific" transfusion reactions *877
Brodie, Bernard B. See PETERSON, PIERCE, WYNGAARDEN, BUNIM, and BRODIE 1301
Brodsky, William A. See APPELBOOM and BRODSKY *869
Brothers, Milton. See SPENCER, LASZLO, and BROTHERS 680
Brown, H. See GUBLER, BROWN, MARKOWITZ, CARTWRIGHT, and WINTROBE 1208
Brown, John F. See ROWE, EMANUEL, MAXWELL, BROWN, CASTILLO, SCHUSTER, MURPHY, and CRUMPTON 844
Brown, R. R. See PRICE, BROWN, and LARSON 1600
Bukantz, Samuel C., and **Berns, Aline W.** Paper electrophoresis and gel diffusion of sputum in the diagnosis of pulmonary carcinomatosis; identification of the fast moving component as albumin *877
Bunim, Joseph J. See PETERSON, PIERCE, WYNGAARDEN, BUNIM, and BRODIE 1301
Burch, G. E. See LOVE and BURCH 468
—. See LOVE and BURCH 479
Burch, Helen B., Arroyave, Guillermo, Schwartz, Ruth, Padilla, Ana Maria, Béhar, Moisés, Viteri, Fernando, and **Scrimshaw, Nevin S.** Biochemical changes in liver associated with kwashiorkor 1579
Burg, Maurice B. See PAPPER, SAXON, BURG, SEIFER, and ROSENBAUM *918
Burnell, James M. See SCRIBNER, SWANSON, and BURNELL *928
Burrows, Belton A., Peters, Theodore, and **Lowell, Francis C.** Physical binding of insulin by gamma globulins of insulin-resistant subjects 393
—. See SLINGERLAND and BURROWS *930
—. See RELMAN, LAMBIE, BURROWS, and ROY 1249
Butler, Thomas C. See WADDELL and BUTLER 1217
Buttenwieser, Ellen. See BEUTLER, ROBSON, and BUTTENWIESER 617
Byers, Sanford O. See ROSENMAN, BYERS, and FRIEDMAN 1558
Byron, R. L., Jr. See BIERMAN, KELLY, BYRON, RATTUNDE, and CORDES *875

C

Cabrera, G. See KAKO and CABRERA *906
Cade, Robert. See PORTWOOD, SELDIN, RECTOR, and CADE *920
Cader, Gordon. See ANDRES, CADER, GOLDMAN, and ZIERLER 723
Calabresi, Paul, and **Abelmann, Walter H.** Portocaval and porto-pulmonary anastomoses in Laennec's cirrhosis and in heart failure 1257
Callaway, Enoch, III, Band, Raymond I., and **Finesinger, Jacob E.** Some psychopharmacological effects of atropine *877
Campbell, Edmund W., and **Lo Pilato, Edith V.** Carbohydrate metabolism as a measure of human platelet preservation *878
Carbone, John, Sborov, Victor, Fanska, Rudolph, and **Ringgold, Kathryn.** The effect of wine in decompensated hepatic cirrhosis *878
Caren, Raymond, and **Corbo, Lucille.** The potentiation of exogenous insulin by tolbutamide in depancreatized dogs 1546
Carey, Francis J. See SMITH, BRAUDE, and CAREY 695
Carroll, R. T., and **Holburn, R. R.** Correction by normal platelets of deficient generation of thromboplastin in a family of hemophilics *878
Cartwright, G. E. See ATHENS, MAUER, ASHENBRUCKER, and CARTWRIGHT *870
—. See GUBLER, BROWN, MARKOWITZ, CARTWRIGHT, and WINTROBE 1208
Castillo, Cesar. See ROWE, EMANUEL, MAXWELL, BROWN, CASTILLO, SCHUSTER, MURPHY, and CRUMPTON 844
Castle, William B. See GREENBERG, KASS, and CASTLE 833
—. See JANDL, JONES, and CASTLE 1428
Cathey, Charles W. See HAMMARSTEN, CATHEY, REDMOND, and WOLF *897
Ceppellini, R. See KUNKEL, CEPPELLINI, MÜLLER-EBERHARD, and WOLF 1615
Chalmers, Thomas C. See IBER and CHALMERS 706
Chanutin, Alfred. See BERRY AND CHANUTIN 225
Chaplin, H., Jr. See BRITTINGHAM and CHAPLIN *877
Chapman, Carleton B. See MITCHELL and CHAPMAN *915
Chasen, William H. See LEMON, MUELLER, CHASEN, and LOONEY *909
Cheek, Donald B., West, Clark D., and **Golden, Catherine Carter.** The distribution of sodium and chloride and the extracellular fluid volume in the rat 340
Cherry, R. B. See COOK, SUTHERLAND, SEGAL, CHERRY, MEAD, MCILROY, and SMITH 440
Chesley, Leon C., and **Lenobel, Abraham.** An evaluation of the single injection thiosulfate method for the measurement of extracellular water 327
Chetrick, Allen. See GOODYER and CHETRICK *894
Chiappori, Miguel. See MARKLEY, BOCANEGRA, MORALES, and CHIAPPORI 303
Childs, Barton. See ZINKHAM and CHILDS *938

Chinard, Francis P., Taylor, W. Rowland, Nolan, Mary F., and **Enns, Theodore.** Renal handling of glucose in the dog *879
Chobanian, A. V. See HOLLANDER and CHOBANIAN *901
Chodos, Robert B., Ross, Joseph F., Apt, Leonard, Pollycove, Myron, and **Halkett, James A. E.** The absorption of radioiron labeled foods and iron salts in normal and iron-deficient subjects and in idiopathic hemochromatosis 314
Christy, Nicholas P., Longson, Donald, Horwitz, William A., and **Knight, Mary M.** Inhibitory effect of chlorpromazine upon the adrenal cortical response to insulin hypoglycemia in man 543
—. See JAILER, LONGSON, and CHRISTY 1608
Clark, J. K. See BARKER, SINGER, ELKINTON, and CLARK 515
—. See BARKER and CLARK *872
Clatanoff, Dallas V. See SCHLOESSER, KORST, CLATANOFF, and SCHILLING 1470
Clauss, R. H. See FRITTS, HARRIS, CLAUSS, and COURNAND *890
Coburn, Alvin F. See HESS, COBURN, BATES, and MURPHY 449
Code, Charles F. See HIGGINS, LEE, SCHOLER, REITEMEIER, CODE, and WOLLAEGER 265
Coffman, Jay D. See WOOD and COFFMAN *937
Cohen, Henry W. See ROSENBAUM, PAPPER, COHEN, and MCLEAN 1202
Cohen, Sidney, and **Geronimus, Lippman H.** Inducible (adaptive) stimulation of staphylococcal penicillinase *in vivo* *879
Coleman, Joseph. See CRISPELL, COLEMAN, and HYER *881
Collier, Clarence. See BORST, BERGLUND, WHITTENBERGER, MEAD, MCGREGOR, and COLLIER 1708
Combes, B., Preedy, J. R. K., Wheeler, H. O., Hays, R. M., and **Bradley, S. E.** The hemodynamic effects of hexamethonium bromide in the dog, with special reference to "splanchnic pooling" 860
Conn, Hadley L., Jr., and **Wood, John C.** Studies on kinetics and mechanisms of potassium transfer in *in vivo* skeletal muscle *879
Conrad, Loyal L. See FURMAN and CONRAD 713
Cook, C. D., Sutherland, J. M., Segal, S., Cherry, R. B., Mead, J., McIlroy, M. B., and **Smith, C. A.** Studies of respiratory physiology in the newborn infant. III. Measurements of mechanics of respiration 440
Cooper, G. See JEFFERIES, LEVY, KELLY, and COOPER *905
Cope, Oliver. See BARNES, GORDON, and COPE 1239
Corbo, Lucille. See CAREN and CORBO 1546
Corbus, Howard F. See MILLER, CORBUS, and SULLIVAN 18
Cordes, F. See BIERMAN, KELLY, BYRON, RATTUNDE, and CORDES *875
Cornett, Robert W., and **Metcalfe, James.** A method for serial cardiac output determinations applied to the study of pregnancy associated with heart disease *880
Cournand, A. See FRITTS, HARRIS, CLAUSS, and COURNAND *890
Cox, R. I., and **Finkelstein, M.** Pregnane-3α, 17α, 20α-triol and pregnane-3α, 17α, 20α-triol-11-one excretion by patients with adrenocortical dysfunction 1726
Crawford, J. D., Cushman, A. N., Parisi, A., and **Terry, M. L.** The influence of Pitressin® and osmolar excretion on urine water concentration in normal man *880
Crispell, K. R., Coleman, Joseph, and **Hyer, Harry.** A study of the factors affecting the equilibrium between human erythrocytes and human plasma for radioactive L-thyroxine *881
Crockett, Wayne. See HUFF, PARRISH, and CROCKETT *901
Cronkite, Eugene P., Bond, Victor P., Robertson, James S., and **Paglia, Donald E.** The survival, distribution and apparent interaction with capillary endothelium of transfused radiosulfate labeled platelets in the rat *881
Crooks, J. See MULDOWNEY, CROOKS, and BLUHM 1375
Crosby, William H., and **Sullivan, Benjamin H.** Investigation of the human small intestine by intraluminal biopsy *881
Crump, Charles H. See ROBIN, WHALLEY, CRUMP, and TRAVIS *924
Crumpton, Charles W. See ROWE, EMANUEL, MAXWELL, BROWN, CASTILLO, SCHUSTER, MURPHY, and CRUMPTON 844
Culbertson, James W., Eckstein, John W., Kirkendall, Walter M., and **Bedell, George N.** General hemodynamics and splanchnic circulation in patients with coarctation of the aorta 1537
Cushman, A. N. See CRAWFORD, CUSHMAN, PARISI, and TERRY *880

D

Dahlqvist, A. See BORGSTRÖM, DAHLQVIST, LUNDH, and SJÖVALL 1521
Dancis, Joseph, Braverman, Nancy, and **Lind, John.** Plasma protein synthesis in the human fetus and placenta 398
Danielson, Ethel. See HOLLAND, BRENNER, ROCK, and DANIELSON *901
Daughaday, William H. Corticosteroid binding by a plasma alpha globulin *881
Davidson, Charles S. See SUMMERSKILL, WOLFE, and DAVIDSON 361
Davidson, Douglas G., Levinsky, Norman G., and **Berliner, Robert W.** Maintenance of potassium excretion despite reduction of glomerular filtration during sodium diuresis *882
—. See ORLOFF, DAVIDSON, and WAGNER *918
—. See BERLINER and DAVIDSON 1416
Davidson, J., Sjoerdsma, A., Loomis, L. N., and **Udenfriend, S.** Studies with the serotonin precursor, 5-hydroxytryptophan, in experimental animals and man 1594
—. See STEINFELD, DAVIDSON, and GORDON *931
Davis, James O., Pechet, Maurice M., Ball, Wilmot C., Jr., and **Goodkind, M. Jay.** Increased aldosterone secretion in dogs with right-sided congestive heart failure and in dogs with thoracic inferior vena cava constriction 689
DeBernard, Benedetto. See RABINOWITZ, ESTERBROOK, and DEBERNARD *921
Dempsey, Eleanor F. Urinary oxalate excretion in relation to renal stone formation *882

Dennis, Edward W. See ALEXANDER, MISE, DENNIS, and HERSHBERGER *869
Denny, Floyd W., Jr., Perry, William D., and Wannamaker, Lewis W. Type-specific streptococcal antibody 1092
Despointes, Rene H. See DINGMAN and DESPOINTES *882
DeWall, Richard A. See MELBY, DEWALL, STOREY, and EGDAHL *914
Dewey, Priscilla A. See TOFIBARA, TEREPKA, and DEWEY 738
Didisheim, Paul. See LEWIS and DIDISHEIM *910
Di Ferrante, Nicola. Urinary excretion of acid mucopolysaccharides by patients with rheumatoid arthritis 1516
Dingman, Joseph F., and Despointes, Rene H. Adrenal steroids and water metabolism *882
DiPalma, Joseph R. On the mechanism of transmission of the atrial impulse to the ventricle *883
Di Prisco, Estela. See ROCHE, PEREZ-GIMENEZ, LAYRISSE, and DI PRISCO 1183
Dodge, Harold T., and Murdaugh, H. V., Jr. Drug driving of the heart in man *883
Dole, Vincent P., Bierman, Edwin L., and Roberts, Thomas N. Plasma NEFA as an index of carbohydrate utilization *884
Donahue, Virginia M. See BERNFELD, BERKOWITZ, and DONAHUE 1363
Doscherholmen, Alfred, and Hagen, Paul S. A dual vitamin B_{12} plasma absorption mechanism *884
—, and **Hagen, Paul S.** A dual mechanism of vitamin B_{12} plasma absorption 1551
Dow, Elias C., Baker, William H., and Stanbury, John B. Comparative analysis of radioactive strontium and calcium administered simultaneously to man *884
Dowling, J. Thomas. See FREINKEL, INGBAR, and DOWLING 25
Doyle, J. T. See PATTERSON, WARREN, DOYLE, GAUER, KEEN, and GOETZ *919
Drabkin, D. L. See LUDWIG, BLAKEMORE, and DRABKIN *912
Dreifus, Leonard S., and Stamler, Jeremiah. The production of a hypernatremia and hyperosmolarity in the diabetes insipidus dog infused with Ringer's solution *885
Dreiling, David A. See JANOWITZ and DREILING *904
Dressler, S. H. See RUSSELL, DRESSLER, and MIDDLEBROOK *926
DuBois, Arthur B., and Marshall, Robert. Measurements of pulmonary capillary blood flow and gas exchange throughout the respiratory cycle in man 1566
Ducci, Héctor. See KATZ, DUCCI, and ALESSANDRI 1370
Duncan, Charles H., and Best, Maurice M. Effects of the formic acid analogues of thyroxine and triiodothyronine on cholesterol metabolism *885
Dunn, Max S. See SALISBURY, DUNN, and MURPHY 1227
Dustan, Harriet P., and Poutasse, Eugene F. Some determinants of urine composition in man: Separated renal functions in patients with unilateral and bilateral renal diseases *885
Dyrenfurth, I. See BECK, MCGARRY, DYRENFURTH, and VENNING *873

E

Ebaugh, Franklin G., Jr., Bove, Joseph R., and Stemler, Richard S. The effect of exposure of erythrocytes from acid citrate dextrose (ACD) whole blood to 5 grams per cent dextrose and 0.225 grams per cent sodium chloride on RBC size, potassium concentration and content, glucose content, and *in vivo* survival in man *886
Eckstein, John W., and Hamilton, William K. The pressure-volume characteristics of human forearm veins during epinephrine infusion *886
—, and **Hamilton, William K.** The pressure-volume responses of human forearm veins during epinephrine and norepinephrine infusions 1663
—. See CULBERTSON, ECKSTEIN, KIRKENDALL, and BEDELL 1537
Edelman, I. S., Leibman, J., O'Meara, M. P., and Birkenfeld, L. W. The relationships among serum sodium concentration, serum osmolarity and body composition in man *886
—. See SWEET, NADELL, and EDELMAN 279
—. See GOTCH, NADELL, and EDELMAN 289
—. See O'MEARA, BIRKENFELD, GOTCH, and EDELMAN 784
Egdahl, Richard H. See MELBY, DEWALL, STOREY, and EGDAHL *914
Eich, Robert. See FISHER, EICH, and FALOON *888
Eliel, Leonard P., Smith, William O., and Hawrylko, Josephine. Metabolic interrelations of calcium and magnesium in patients with and without osteolytic disease *887
Elkinton, J. R. See BARKER, SINGER, ELKINTON, and CLARK 515
Ellenbogen, Eric. See MERCHANT, MASOUREDIS, and ELLENBOGEN *914
Elliott, David W. See WERK, GIUSEFFI, LARSON, ELLIOTT, and OIKAWA *935
Ellis, F. Henry, Jr. See WOODWARD, ELLIS, and WOOD *937
Ellison, Haskell E. See HAMOLSKY, ELLISON, and FREEDBERG 1486
Ellison, Rose Ruth. Collateral sensitivity to methotrexate in 6-mercaptopurine-responsive adult acute leukemics *887
Elrick, Harold, Arai, Y., and Yearwood-Drayton, V. Observations on the action of combined glucagon-insulin infusions in diabetic patients *887
Emanuel, Dean A. See ROWE, EMANUEL, MAXWELL, BROWN, CASTILLO, SCHUSTER, MURPHY, and CRUMPTON 844
Emerson, Charles P. See FREIREICH, ROSS, BAYLES, EMERSON, and FINCH 1043
Engle, Ralph L., Jr., Woods, Kenneth R., and Pert, James H. Starch gel electrophoresis of serum proteins and urinary proteins from patients with multiple myeloma *888
Enns, Theodore. See CHINARD, TAYLOR, NOLAN, and ENNS *879
Epstein, Franklin H., Kleeman, Charles R., and Hendrikx, Achiel. The influence of bodily hydration on the renal concentrating process 629
—, **Kleeman, Charles R., Pursel, Stewart, and Hendrikx, Achiel.** The effect of feeding protein and urea on the renal concentrating process 635
—. See LEVITIN, BRANSCOME, and EPSTEIN *910
Esterbrook, Ronald. See RABINOWITZ, ESTERBROOK, and DEBERNARD *921

F

Fagan, Violet M. See SIPERSTEIN and FAGAN *929

Fahey, John L. Toxicity and blood ammonia rise resulting from intravenous amino acid administration in man: The protective effect of L-arginine 1647

Faloon, William W. See FISHER, EICH, and FALOON *888

Fanska, Rudolph. See CARBONE, SBOROV, FANSKA, and RINGGOLD *878

Farber, Saul J., and **Schubert, Maxwell.** The binding of cations by chondroitin sulfate 1715

Feigelson, Philip. See MARKS and FEIGELSON 1279

Ferguson, Thomas B. See SHADLE, FERGUSON, SABISTON, and GREGG 335

Ferris, B. G., Jr. See FRANK, MEAD, and FERRIS 1680

Field, James B., Tietze, Frank, and **Stetten, DeWitt, Jr.** Further characterization of an insulin antagonist in the serum of patients in diabetic acidosis 1588

Figueroa, William G. See BORUN, FIGUEROA, and PERRY 676

Finberg, Laurence. Experimental studies of the mechanisms producing hypocalcemia in hypernatremic states 434

Finch, Clement A. See HENNESSEY, FINCH, and GABRIO 429

—. See BOTHWELL, NOYES, and FINCH *875

Finch, Stuart C. See FREIREICH, ROSS, BAYLES, EMERSON, and FINCH 1043

Finesinger, Jacob E. See CALLAWAY, BAND, and FINESINGER *877

Finkelstein, M. See COX and FINKELSTEIN 1726

Fischer, George L. See RECANT and FISCHER *922

Fisher, Curtis J., Eich, Robert, and **Faloon, William W.** The effect of exclusion of the erythematous palm upon venous ammonia in hepatic cirrhosis *888

Fleming, J. W., and **Bloom, W. L.** Further observations on the hemodynamic effect of plasma volume expansion by dextran 1233

Fletcher, Anthony P., and **Johnson, Alan J.** The clearance rate of I^{131} labelled streptokinase from the circulation of man *888

Foley, Joseph. See SEGAL, WYNGAARDEN, and FOLEY 1383

—. See WYNGAARDEN, SEGAL, and FOLEY 1395

Forbes, Allan L. See MUELLER, IACONO, and FORBES *917

Fordham, Christopher C., III. See HOLLANDER, WILLIAMS, FORDHAM, and WELT 1059

Forster, R. E. See OGILVIE, FORSTER, BLAKEMORE, and MORTON 1

—. See RANKIN, MCNEILL, and FORSTER *922

Fourman, Paul. See BARTTER and FOURMAN *872

Fowler, Noble O., and **Bloom, Walter L.** Systolic-diastolic pressure relationships in the isolated beating heart *889

Frank, N. R., Mead, J., and **Ferris, B. G., Jr.** The mechanical behavior of the lungs in healthy elderly persons 1680

Frantz, Ivan D., Jr. See TUNA, RECKERS, and FRANTZ *932

Frawley, Thomas F., and **Segal, Stanton.** Studies using glucose and pentoses to determine the mechanism of the hypoglycemic response to sulfonylureas *889

Frayser, R. See HICKAM and FRAYSER *899

Fredrickson, Donald S., and **Gordon, Robert S., Jr.** Metabolism of albumin-bound labeled fatty acids in man *890

Freedberg, A. Stone. See HAMOLSKY, ELLISON, and FREEDBERG 1486

Freinkel, Norbert, Ingbar, Sidney H., and **Dowling, J. Thomas.** The influence of extra-cellular thyroxine-binding protein upon the accumulation of thyroxine by tissue slices 25

Freireich, Emil J., Ross, Joseph F., Bayles, Theodore B., Emerson, Charles P., and **Finch, Stuart C.** Radioactive iron metabolism and erythrocyte survival studies of the mechanism of the anemia associated with rheumatoid arthritis 1043

Freis, Edward D., Schnaper, Harold W., and **Lilienfield, Lawrence S.** Rapid and slow components of the circulation in the human forearm 245

Fremont-Smith, Kenneth, Iber, Frank L., and **Plough, Irvin C.** Thyroid-adrenocortical interrelations: Failure to demonstrate antagonism between triiodothyronine and hydrocortisone in man 1313

Friedman, Meyer. See ROSENMAN and FRIEDMAN 700

—. See ROSENMAN, BYERS, and FRIEDMAN 1558

Friou, George J. Clinical application of lupus serum—Nucleoprotein reaction using the fluorescent antibody technique *890

Fritts, H. W., Jr., Harris, P., Clauss, R. H., and **Cournand, A.** Effect of acetylcholine in the pulmonary circulation of man *890

Froesch, E. Rudolf, Winegrad, Albert I., and **Renold, Albert E.** Mechanism of the glucosuria produced by the administration of steroids with glucocorticoid activity *890

Fudenberg, Hugh, and **Kunkel, Henry G.** Relation of acquired hemolytic anemia to macroglobulins *891

Furman, Robert H., and **Conrad, Loyal L.** Ultracentrifugal characterization of the lipoprotein spectrum in obstructive jaundice: Studies of serum lipid relationships in intra- and extrahepatic biliary obstruction 713

G

Gabrilove, J. Lester. Studies on the ground substance in myxedema. II. Effect of desiccated thyroid, L-triiodothyronine and cortisone in myxedema, localized myxedema, and severe exophthalmos *891

Gabrio, Beverly Wescott. See HENNESSEY, FINCH, and GABRIO 429

Galdston, Morton. Treatment of abnormal regulation of respiration in pulmonary emphysema by pharmacologic means *891

Garcia, Hugo, and **Wallace, John.** Plasma concentrations of epinephrine and norepinephrine in normal individuals, with observations on the arteriovenous difference and *in vitro* disappearance of the amines *892

Gardner, Thomas H. See BERNE, BLACKMON, and GARDNER 1101

Gauer, O. See PATTERSON, WARREN, DOYLE, GAUER, KEEN, and GOETZ *919

Gensini, Goffredo G., Roger, Vicente N., Hawley, Robert L., and **Middlebrook, Gardner.** A new concept in prosthetic material for use in plastic cardiac surgery *892

Geronimus, Lippman H. See COHEN and GERONIMUS *879

Gilbertsen, A. Sigrid, and **Lowry, P. T.** The anabolic significance of the fecal dipyrrylmethene pigments or mesobilifuscin group *893
Giuseffi, Jerome, Jr. See Werk, Giuseffi, Larson, Elliott, and Oikawa *935
Glasgow, Lowell A., and **Morgan, Herbert R.** Cellular damage associated with the delayed hypersensitive state in mumps virus infection *893
Gluecksohn-Waelsch, Salome, Ranney, Helen M., and **Sisken, Betty F.** The hereditary transmission of hemoglobin differences in mice 753
Goetz, R. H. See Patterson, Warren, Doyle, Gauer, Keen, and Goetz *919
Golden, Catherine Carter. See Cheek, West, and Golden 340
Goldman, Peter. See Andres, Cader, Goldman, and Zierler 723
Goldsmith, Richard. A comparison of certain aspects of calcium kinetics in hyperparathyroidism and Paget's disease of bone *893
Goldthwait, David A. Mechanisms of synthesis of purine nucleotides in heart muscle extracts 1572
Goldwasser, Eugene. See Gurney, Goldwasser, Jacobson, and Pan *896
Good, Robert A., Zak, Solomon J., Jensen, Donna R., and **Pappenheimer, A. M., Jr.** Delayed allergy and agammaglobulinemia *894
Goodkind, M. Jay. See Davis, Pechet, Ball, and Goodkind 689
Goodman, Howard C. See Baxter, Goodman, and Havel *873
Goodyer, Allen V. N., and **Chetrick, Allen.** Further studies of the use of the ear oximeter for repeated measurements of cardiac output at rest and during exercise *894
Gordon, Edwin E., and **Sheps, Sheldon G.** The effect of acetazolamide (Diamox®) on calcium and citrate metabolism in humans *894
—. See Troen and Gordon *932
Gordon, Esther B. See Barnes, Gordon, and Cope 1239
Gordon, J. See Sehon, Gyenes, Gordon, Richter, and Rose 456
Gordon, Robert S., Jr. Unesterified fatty acid in human blood plasma. II. The transport function of unesterified fatty acid 810
—. See Fredrickson and Gordon *890
—. See Steinfeld, Davidson, and Gordon *931
Gorlin, Richard, Bozer, John M., and **Vester, John W.** The effect of nitroglycerin on the coronary circulation and myocardial metabolism in man *895
Gotch, F., Nadell, J., and **Edelman, I. S.** Gastrointestinal water and electrolytes. IV. The equilibration of deuterium oxide (D_2O) in gastrointestinal contents and the proportion of total body water (T.B.W.) in the gastrointestinal tract 289
—. See O'Meara, Birkenfeld, Gotch, and Edelman 784
Graf, W. The effect of histamine on skin and deep temperatures in man with particular reference to liver temperature 1285
Graff, Ada. See Osserman, Graff, Marshall, Lawlor, and Graff 352
Graff, Samuel. See Osserman, Graff, Marshall, Lawlor, and Graff 352
Graham, John B., Barrow, Emily M., and **Hougie, Cecil.** Stuart clotting defect. II. Genetic aspects of a 'new' hemorrhagic state 497
—. See Hougie, Barrow, and Graham 485
Greben, Stanley E. See Schulman and Greben 74
Greenberg, Mortimer S., Kass, Edward H., and **Castle, William B.** Studies on the destruction of red blood cells. XII. Factors influencing the role of S hemoglobin in the pathologic physiology of sickle cell anemia and related disorders. 833
Greene, William A., Jr. Psychological factors and the manifest development of leukemia and lymphoma in humans *895
Gregg, Donald E. See Shadle, Ferguson, Sabiston, and Gregg 335
Greisman, Sheldon E. *In vivo* capillary alterations in man during hemorrhagic fever and other infectious illnesses *895
—. Capillary observations in patients with hemorrhagic fever and other infectious illnesses 1688
Grossman, Jacob, Yalow, A. Aaron, and **Weston, Raymond E.** Effects of corticotropin, hydrocortisone, and stress on albumin synthesis and catabolism in man *896
Gubler, C. J., Brown, H., Markowitz, H., Cartwright, G. E., and **Wintrobe, M. M.** Studies on copper metabolism. XXIII. Portal (Laennec's) cirrhosis of the liver 1208
Guild, Warren R. See Rees, Scheitlin, Pond, McManus, Guild, and Merrill *923
Gurevitch, J. See Nelken, Gurevitch, and Neuman 749
Gurney, Clifford W., Goldwasser, Eugene, Jacobson, Leon O., and **Pan, Chao.** Demonstration of erythropoietin in human plasma *896
Gursey, Deha. See Olson, Vester, Gursey, and Longman *917
Gutman, A. B. See Bearn, Yü, and Gutman 1107
Gyenes, L. See Sehon, Gyenes, Gordon, Richter, and Rose 456

H

Haavik, A. See Lipsky, Haavik, Hooper, and McDivitt 233
Hagen, Paul S. See Doscherholmen and Hagen *884
—. See Doscherholmen and Hagen 1551
Halden, E. Richard, Sproule, Brian J., and **Muirhead, E. E.** Peripheral arteriovenous shunting mechanisms in patients with "S" type hemoglobin *896
Hale, Henry B., Sayers, George, Sydnor, Katherine L., Sweat, Max L., and **Van Fossan, Donald D.** Blood adrenocorticotrophic hormone and plasma corticosteroids in men exposed to adverse environmental conditions 1642
Halkett, James A. E. See Chodos, Ross, Apt, Pollycove, and Halkett 314
Hamilton, William K. See Eckstein and Hamilton *886
—. See Eckstein and Hamilton 1663
Hammack, William J., Starnes, Willard R., and **Hill, S. Richardson, Jr.** Studies on the spinal fluid and serum protein electrophoretic pattern in patients with diabetes mellitus *897
Hammaker, Lydia. See Schmid, Axelrod, Hammaker, and Rosenthal *927

Hammarsten, James F., Cathey, Charles W., Redmond, Robert F., and Wolf, Stewart. Serum cholesterol diet and stress in patients with coronary artery disease *897

Hamolsky, Milton W., Ellison, Haskell E., and Freedberg, A. Stone. The thyroid hormone-plasma protein complex in man. I. Differences in different states of thyroid function 1486

Hanna, Lavelle. See JAWETZ, MITSUI, HANNA, THYGESON, and KIMURA *905

Harris, P. See FRITTS, HARRIS, CLAUSS, and COURNAND *890

Hatten, Betty. See BRAUDE, BONE, WAGGONER, and HATTEN *876

Havel, Richard J. Early effects of fat ingestion on lipids and lipoproteins of serum in man 848

—. Early effects of fasting and of carbohydrate ingestion on lipids and lipoproteins of serum in man 855

—. See BAXTER, GOODMAN, and HAVEL *873

Hawley, Robert L. See GENSINI, ROGER, HAWLEY, and MIDDLEBROOK *892

Hawrylko, Josephine. See ELIEL, SMITH, and HAWRYLKO *887

Haynes, Florence W. See NOVACK, SCHLANT, HAYNES, and PHINNEY *917

Hays, R. M. See COMBES, PREEDY, WHEELER, HAYS, and BRADLEY 860

Heath, Joseph M. See HECHT, HEATH, MAIER, LANGE, and NELSON *897

Hecht, Hans H., Heath, Joseph M., Maier, Eugene S., Lange, Ramon L., and Nelson, Clifford V. The cellular basis for the electrocardiographic changes associated with alterations in serum potassium *897

Hellman, Leon, Rosenfeld, Robert S., Insull, William, Jr., and Ahrens, Edward H., Jr. Intestinal excretion of cholesterol: A mechanism for regulation of plasma levels *898

Hendrikx, Achiel. See EPSTEIN, KLEEMAN, and HENDRIKX 629

—. See EPSTEIN, KLEEMAN, PURSEL, and HENDRIKX 635

Henneman, Dorothy H., and Vandam, Leroy D. Alterations in phosphorus metabolism during general anesthesia in man *898

—. See MCDERMOTT, HENNEMAN, and LAUMONT *913

Henneman, Philip H., and Baker, William H. Two mechanisms of sustained hypercalcemia following hypervitaminosis D and the milk-alkali syndrome *899

Hennessey, Marion, Finch, Clement A., and Gabrio, Beverly Wescott. Erythrocyte preservation. VIII. Metabolic degradation of nucleosides *in vitro* and *in vivo* 429

Hershberger, Robert L. See ALEXANDER, MISE, DENNIS, and HERSHBERGER *869

Hertz, R., Bergenstal, D. M., Lubs, H. A., and Jackson, S. J. The suppression of hyperadrenocorticism by amphenone in man *899

Hess, Eugene L., Coburn, Alvin F., Bates, Richard C., and Murphy, Priscilla. A new method for measuring sialic acid levels in serum and its application to rheumatic fever 449

Hiatt, Howard H., and Thompson, David D. The effects of parathyroid extract on renal function in man 557

—, and **Thompson, David D.** Some effects of intravenously administered calcium on inorganic phosphate metabolism 573

—. The pentose phosphate pathway in human metabolism *899

—. Studies of ribose metabolism. I. The pathway of nucleic acid ribose synthesis in a human carcinoma cell in tissue culture 1408

—. See THOMPSON and HIATT 550

—. See THOMPSON and HIATT 566

Hickam, J. B., and Frayser, R. Estimation of the retinal venous blood oxygen in man by photographic means *899

—. See BONDURANT, HICKAM, and ISLEY 59

Higgins, John A., Lee, Philip R., Scholer, John F., Reitemeier, Richard J., Code, Charles F., and Wollaeger, Eric E. Absorption of water and sodium from the small intestine of patients with nontropical sprue 265

Higginson, J., Keeley, K. J., Andersson, M., and Walker, A. R. P. Serum iron levels in siderosis due to habitually excessive iron intake 1723

Hill, S. Richardson, Jr. See HAMMACK, STARNES, and HILL *897

Hilleman, M. R., Hodges, R. E., Warfield, M. S., and Anderson, S. A. Acute respiratory illness in volunteers following intramuscular administration of live adenovirus 1072

Hinz, Carl F., Jr. The effect of an antibody to properdin on hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) *900

Hirschowitz, B. I., Streeten, D. H. P., London, J. A., and Pollard, H. M. Effects of eight-hour intravenous infusions of ACTH and the adrenocortical steroids in normal man. I. Basal gastric secretion, and plasma and urinary pepsinogen 1171

Ho, Monto, and Kass, Edward H. A plasma factor that protects against the lethal action of endotoxin *900

Hodges, R. E. See HILLEMAN, HODGES, WARFIELD, and ANDERSON 1072

Hogness, John R., Lee, Norman D., Berg, Margaret, and Williams, Robert H. The concentration and binding of thyroxine and triiodothyronine by rat diaphragm 803

Holaday, Duncan A., Ma, Dorothy, and Papper, E. M. The immediate effects of respiratory depression on acid-base balance in anesthetized man 1121

Holburn, R. R. See CARROLL and HOLBURN *878

Holland, James F., Brenner, Robert, Rock, Elton, and Danielson, Ethel. The effect of induced hypocalcemia on urinary phosphorus excretion in dogs *901

Hollander, W., and Chobanian, A. V. Further studies in electrolyte and water metabolism in cardiac patients without peripheral edema *901

—, and **Judson, Walter E.** Electrolyte and water excretion in arterial hypertension. I. Studies in nonmedically treated subjects with essential hypertension 1460

Hollander, Walter, Jr., Williams, T. Franklin, Fordham, Christopher C., III, and Welt, Louis G. A study of the quantitative relationship between antidiuretic hormone (vasopressin) and the renal tubular reabsorption of water 1059

Hollifield, Guy, and **Parson, William.** Studies of the satiety response in mice 1638
Hopper, C. L. See LIPSKY, HAAVIK, HOPPER, and MCDIVITT 233
Horwitz, William A. See CHRISTY, LONGSON, HORWITZ, and KNIGHT 543
Hougie, Cecil, Barrow, Emily M., and **Graham, John B.** Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called "stable factor" (SPCA, proconvertin, factor VII) deficiency 485
—. See GRAHAM, BARROW, and HOUGIE 497
Huff, Rex L., Parrish, Daniel, and **Crockett, Wayne.** Pulmonary and cardiac blood volumes of patients with and without heart disease *901
Hulet, William H. See BALDWIN, BIGGS, and HULET *871
Hultgren, Herbert, and **Leo, Thomas.** Gallop rhythm in mitral valve disease *902
Husson, George, and **Otis, A. B.** Adaptive value of respiratory adjustments to shunt hypoxia and to altitude hypoxia 270
Hyer, Harry. See CRISPELL, COLEMAN, and HYER *881

I

Iacono, Jack M. See MUELLER, IACONO, and FORBES *917
Iber, Frank L., and **Chalmers, Thomas C.** Biochemical observations on the use of L-glutamic acid in the treatment of hepatic coma 706
—. See FREMONT-SMITH, IBER, and PLOUGH 1313
Ingbar, Sidney H. See FREINKEL, INGBAR, and DOWLING 25
Ingelfinger, Franz J. See ATKINSON, KRAMER, WYMAN, and INGELFINGER 581
—. See KRAMER, ATKINSON, WYMAN, and INGELFINGER 589
Insull, William, Jr. See HELLMAN, ROSENFELD, INSULL, and AHRENS *898
Isaacs, Marian. See PERMUTT, ISAACS, and VARNAUSKAS *919
Isley, Joseph K. See BONDURANT, HICKAM, and ISLEY 59
Isselbacher, Kurt J. Evidence for an accessory pathway of galactose metabolism in man *902
Izzo, M. J. See ALTMAN, TABECHIAN, YOUNG, IZZO, MURPHY, and ROBERTS *869

J

Jackson, S. J. See HERTZ, BERGENSTAL, LUBS, and JACKSON *899
Jacobson, Leon O. See GURNEY, GOLDWASSER, JACOBSON, and PAN *896
Jacox, Ralph F. Characteristics of a previously unidentified protein present in normal rat serum *902
Jaenike, John R., and **Waterhouse, Christine.** Cellular and extracellular alterations in heart failure: Studies during diuresis *903
Jaffé, Ernst R., Vanderhoff, Grace A., Lowy, Bertram A., and **London, Irving M.** The effect of nucleosides on osmotic resistance of mammalian erythrocytes in relation to the age of the cells *903
—, **Lowy, Bertram A., Vanderhoff, Grace A., Aisen, Philip A.,** and **London, Irving M.** The effects of nucleosides on the resistance of normal human erythrocytes to osmotic lysis 1498
Jager, B. V. Serum atropinase *903
Jailer, Joseph W., Longson, Donald, and **Christy, Nicholas P.** Studies in Cushing's syndrome. II. Adrenal weight-maintaining activity in the plasma of patients with Cushing's syndrome 1608
James, G. Watson, III, and **Riskin, Lois.** Vitamin B_{12} activity of leukemic sera and tissues *904
Jandl, James H. Pyrogenic and leukopenic effects of immune hemolysis in man *904
—, **Jones, A. Richardson,** and **Castle, William B.** The destruction of red cells by antibodies in man. I. Observations on the sequestration and lysis of red cells altered by immune mechanisms 1428
Janowitz, Henry D., and **Dreiling, David A.** Mechanisms of pancreatic secretion of electrolytes in man: The effects of Diamox® and disease *904
Jawetz, Ernest, Mitsui, Yukihiko, Hanna, Lavelle, Thygeson, Phillips, and **Kimura, Samuel.** Etiology of epidemic keratoconjunctivitis *905
Jefferies, W. McK., Levy, R. P., Kelly, L. W., Jr., and **Cooper, G.** The response of diffuse hyperfunctioning goiter to thyrotropin *905
Jensen, Donna R. See GOOD, ZAK, JENSEN, and PAPPENHEIMER *894
Jensen, Wallace N., Rucknagel, Donald L., and **Taylor, W. Jape.** Arterial oxygen unsaturation and possible mechanisms of its production in sickle cell anemia *905
Johnson, Alan J. See FLETCHER and JOHNSON *888
Johnson, Ben B., Lieberman, Amos H., and **Mulrow, Patrick J.** Aldosterone excretion in normal subjects depleted of sodium and potassium 757
Jones, A. Richardson. See JANDL, JONES, and CASTLE 1428
Jones, Hardin B. See WHITE and JONES *936
Judson, Walter E. See HOLLANDER and JUDSON 1460

K

Kabat, Elvin A., Turino, Gerard M., Tarrow, Arthur B., and **Maurer, Paul H.** Studies on the immunochemical basis of allergic reactions to dextran in man 1160
Kaegi, Jeremias H. R. See VALLEE, WACKER, and KAEGI *933
Kako, K., and **Cabrera, G.** The contractility of actomyosin bands prepared from human heart muscle *906
Kark, Robert M. See POLLAK, NETTLES, PIRANI, KARK, and BONTING *920
Kass, Edward H. See GREENBERG, KASS, and CASTLE 833
—. See Ho and KASS *900
Katz, Jay H. See WESSLER, BALLON, and KATZ *935
Katz, Ricardo, Ducci, Héctor, and **Alessandri, Hernán.** Influence of cortisone and prednisolone in hyperbilirubinemia 1370
Keeley, K. J. See HIGGINSON, KEELEY, ANDERSSON, and WALKER 1723
Keen, T. See PATTERSON, WARREN, DOYLE, GAUER, KEEN, and GOETZ *919

Kelly, K. H. See BIERMAN, KELLY, BYRON, RATTUNDE, and CORDES *875
Kelly, L. W., Jr. See JEFFERIES, LEVY, KELLY, and COOPER *905
Kendall, Forrest E. See RUDMAN and KENDALL 530
—. See RUDMAN and KENDALL 538
Kenis, Y. See BERTINCHAMPS, KENIS, and TAGNON *874
Kennedy, Charles, and Sokoloff, Louis. An adaptation of the nitrous oxide method to the study of the cerebral circulation in children; Normal values for cerebral blood flow and cerebral metabolic rate in childhood 1130
Kessler, R. H., Lozano, R., and Pitts, R. F. Studies on structure diuretic activity relationships of organic compounds of mercury 656
Keys, Ancel. See ANDERSON, LAWLER, and KEYS 81
Kibler, Robert F., and Taylor, W. Jape. The effects of muscular exercise on net splanchnic glucose production (NSGP) in man *906
Kimura, Samuel. See JAWETZ, MITSUI, HANNA, THYGESON, and KIMURA *905
Kirkendall, Walter M. See CULBERTSON, ECKSTEIN, KIRKENDALL, and BEDELL 1537
Klatskin, Gerald, and Tisdale, William Allan. The effects of experimental hepatobiliary disease on certain aspects of tocopherol metabolism in the rat 1627
Kleeman, Charles R. See EPSTEIN, KLEEMAN, and HENDRIKX 629
—. See EPSTEIN, KLEEMAN, PURSEL, and HENDRIKX 635
Kleinerman, Jerome. See WEBSTER and KLEINERMAN *934
Knight, Mary M. See CHRISTY, LONGSON, HORWITZ, and KNIGHT 543
Knight, Vernon, and White, Arthur. Effect of mycobacteriophage on mycobacteria *in vivo* *906
Knowlton, Abbie I., and Loeb, Emily N. Depletion of carcass potassium in rats made hypertensive with desoxycorticosterone acetate (DCA) and with cortisone 1295
Korst, Donald R. See SCHLOESSER, KORST, CLATANOFF, and SCHILLING 1470
Kory, Ross C., Watson, Robert N., Bradley, Matthew H., and Peters, Bruno J. A six-month evaluation of an anabolic drug, norethandrolone, in chronically underweight individuals *907
Kramer, Philip, Atkinson, Michael, Wyman, Stanley M., and Ingelfinger, Franz J. The dynamics of swallowing. II. Neuromuscular dysphagia of pharynx 589
—. See ATKINSON, KRAMER, WYMAN, and INGELFINGER 581
Kunkel, H. G., Ceppellini, R., Müller-Eberhard, U., and Wolf, J. Observations on the minor basic hemoglobin component in the blood of normal individuals and patients with thalassemia 1615
—. See FUDENBERG and KUNKEL *891
Kuo, Peter T., and Whereat, Arthur F. Factors in the genesis of pulsus bisferiens *907
—, **Schnabel, Truman G., Jr., Blakemore, William S., and Whereat, Arthur F.** Diastolic gallop sounds, the mechanism of production 1035

L

LaDu, Bert N. See SEEGMILLER, LADU, ZANNONI, and LASTER *928
Lambie, Anne T. See RELMAN, LAMBIE, BURROWS, and ROY 1249
Lange, Ramon L. See HECHT, HEATH, MAIER, LANGE, and NELSON *897
Lanman, John. See LEACH, MADDOCK, PAULSEN, LANMAN, and NELSON *909
Laragh, John H., and Stoerk, Herbert C. A study of the mechanism of secretion of the sodium-retaining hormone (aldosterone) 383
Larson, Frank C. See PRICE, BROWN, and LARSON 1600
Larson, Paul U. See WERK, GIUSEFFI, LARSON, ELLIOTT, and OIKAWA *935
Lasagna, Louis. The pharmacology of the placebo *907
Laster, Leonard, Seegmiller, J. E., Stetten, DeWitt, Jr., and Liddle, Lois V. Uric acid formation in patients with gout. The incorporation of 4-amino-5-imidazolecarboxamide-6^{13} into uric acid *908
—. See SEEGMILLER, LADU, ZANNONI, and LASTER *928
Laszlo, Daniel. See SPENCER, LASZLO, and BROTHERS 680
Lathem, Willoughby, and Benjamin, Alvin D. Urinary hemoglobin excretion and renal circulatory dynamics: A study of the effect of l-norepinephrine in the dog 89
—. The renal transport of hemoglobin in renal disease *908
Laumont, Claude. See MCDERMOTT, HENNEMAN, and LAUMONT *913
Lawler, Adrian. See ANDERSON, LAWLER, and KEYS 81
Lawlor, Dolores. See OSSERMAN, GRAFF, MARSHALL, LAWLOR, and GRAFF 352
Lawrence, H. S., and Pappenheimer, A. M., Jr. Effect of specific antigen on release from human leucocytes of the factor concerned in transfer of delayed hypersensitivity *908
Lawrence, Walter, Jr. See SCHWARTZ, LAWRENCE, and ROBERTS *927
Layrisse, Miguel. See ROCHE, PEREZ-GIMENEZ, LAYRISSE, and DI PRISCO 1183
Leach, Robert B., Maddock, William O., Paulsen, C. Alvin, Lanman, John, and Nelson, Warren O. Positive response to chorionic gonadotrophin in Klinefelter's syndrome *909
Lebovits, Benjamin F. See OSTFELD and LEBOVITS *918
Lee, Norman D. See HOGNESS, LEE, BERG, and WILLIAMS 803
Lee, Philip R. See HIGGINS, LEE, SCHOLER, REITEMEIER, CODE, and WOLLAEGER 265
Leevy, Carroll M. Effects of prednisone on glucose tolerance in liver disease *909
Leibman, J. See EDELMAN, LEIBMAN, O'MEARA, and BIRKENFELD *886
Lemon, Henry M., Mueller, Julius H., III, Chasen, William H., and Looney, Joseph M. Citric acid metabolism in bone and joint disease *909
Lenobel, Abraham. See CHESLEY and LENOBEL 327
Leo, Thomas. See HULTGREN and LEO *902
Leonard, James J., Weissler, Arnold M., and Warren, James V. The mechanism of the auricular gallop *910

—. See WEISSLER, LEONARD, and WARREN 1656
Levinsky, Norman G. See DAVIDSON, LEVINSKY, and BERLINER *882
Levitin, Howard, Branscome, William, and **Epstein, Franklin H.** The genesis of hypochloremia in chronic respiratory acidosis *910
Levy, R. P. See JEFFERIES, LEVY, KELLY, and COOPER *905
Lewis, Jessica H., and **Didisheim, Paul.** An immunological approach to problems of blood coagulation *910
Liddle, Lois V. See LASTER, SEEGMILLER, STETTEN, and LIDDLE *908
Lieberman, Amos H., and **Luetscher, John A., Jr.** Stimulation of adrenocortical secretions after air encephalography *911
—. See JOHNSON, LIEBERMAN, and MULROW 757
Lilienfield, Lawrence S. See FREIS, SCHNAPER, and LILIENFIELD 245
Lind, John. See DANCIS, BRAVERMAN, and LIND 398
Lipkin, Martin, and **Sleisenger, Marvin H.** Quantitative aspects of the stimulus resulting in pain in esophagus, small and large intestines *911
Lipsett, Mortimer B., and **Pearson, Olof H.** Metabolic studies of sodium depletion in adrenalectomized humans *911
Lipsky, S. R., Haavik, A., Hopper, C. L., and **McDivitt, R. W.** The biosynthesis of the fatty acids of the plasma of man. I. The formation of certain chromatographically separated higher fatty acids of the major lipide complexes from acetate-1-C^{14} 233
Loeb, Emily N. See KNOWLTON and LOEB 1295
London, Irving M. See JAFFÉ, VANDERHOFF, LOWY, and LONDON *903
—. See JAFFÉ, LOWY, VANDERHOFF, AISEN, and LONDON 1498
London, J. A. See HIRSCHOWITZ, STREETEN, LONDON, and POLLARD 1171
Longman, Doris. See OLSON, VESTER, GURSEY, and LONGMAN *917
Longson, Donald. See CHRISTY, LONGSON, HORWITZ, and KNIGHT 543
—. See JAILER, LONGSON, and CHRISTY 1608
Loomis, L. N. See DAVIDSON, SJOERDSMA, LOOMIS, and UDENFRIEND 1594
Looney, Joseph M. See LEMON, MUELLER, CHASEN, and LOONEY *909
Lo Pilato, Edith V. See CAMPBELL and LO PILATO *878
Love, W. D., and **Burch, G. E.** A study in dogs of methods suitable for estimating the rate of myocardial uptake of Rb^{86} in man, and the effect of 1-norepinephrine and Pitressin® on Rb^{86} uptake 468
—, and **Burch, G. E.** Differences in the rate of Rb^{86} uptake by several regions of the myocardium of control dogs and dogs receiving 1-norepinephrine or Pitressin® 479
Lowell, Francis C. See BURROWS, PETERS, and LOWELL 393
Lowry, P. T. See GILBERTSEN and LOWRY *893
Lowy, Bertram A. See JAFFÉ, VANDERHOFF, LOWY, and LONDON *903
—. See JAFFÉ, LOWY, VANDERHOFF, and LONDON 1498
Lozano, R. See KESSLER, LOZANO, and PITTS 656
Lubs, H. A. See HERTZ, BERGENSTAL, LUBS, and JACKSON *899
Ludwig, G. D., Blakemore, W. S., and **Drabkin, D. L.** Production of carbon monoxide by hemin oxidation *912
Luetscher, John A., Jr. See LIEBERMAN and LUETSCHER *911
Lund, Charles C. See MCMENAMY, LUND, and ONCLEY 1672
Lundh, G. See BORGSTRÖM, DAHLQVIST, LUNDH, and SJÖVALL 1521
Luttrell, Charles N., and **Bang, Frederick B.** A pathophysiological study of myoclonus due to a virus *912

M

Ma, Dorothy. See HOLADAY, MA, and PAPPER 1121
MacDowell, Muriel. See OLIVER and MACDOWELL 99
Maddock, William O. See LEACH, MADDOCK, PAULSEN, LANMAN, and NELSON *909
Maier, Eugene S. See HECHT, HEATH, MAIER, LANGE, and NELSON *897
Maloof, F., and **Soodak, M.** The uptake and metabolism of S^{35} labeled thiourea, thiouracil, and potassium thiocyanate by the thyroid and other tissues *912
Markley, Kehl, Bocanegra, Manuel, Morales, Guillermo, and **Chiappori, Miguel.** Oral sodium loading in normal individuals 303
Markowitz, H. See GUBLER, BROWN, MARKOWITZ, CARTWRIGHT, and WINTROBE 1208
Marks, Paul A., and **Bishop, Jonathan S.** The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of an intravenous glucose tolerance test 254
—. A relationship between human erythrocyte aging *in vivo* and the activities of glucose-6-phosphate and 6-phosphogluconic dehydrogenases *913
—, and **Feigelson, Philip.** Pathways of glycogen formation in liver and skeletal muscle in fed and fasted rats 1279
Marsh, James T. See RASMUSSEN, MARSH, and BRILL *922
Marshall, Margaret. See OSSERMAN, GRAFF, MARSHALL, LAWLOR, and GRAFF 352
Marshall, Robert. See DUBOIS and MARSHALL 1558
Martin, Christopher M., Waite, John B., and **McCullough, Norman B.** Antibody protein synthesis by lymph nodes homotransplanted to a hypogammaglobulinemic adult 405
Masouredis, S. P. See MERCHANT, MASOUREDIS, and ELLENBOGEN *914
Mauer, A. M. See ATHENS, MAUER, ASHENBRUCKER, and CARTWRIGHT *870
Maurer, Paul H. See KABAT, TURINO, TARROW, and MAURER 1160
Maxwell, George M. See ROWE, EMANUEL, MAXWELL, BROWN, CASTILLO, SCHUSTER, MURPHY, and CRUMPTON 844
Mead, J. See COOK, SUTHERLAND, SEGAL, CHERRY, MEAD, MCILROY, and SMITH 440
—. See FRANK, MEAD, and FERRIS 1680
—. See BORST, BERGLUND, WHITTENBERGER, MEAD, MCGREGOR, and COLLIER 1708
Melby, James C., DeWall, Richard A., Storey, James L., and **Egdahl, Richard H.** The production and catabolism of cortisol in experimental endotoxin shock *914

Merchant, William R., Masouredis, S. P., and Ellenbogen, Eric. The effects of heat and pasteurization on albumin preparations in particular reference to radioisotope labeled materials *914
Meroney, William H., Arney, Glen K., Segar, William E., and Balch, Henry H. The acute calcification of traumatized muscle, with particular reference to acute post-traumatic renal insufficiency 825
—, and **Rubini, M. E.** Active function of renal tubules during acute tubular necrosis *914
—. See AUSTEN, RUBINI, MERONEY, and WOLFF *870
—. See RUBINI, BLYTHE, and MERONEY *926
Merrill, John P. See REES, SCHEITLIN, POND, MCMANUS, GUILD, and MERRILL *923
Merskey, Clarence. Abnormalities of blood coagulation produced in rabbits by feeding cholesterol *915
Metcalfe, James. See CORNETT and METCALFE *880
Middlebrook, Gardner. See GENSINI, ROGER, HAWLEY, and MIDDLEBROOK *892
—. See RUSSELL, DRESSLER, and MIDDLEBROOK *926
Migeon, Claude J., Bertrand, Jean, and Wall, Patricia E. Physiological disposition of 4-C^{14}-cortisol during late pregnancy 1350
Miller, Aaron, Corbus, Howard F., and Sullivan, John F. The plasma disappearance, excretion, and tissue distribution of cobalt^{60} labelled vitamin B_{12} in normal subjects and patients with chronic myelogenous leukemia 18
—. Abnormal binding of vitamin B_{12} by sera from patients with chronic myelogenous leukemia *915
Miller, O. Neal, and Unglaub, Walter G. A study of etiology of macrocytic anemia *915
Mise, Junichi. See ALEXANDER, MISE, DENNIS, and HERSHBERGER *869
Mitchell, Jere, and Chapman, Carleton B. The relation of maximal oxygen uptake to cardiac capacity and arterial oxygen saturation in normal subjects and in patients with mitral stenosis *915
Mitsui, Yukihiko. See JAWETZ, MITSUI, HANNA, THYGESON, and KIMURA *905
Moore, Alice E. See WRÓBLEWSKI and MOORE *937
Morales, Guillermo. See MARKLEY, BOCANEGRA, MORALES, and CHIAPPORI 303
Morell, Anatol G. See SCHEINBERG and MORELL *927
—. See SCHEINBERG and MORELL 1193
Morgan, H. E., and Park, C. R. The effect of insulin, alloxan diabetes, and phlorhidzin on sugar transport across the muscle cell membrane *916
Morgan, Herbert R. See GLASGOW and MORGAN *893
Morrow, A. G. See BRAUNWALD, WELCH, SARNOFF, and MORROW *876
Morton, J. W. See OGILVIE, FORSTER, BLAKEMORE, and MORTON 1
Moschides, Elly, and Stefanini, Mario. Abnormal cholesterol metabolism in lymphoma: A comparison of findings in serum and splenic tissue *916
Mueller, John F., Iacono, Jack M., and Forbes, Allan L. Some observations of the effect on serum cholesterol of an unsaturated oil administered intravenously to normal healthy adult men *917
Mueller, Julius H., III. See LEMON, MUELLER, CHASEN, and LOONEY *909
Muirhead, E. E. See HALDEN, SPROULE, and MUIRHEAD *896
Muldowney, F. P., Crooks, J., and Bluhm, M. M. The relationship of total exchangeable potassium and chloride to lean body mass, red cell mass and creatinine excretion in man 1375
Müller-Eberhard, U. See KUNKEL, CEPPELLINI, MÜLLER-EBERHARD, and WOLF 1615
Mulrow, Patrick J. See JOHNSON, LIEBERMAN, and MULROW 757
Murdaugh, H. V., Jr. See DODGE and MURDAUGH *883
Murphy, Edward A. See SALISBURY, DUNN, and MURPHY 1227
Murphy, M. See ALTMAN, TABECHIAN, YOUNG, IZZO, MURPHY, and ROBERTS *869
Murphy, Priscilla. See HESS, COBURN, BATES, and MURPHY 449
Murphy, Q. R. See ROWE, EMANUEL, MAXWELL, BROWN, CASTILLO, SCHUSTER, MURPHY, and CRUMPTON 844

Mc

McCullough, Norman B. See MARTIN, WAITE, and MCCULLOUGH 405
McDermott, William V., Jr., Henneman, Dorothy H., and Laumont, Claude. The metabolic effects of glutamic acid and arginine in "hepatic coma" with hyperammoniemia *913
McDivitt, R. W. See LIPSKY, HAAVIK, HOPPER, and MCDIVITT 233
McGarry, E. E. See BECK, MCGARRY, DYRENFURTH, and VENNING *873
McGregor, Maurice. See BORST, BERGLUND, and MCGREGOR 669
—. See BORST, BERGLUND, WHITTENBERGER, MEAD, MCGREGOR, and COLLIER 1708
McIlroy, M. B. See COOK, SUTHERLAND, SEGAL, CHERRY, MEAD, MCILROY, and SMITH 440
McLean, Regina. See ROSENBAUM, PAPPER, COHEN, and MCLEAN 1202
McManus, Thomas J. See REES, SCHEITLIN, POND, MCMANUS, GUILD, and MERRILL *923
McMenamy, Rapier H., Lund, Charles C., and Oncley, J. Lawrence. Unbound amino acid concentrations in human blood plasmas 1672
McNeely, William F. See RAISZ, MCNEELY, SAXON, and ROSENBAUM 767
McNeill, Ronald S. See RANKIN, MCNEILL, and FORSTER *922

N

Nadell, J. See SWEET, NADELL, and EDELMAN 279
—. See GOTCH, NADELL, and EDELMAN 289
Nelken, D., Gurevitch, J., and Neuman, Z. A and B antigens in the human epidermis 749
Nelson, Clifford V. See HECHT, HEATH, MAIER, LANGE, and NELSON *897
Nelson, Don H. See BETHUNE, NELSON, and THORN 1701
Nelson, Warren O. See LEACH, MADDOCK, PAULSEN, LANMAN, and NELSON *909
Nettles, John B. See POLLAK, NETTLES, PIRANI, KARK, and BONTING *920
Neuman, Z. See NELKEN, GUREVITCH, and NEUMAN 749
Nolan, Mary F. See CHINARD, TAYLOR, NOLAN, and ENNS *879
Novack, Paul, Schlant, Robert C., Haynes, Florence W., and Phinney, Arthur O., Jr. The hemodynamics of mitral valvular disease *917
Noyes, W. D. See BOTHWELL, NOYES, and FINCH *875
Numa, Shosaku. See BALLY and NUMA *872

O

Ogilvie, C. M., Forster, R. E., Blakemore, W. S., and Morton, J. W. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide 1

Oikawa, Yoichi. See WERK, GIUSEFFI, LARSON, ELLIOTT, and OIKAWA *935
Oliver, Jean, and **MacDowell, Muriel.** The renal lesion in epidemic hemorrhagic fever 99
Olson, Robert E., Vester, John W., Gursey, Deha, and **Longman, Doris.** Effect of low protein diets upon serum cholesterol in man *917
O'Meara, M. P., Birkenfeld, L. W., Gotch, F. A., and **Edelman, I. S.** The equilibration of radiosodium (Na^{24}), radiopotassium (K^{42}), and deuterium oxide (D_2O) in hydropic human subjects 784
—. See EDELMAN, LEIBMAN, O'MEARA, and BIRKENFELD *886
Oncley, J. Lawrence. See MCMENAMY, LUND, and ONCLEY 1672
Orloff, Jack, Davidson, Douglas, and **Wagner, Henry N., Jr.** The effect of potassium on urinary dilution *918
Ørning, Karl J. See SCHWARTZ, ØRNING, and PORTER 373
Osserman, Elliott F., Graff, Ada, Marshall, Margaret, Lawlor, Dolores, and **Graff, Samuel.** Incorporation of N^{15}-l-aspartic acid into the abnormal serum and urine proteins of multiple myeloma (studies of the inter-relationship of these proteins) 352
Ostfeld, Adrian M., and **Lebovits, Benjamin F.** Personality, behavior, and vasopressor mechanisms in hypertension *918
Otis, A. B. See HUSSON and OTIS 270

P

Padilla, Ana Maria. See BURCH, ARROYAVE, SCHWARTZ, PADILLA, BÉHAR, VITERI, and SCRIMSHAW 1579
Paglia, Donald E. See CRONKITE, BOND, ROBERTSON, and PAGLIA *881
Pan, Chao. See GURNEY, GOLDWASSER, JACOBSON, and PAN *896
Pappenheimer, A. M., Jr. See GOOD, ZAK, JENSEN, and PAPPENHEIMER *894
—. See LAWRENCE and PAPPENHEIMER *908
Papper, E. M. See HOLADAY, MA, and PAPPER 1121
Papper, Solomon, Saxon, Lawrence, Burg, Maurice B., Seifer, Harold W., and **Rosenbaum, Jack D.** The effect of morphine upon the renal excretion of water and solute in man *918
—. See ROSENBAUM, PAPPER, COHEN, and MCLEAN 1202
Parisi, A. See CRAWFORD, CUSHMAN, PARISI, and TERRY *880
Park, C. R. See MORGAN and PARK *916
Parrish, Daniel. See HUFF, PARRISH, and CROCKETT *901
Parson, William. See HOLLIFIELD and PARSON 1638
Patterson, J. L., Jr., Warren, J. V., Doyle, J. T., Gauer, O., Keen, T., and **Goetz, R. H.** Circulation and respiration in the giraffe *919
Paulsen, C. Alvin. See LEACH, MADDOCK, PAULSEN, LANMAN, and NELSON *909
Payne, R. W. See STIDWORTHY, PAYNE, SHETLAR, and SHETLAR 309
Pearson, Olof H. See LIPSETT and PEARSON *911
Pechet, Maurice M. Physiological activities as a function of chemical structure of anabolic and anti-anabolic steroids in man *919
—. See DAVIS, PECHET, BALL, and GOODKIND 689
Perez-Gimenez, Maria Enriqueta. See ROCHE, PEREZ-GIMENEZ, LAYRISSE, and DI PRISCO 1183
Perlmutter, Martin. See WEISSMAN and PERLMUTTER 780
Permutt, Solbert, Isaacs, Marian, and **Varnauskas, Edvardas.** The influence of arm circulation on clinical circulation-time measurements *919
Perry, Seymour M. See BORUN, FIGUEROA, and PERRY 676
Perry, William D. See DENNY, PERRY, and WANNAMAKER 1092
Pert, James H. See ENGLE, WOODS, and PERT *888
—. See SLEISENGER and PERT *930
Petermann, Mary L. See ROBBINS, RALL, and PETERMANN 1333
Peters, Bruno J. See KORY, WATSON, BRADLEY, and PETERS *907
Peters, Theodore. See BURROWS, PETERS, and LOWELL 393
Peterson, Ralph E. Studies in adrenocortical function in liver disease *920
—, **Pierce, Charles E., Wyngaarden, James B., Bunim, Joseph J.,** and **Brodie, Bernard B.** The physiological disposition and metabolic fate of cortisone in man 1301
Phinney, Arthtur O., Jr. See NOVACK, SCHLANT, HAYNES, and PHINNEY *917
Pierce, Charle E. See PETERSON, PIERCE, WYNGAARDEN, BUNIM, and BRODIE 1301
Pirani, Conrad L. See POLLAK, NETTLES, PIRANI, KARK, and BONTING *920
Pitts, R. F. See KESSLER, LOZANO, and PITTS 656
Plough, Irvin C. See FREMONT-SMITH, IBER, and PLOUGH 1313
Pollak, Victor E., Nettles, John B., Pirani, Conrad L., Kark, Robert M., and **Bonting, Sjoerd L.** Serial renal biopsies in toxemia of pregnancy *920
Pollard, H. M. See HIRSCHOWITZ, STREETEN, LONDON, and POLLARD 1171
Pollycove, Myron. See CHODOS, ROSS, APT, POLLYCOVE, and HALKETT 314
—. See APT, POLLYCOVE, and ROSS 1150
Pond, John C. See REES, SCHEITLIN, POND, MCMANUS, GUILD, and MERRILL *923
Porter, Richard. See SCHWARTZ, ØRNING, and PORTER 373
Portwood, Richard M., Seldin, Donald W., Rector, Floyd C., Jr., and **Cade, Robert.** Relation of filtered bicarbonate to bicarbonate excretion during Diamox® administration *920
Poutasse, Eugene F. See DUSTAN and POUTASSE *885
Preedy, J. R. K. See COMBES, PREEDY, WHEELER, HAYS, and BRADLEY 860
Price, J. M., Brown, R. R., and **Larson, Frank C.** Quantitative studies on human urinary metabolites of tryptophan as affected by isoniazid and deoxypyridoxine 1600
Prout, Thaddeus E., Weaver, John A., Scott, George W., and **Asper, Samuel P., Jr.** The hypoglycemic properties of dimercaprol (BAL) *921
Pursel, Stewart. See EPSTEIN, KLEEMAN, PURSEL, and HENDRIKX 635

Q

Quinn, Robert W. The response of rheumatic and non-rheumatic children to streptolysin O concentrate 793

R

Raben, M. S. Preparation of growth hormone from human pituitaries *921
Rabinowitz, Murray, Esterbrook, Ronald, and **De-Bernard, Benedetto.** Kinetic spectrophotometric studies of a DPNH-succinate cytochrome *c* reductase from heart muscle *921
Raisz, Lawrence G., McNeely, William F., Saxon, Lawrence, and **Rosenbaum, Jack D.** The effects of cortisone and hydrocortisone on water diuresis and renal function in man 767
Rakita, Louis. See SANCETTA and RAKITA 1138
Rall, J. E. See ROBBINS and RALL *923
—. See ROBBINS, RALL, and PETERMANN 1333
Rankin, John, McNeill, Ronald S., and **Forster, Robert E.** Diffusion characteristics of the pulmonary membrane and capillary bed in various diseases of the lungs and cardiovascular system *922
Ranney, Helen M. See GLUECKSOHN-WAELSCH, RANNEY, and SISKEN 753
Rasmussen, A. F., Jr., Marsh, James T., and **Brill, Norman Q.** Increased susceptibility to viral infection induced experimentally by psychophysiologic stress *922
Rattunde, H. See BIERMAN, KELLY, BYRON, RATTUNDE, and CORDES *875
Recant, Lillian, and **Fischer, George L.** An hepatic mechanism for tolbutamide hypoglycemia in animal and human subjects *922
Reckers, Lois. See TUNA, RECKERS, and FRANTZ *932
Rector, Floyd C., Jr. See PORTWOOD, SELDIN, RECTOR, and CADE *920
Redmond, Robert F. See HAMMARSTEN, CATHEY, REDMOND, and WOLF *897
Rees, Searle B., Scheitlin, Walter G., Pond, John C., McManus, Thomas J., Guild, Warren R., and **Merrill, John P.** Effect of dialysis and purine ribosides upon the anemia of uremia *923
Reitemeier, Richard J. See HIGGINS, LEE, SCHOLER, REITEMEIER, CODE, and WOLLAEGER 265
Relman, Arnold S., and **Schwartz, William B.** Electrolyte balance and acid-base metabolism in primary aldosteronism *923
—, **Lambie, Anne T., Burrows, Belton A.,** and **Roy, Arlene M.** Cation accumulation by muscle tissue: The displacement of potassium by rubidium and cesium in the living animal 1249
Renold, Albert E. See FROESCH, WINEGRAD, and RENOLD *890
Richter, M. See SEHON, GYENES, GORDON, RICHTER, and ROSE 456
Ringgold, Kathryn. See CARBONE, SBOROV, FANSKA, and RINGGOLD *878
Riskin, Lois. See JAMES and RISKIN *904
Robbins, Jacob, and **Rall, J. E.** Physiological implications of thyroxine-binding by serum proteins *923
—, **Rall, J. E.,** and **Petermann, Mary L.** Thyroxine-binding by serum and urine proteins in nephrosis. Qualitative aspects 1333
Roberts, G. See ALTMAN, TABECHIAN, YOUNG, IZZO, MURPHY, and ROBERTS *869
Roberts, Kathleen E. See SCHWARTZ, LAWRENCE, and ROBERTS *927
Roberts, Thomas N. See DOLE, BIERMAN, and ROBERTS *884
Robertson, James S. See CRONKITE, BOND, ROBERTSON, and PAGLIA *881
Robin, Eugene D., Whaley, Robert D., Crump, Charles H., and **Travis, David M.** The nature of the respiratory acidosis of sleep and of the respiratory alkalosis of hepatic coma *924
Robson, Melba. See BEUTLER, ROBSON, and BUTTENWIESER 617
Roche, Marcel, Perez-Gimenez, Maria Enriqueta, Layrisse, Miguel, and **Di Prisco, Estela.** Study of urinary and fecal excretion of radioactive chromium Cr^{51} in man. Its use in the measurement of intestinal blood loss associated with hookworm infection 1183
Rock, Elton. See HOLLAND, BRENNER, ROCK, and DANIELSON *901
Roger, Vicente N. See GENSINI, ROGER, HAWLEY, and MIDDLEBROOK *892
Rose, B. See SEHON, GYENES, GORDON, RICHTER, and ROSE 456
Rose, John C. Pulmonary vascular responses to serotonin and the effects of serotonin antagonists *924
Rosenbaum, Jack D., Papper, Solomon, Cohen, Henry W., and **McLean, Regina.** The influence of ethanol upon maintained water diuresis in man 1202
—. See RAISZ, MCNEELY, SAXON, and ROSENBAUM 767
—. See PAPPER, SAXON, BURG, SEIFER, and ROSENBAUM *918
Rosenberg, I. N. Zone electrophoretic studies of serum alkaline phosphatase activity *924
Rosenfeld, Robert S. See HELLMAN, ROSENFELD, INSULL, and AHRENS *898
Rosenman, Ray H., and **Friedman, Meyer.** *In vivo* studies of the role of albumin in endogenous and heparin-activated lipemia-clearing in nephrotic rats 700
—. The use of albumin-heparin infusion as an antilipemic agent *925
—, **Byers, Sanford O.,** and **Friedman, Meyer.** Plasma lipid interrelationships in experimental nephrosis 1558
Rosenthal, Ira M. See SCHMID, AXELROD, HAMMAKER, and ROSENTHAL *927
Rosenthal, Sol Roy, Samet, Charles, Winzler, Richard J., and **Shkolnik, Selwyn.** Substances released from the skin following thermal injury. I. Histamine and proteins 38
Ross, Joseph F. See CHODOS, ROSS, APT, POLLYCOVE, and HALKETT 314
—. See FREIREICH, ROSS, BAYLES, EMERSON, and FINCH 1043
—. See APT, POLLYCOVE, and ROSS 1150
Rothschild, Marcus A., Bauman, Arthur, Yalow, Rosalyn S., and **Berson, Solomon A.** The effect of large doses of desiccated thyroid on the distribution and metabolism of albumin-I^{131} in euthyroid subjects 422
Rowe, George C., Emanuel, Dean A., Maxwell, George M., Brown, John F., Castillo, Cesar, Schuster, Benjamin, Murphy, Q. R., and **Crumpton, Charles W.** Hemodynamic effects of quinidine: Including studies of cardiac work and coronary blood flow 844
Roy, Arlene M. See RELMAN, LAMBIE, BURROWS, and ROY 1249
Rubin, Cyrus E. Observations on the pathogenesis of juvenile pernicious anemia *925

Rubini, M. E., Blythe, W. B., and **Meroney, W. H.** Effect of the type of urinary solute on the process of urine concentration *926
—. See AUSTEN, RUBINI, MERONEY, and WOLFF *870
—. See MERONEY and RUBINI *914
Rucknagel, Donald L. See JENSEN, RUCKNAGEL, and TAYLOR *905
Rudman, Daniel, and **Kendall, Forrest E.** Bile acid content of human serum. I. Serum bile acids in patients with hepatic disease 530
—, and **Kendall, Forrest E.** Bile acid content of human serum. II. The binding of cholanic acids by human plasma proteins 538
Russell, W. F., Jr., Dressler, S. H., and **Middlebrook, G.** Results of clinical application of certain microbiologic and metabolic observations in the chemotherapy of pulmonary tuberculosis *926

S

Sabiston, David C., Jr. See SHADLE, FERGUSON, SABISTON, and GREGG 335
Salisbury, Peter F., Dunn, Max S., and **Murphy, Edward A.** Apparent free amino acids in deproteinized plasma of normal and uremic persons 1227
Samet, Charles. See ROSENTHAL, SAMET, WINZLER, and SHKOLNIK 38
Sancetta, Salvatore M., and **Rakita, Louis.** Response of pulmonary artery pressure and total pulmonary resistance of untrained, convalescent man to prolonged mild steady state exercise 1138
Sandberg, Avery A., and **Slaunwhite, W. Roy, Jr.** Studies on phenolic steroids in human subjects. II. The metabolic fate and hepato-biliary-enteric circulation of C^{14}-estrone and C^{14}-estradiol in women 1266
Sarnoff, S. J. See BRAUNWALD, WELCH, SARNOFF, and MORROW *876
Sass, Martin, and **Spear, Paul W.** Whole blood transaminase levels in anemia *926
Saxon, Lawrence. See RAISZ, MCNEELY, SAXON, and ROSENBAUM 767
—. See PAPPER, SAXON, BURG, SEIFER, and ROSENBAUM *918
Sayers, George. See HALE, SAYERS, SYDNOR, SWEAT, and VAN FOSSAN 1642
Sborov, Victor. See CARBONE, SBOROV, FANSKA, and RINGGOLD *878
Schachter, David. The chemical estimation of acyl glucuronides and its application to studies on the metabolism of benzoate and salicylate in man 297
Scheinberg, I. Herbert, and **Morell, Anatol G.** Exchange of ceruloplasmin copper with ionic copper^{64} and its relation to Wilson's disease *927
—, and **Morell, Anatol G.** Exchange of ceruloplasmin copper with ionic CU^{64} with reference to Wilson's disease 1193
Scheitlin, Walter G. See REES, SCHEITLIN, POND, MCMANUS, GUILD, and MERRILL *923
Scheuer, James, and **Bondy, Philip K.** The effect of intravenous cortisol injections on the plasma cortisol concentration in man 67
Schilling, Robert F. See SCHLOESSER, KORST, CLATANOFF, and SCHILLING 1470
Schlant, Robert C. See NOVACK, SCHLANT, HAYNES, and PHINNEY *917
Schloesser, Lee L., Korst, Donald R., Clatanoff, Dallas V., and **Schilling, Robert F.** Radioactivity over the spleen and liver following the transfusion of chromium^{51}-labelled erythrocytes in hemolytic anemia 1470
Schmid, Rudi, Axelrod, Julius, Hammaker, Lydia, and **Rosenthal, Ira M.** Congenital defects in bilirubin metabolism *927
Schnabel, Truman G., Jr. See KUO, SCHNABEL, BLAKEMORE, and WHEREAT 1035
Schnaper, Harold W. See FREIS, SCHNAPER, and LILIENFIELD 245
Scholer, John F. See HIGGINS, LEE, SCHOLER, REITEMEIER, CODE, and WOLLAEGER 265
Schroeder, W. A. See ALLEN and SCHROEDER 1343
Schubert, Maxwell. See FARBER and SCHUBERT 1715
Schulman, Jerome L., and **Greben, Stanley E.** The effect of glucagon on the blood glucose level and the clinical state in the presence of marked insulin hypoglycemia 74
Schuster, Benjamin. See ROWE, EMANUEL, MAXWELL, BROWN, CASTILLO, SCHUSTER, MURPHY, and CRUMPTON 844
Schwartz, Arthur E., Lawrence, Walter, Jr., and **Roberts, Kathleen E.** Elevation of peripheral blood ammonia following muscular exercise *927
Schwartz, Ruth. See BURCH, ARROYAVE, SCHWARTZ, PADILLA, BÉHAR, VITERI, and SCRIMSHAW 1579
Schwartz, William B., Ørning, Karl J., and **Porter, Richard.** The internal distribution of hydrogen ions with varying degrees of metabolic acidosis 373
—. See RELMAN and SCHWARTZ *923
Scott, George W. See PROUT, WEAVER, SCOTT, and ASPER *921
Scribner, Belding H., Swanson, August G., and **Burnell, James M.** Alkalinization by gastrodialysis as a means of preventing CO_2 narcosis *928
Scrimshaw, Nevin S. See BURCH, ARROYAVE, SCHWARTZ, PADILLA, BÉHAR, VITERI, and SCRIMSHAW 1579
Seegmiller, J. E., LaDu, Bert N., Zannoni, Vincent G., and **Laster, Leonard.** The nature of the metabolic defect in alcaptonuria *928
—. See LASTER, SEEGMILLER, STETTEN, and LIDDLE *908
Segal, S. See COOK, SUTHERLAND, SEGAL, CHERRY, MEAD, MCILROY, and SMITH 440
Segal, Stanton, Wyngaarden, James B., and **Foley, Joseph.** The effect of insulin on blood levels of infused pentoses in man 1383
—. See FRAWLEY and SEGAL *889
—. See WYNGAARDEN, SEGAL, and FOLEY 1395
Segaloff, Albert, and **Steelman, Sanford.** Isolation studies on human menopausal gonadotrophins *928
Segar, William E. See MERONEY, ARNEY, SEGAR, and BALCH 825
Sehon, A. H., Gyenes, L., Gordon, J., Richter, M., and **Rose, B.** Physico-chemical and immunologic studies on macroglobulins 456
Seifer, Harold W. See PAPPER, SAXON, BURG, SEIFER, and ROSENBAUM *918
Seldin, Donald W. See PORTWOOD, SELDIN, RECTOR, and CADE *920
Selikoff, Irving J. See BADER, BADER, and SELIKOFF *871
Seraydarian, Maria W. See BOLLET, SERAYDARIAN, and TURNER *875
—. See BOLLET, SERAYDARIAN, and SIMPSON 1328

Shadle, Oscar W., Ferguson, Thomas B., Sabiston, David C., Jr., and **Gregg, Donald E.** The hemodynamic response to lanatoside C of dogs with experimental aortic-caval fistulas 335
Sheps, Sheldon G. See GORDON and SHEPS *894
Shetlar, Clara L. See STIDWORTHY, PAYNE, SHETLAR, and SHETLAR 309
Shetlar, M. R. See STIDWORTHY, PAYNE, SHETLAR, and SHETLAR 309
Shkolnik, Selwyn. See ROSENTHAL, SAMET, WINZLER, and SHKOLNIK 38
Shock, Nathan W. See SILVERSTONE, BRANDFONBRENER, SHOCK, and YIENGST 504
Shorr, Ephraim. See WHEDON and SHORR 941
—. See WHEDON and SHORR 966
—. See WHEDON and SHORR 982
—. See WHEDON and SHORR 995
Shulman, N. Raphael. A model for an immunoreaction involving antibody, haptene, platelets, and complement, in quinidine purpura *929
Sidbury, James B., Jr. The enzymatic lesions in galactosemia *929
Silverstone, Felix A., Brandfonbrener, Martin, Shock, Nathan W., and **Yiengst, Marvin J.** Age differences in the intravenous glucose tolerance tests and the response to insulin 504
Simpson, William F. See BOLLET, SERAYDARIAN, and SIMPSON 1328
Singer, R. B. See BARKER, SINGER, ELKINTON, and CLARK 515
Siperstein, Marvin D., and **Fagan, Violet M.** The role of glucose oxidation in the synthesis of cholesterol and fatty acids *929
Sisken, Betty F. See GLUECKSOHN-WAELSCH, RANNEY, and SISKEN 753
Sjoerdsma, A. See DAVIDSON, SJOERDSMA, LOOMIS, and UDENFRIEND 1594
Sjövall, J. See BORGSTRÖM, DAHLQVIST, LUNDH, and SJÖVALL 1521
Slaunwhite, W. Roy, Jr. See SANDBERG and SLAUNWHITE 1266
Sleisenger, Marvin H., and **Pert, James H.** Esophageal catheterization studies—The mechanism of swallowing in normal subjects and patients with dysphagia with particular reference to the esophago-gastric sphincter (vestibule) *930
—. See LIPKIN and SLEISENGER *911
Slingerland, D. Ward, and **Burrows, Belton A.** The estimation of non-thyroxine iodine released by the thyroid gland in hyperthyroidism *930
Smith, C. A. See COOK, SUTHERLAND, SEGAL, CHERRY, MEAD, MCILROY, and SMITH 440
Smith, Richard T., and **Von Korff, Richard W.** A heparin-precipitable fraction of human plasma. I. Isolation and characterization of the fraction 596
—. A heparin-precipitable fraction of human plasma. II. Occurrence and significance of the fraction in normal individuals and in various disease states 605
—, **Braude, Abraham I.,** and **Carey, Francis J.** The distribution of Cr^{51} labeled *E. coli* endotoxin in the generalized Shwartzman reaction 695
Smith, William O. See ELIEL, SMITH, and HAWRYLKO *887
Sokoloff, Louis. See KENNEDY and SOKOLOFF 1130
Soodak, M. See MALOOF and SOODAK *912
Spear, Paul W. See SASS and SPEAR *926
Spencer, Herta, Laszlo, Daniel, and **Brothers, Milton.** Strontium^{85} and calcium^{45} metabolism in man 680
Sproule, Brian J. See HALDEN, SPROULE, and MUIRHEAD *896
Stahlman, Mildred T. Pulmonary ventilation and diffusion in the human newborn infant 1081
Stamler, Jeremiah. See DREIFUS and STAMLER *885
Stanbury, John B. See DOW, BAKER, and STANBURY *884
Starnes, Willard R. See HAMMACK, STARNES, and HILL *897
Stauffer, J. C. See BESSMAN and STAUFFER *874
Steelman, Sanford. See SEGALOFF and STEELMAN *928
Stefanini, Mario. See MOSCHIDES and STEFANINI *916
Steinfeld, Jesse L., Davidson, John D., and **Gordon, Robert S., Jr.** A mechanism for hypoalbuminemia in patients with ulcerative colitis and regional enteritis *931
Stemler, Richard S. See EBAUGH, BOVE, and STEMLER *886
Sterling, Kenneth. The rate of degradation of thyroxine in patients with thyroid disease after therapy *931
Stetten, DeWitt, Jr. See LASTER, SEEGMILLER, STETTEN, and LIDDLE *908
—. See FIELD, TIETZE, and STETTEN 1588
Stidworthy, George, Payne, R. W., Shetlar, Clara L., and **Shetlar, M. R.** Objective evaluation of patients with rheumatic diseases. II. Paper electrophoretic studies of serum glycoprotein and protein from patients with rheumatoid arthritis 309
Stoerk, Herbert C. See LARAGH and STOERK 383
Stokes, James M. See BRICKER, BERNARD, and STOKES *876
Storey, James L. See MELBY, DEWALL, STOREY, and EGDAHL *914
Streeten, D. H. P. See HIRSCHOWITZ, STREETEN, LONDON, and POLLARD 1171
Sullivan, Benjamin H. See CROSBY and SULLIVAN *881
Sullivan, John F. See MILLER, CORBUS, and SULLIVAN 18
Summerskill, W. H. J., Wolfe, Stanley J., and **Davidson, Charles S.** The metabolism of ammonia and α-keto-acids in liver disease and hepatic coma 361
Sutherland, J. M. See COOK, SUTHERLAND, SEGAL, CHERRY, MEAD, MCILROY, and SMITH 440
Swanson, August G. See SCRIBNER, SWANSON, and BURNELL *928
Sweat, Max L. See HALE, SAYERS, SYDNOR, SWEAT, and VAN FOSSAN 1642
Sweet, N. J., Nadell, J., and **Edelman, I. S.** Gastrointestinal water and electrolytes. III. The equilibration of radiobromide in gastrointestinal contents and the proportion of exchangeable chloride (Cl_e) in the gastrointestinal tract 279
Sydnor, Katherine L. See HALE, SAYERS, SYDNOR, SWEAT, and VAN FOSSAN 1642

T

Tabechian, H. See ALTMAN, TABECHIAN, YOUNG, IZZO, MURPHY, and ROBERT. *869
Tagnon, Henry J. See BERTINCHAMPS, KENIS, and TAGNON *874
Tarrow, Arthur B. See KABAT, TURINO, TARROW, and MAURER 1160

Taylor, W. Jape. See JENSEN, RUCKNAGEL, and TAYLOR *905
—. See KIBLER and TAYLOR *906
Taylor, W. Rowland. See CHINARD, TAYLOR, NOLAND, and ENNS *879
Terepka, A. Raymond. See TORIBARA, TEREPKA, and DEWEY 738
Terry, M. L. See CRAWFORD, CUSHMAN, PARISI, and TERRY *880
Thomas, E. Donnall. Observations on deoxyribonucleic acid synthesis by human bone marrow cells *in vitro* *931
Thompson, David D., and **Hiatt, Howard H.** Renal reabsorption of phosphate in normal human subjects and in patients with parathyroid disease 550
—, and **Hiatt, Howard H.** Effects of phosphate loading and depletion on the renal excretion and reabsorption of inorganic phosphate 566
—. See HIATT and THOMPSON 557
—. See HIATT and THOMPSON 573
Thorn, George W. See BETHUNE, NELSON, and THORN 1701
Thygeson, Phillips. See JAWETZ, MITSUI, HANNA, THYGESON, and KIMURA *905
Tietze, Frank. See FIELD, TIETZE, and STETTEN 1588
Tisdale, William Allan. See KLATSKIN and TISDALE 1627
Tomkins, Gordon M. Studies on a physiologically important enzymatic reaction: Adrenal 11-β-hydroxylation *932
Toribara, T. Y., Terepka, A. Raymond, and **Dewey, Priscilla A.** The ultrafiltrable calcium of human serum. I. Ultrafiltration methods and normal values 738
Travis, David M. See ROBIN, WHALEY, CRUMP, and TRAVIS *924
Troen, Philip, and **Gordon, Edwin E.** Perfusion studies of the human placenta: Hormonal effects on citric acid metabolism *932
Tuna, Naip, Reckers, Lois, and **Frantz, Ivan D., Jr.** The fatty acids of normal plasma and of arteriosclerotic plaques *932
Turino, Gerard M. See KABAT, TURINO, TARROW, and MAURER 1160
Turner, Rachel E. See BOLLET, SERAYDARIAN, and TURNER *875

U

Udenfriend, S. See WAALKES, WEISSBACH, BOZECEVICH, and UDENFRIEND 1115
—. See DAVIDSON, SJOERDSMA, LOOMIS, and UDENFRIEND 1594
Unglaub, Walter G. See MILLER and UNGLAUB *915

V

Vallee, Bert L., Wacker, Warren E. C., and **Kaegi, Jeremias H. R.** Zinc metabolism in post-alcoholic cirrhosis *933
Vandam, Leroy D. See HENNEMAN and VANDAM *898
Vanderhoff, Grace A. See JAFFÉ, VANDERHOFF, LOWY, and LONDON *903
—. See JAFFÉ, LOWY, VANDERHOFF, AISEN, and LONDON 1498
Van Fossan, Donald B. See HALE, SAYERS, SYDNOR, SWEAT, and VAN FOSSAN 1642
Varnauskas, Edvardas. See PERMUTT, ISAACS, and VARNAUSKAS *919
Venning, E. H. See BECK, MCGARRY, DYRENFURTH, and VENNING *873
Vester, John W. See GORLIN, BOZER, and VESTER *895
—. See OLSON, VESTER, GURSEY, and LONGMAN *917
Viteri, Fernando. See BURCH, ARROYAVE, SCHWARTZ, PADILLA, BÉHAR, VITERI, and SCRIMSHAW 1579
Von Korff, Richard W. See SMITH and VON KORFF 596

W

Waalkes, T. P., Weissbach, H., Bozicevich, J., and **Udenfriend, S.** Serotonin and histamine release during anaphylaxis in the rabbit 1115
Wacker, Warren E. C. Flame spectrometry, magnesium and the uremic state *933
—. See VALLEE, WACKER, and KAEGI *933
Waddell, William J., and **Butler, Thomas C.** The distribution and excretion of phenobarbital 1217
Waggoner, Billie. See BRAUDE, BONE, WAGGONER, and HATTEN *876
Wagner, Henry N., Jr. The influence of autonomic vasoregulatory reflexes on the rate of sodium and water excretion in man 1319
—. See ORLOFF, DAVIDSON, and WAGNER *918
Waite, John B. See MARTIN, WAITE, and MCCULLOUGH 405
Walker, A. R. P. See HIGGINSON, KEELEY, ANDERSSON, and WALKER 1723
Wall, Patricia E. See MIGEON, BERTRAND, and WALL 1350
Wallace, John. See GARCIA and WALLACE *892
Walser, Mackenzie, and **Bodenlos, Leonard J.** Urea breakdown in normal man *933
Wannamaker, Lewis W. Identification of a new group A streptococcal desoxyribonuclease: The antibody response in scarlet fever and acute rheumatic fever *934
—. See DENNY, PERRY, and WANNAMAKER 1092
Warfield, M. S. See HILLEMAN, HODGES, WARFIELD, and ANDERSON 1072
Warren, James V. See LEONARD, WEISSLER, and WARREN *910
—. See PATTERSON, WARREN, DOYLE, GAUER, KEEN, and GOETZ *919
—. See WEISSLER, LEONARD, and WARREN 1656
Waterhouse, Christine. See JAENIKE and WATERHOUSE *903
Watkin, Donald M. Depression of the total body respiratory quotient in human malignant disease *934
Watson, Robert N. See KORY, WATSON, BRADLEY, and PETERS *907
Weaver, John A. See PROUT, WEAVER, SCOTT, and ASPER *921
Webster, Leslie T., Jr., and **Kleinerman, Jerome.** Effect of a carbonic anhydrase inhibitor, acetazolamide (Diamox®), on cerebral "ammonium" metabolism of patients with and without hepatic cirrhosis *934
Wedgwood, Ralph J. Inhibition of the bactericidal activity of the properdin system with specific bacterial antibodies *935
Weissbach, H. See WAALKES, WEISSBACH, BOZICEVICH, and UDENFRIEND 1115
Weissler, Arnold M., Leonard, James J., and **Warren, James V.** Effects of posture and atropine on the cardiac output 1656
—. See LEONARD, WEISSLER, and WARREN *910

Weissman, Norman, and **Perlmutter, Martin.** An electrophoretic study of serum proteins in thyroiditis 780
Welch, G. H., Jr. See BRAUNWALD, WELCH, SARNOFF, and MORROW *876
Welt, Louis G. See HOLLANDER, WILLIAMS, FORDHAM, and WELT 1059
Werk, Emile E., Jr., Giuseffi, Jerome, Jr., Larson, Paul U., Elliott, David W., and **Oikawa, Yoichi.** The effect of total adrenalectomy in a patient with chronic massive ascites caused by post-necrotic cirrhosis *935
Wessler, Stanford, Ballon, Jonathan D., and **Katz, Jay H.** A distinction between the anticoagulant and antithrombotic effects of Dicumarol® *935
West, Clark D. See CHEEK, WEST, and GOLDEN 340
Weston, Raymond E. See GROSSMAN, YALOW, and WESTON *896
Whaley, Robert D. See ROBIN, WHALEY, CRUMP, and TRAVIS *924
Whedon, G. Donald, and **Shorr, Ephraim.** Metabolic studies in paralytic acute anterior poliomyelitis. I. Alterations in nitrogen and creatine metabolism 941
—, and **Shorr, Ephraim.** Metabolic studies in paralytic acute anterior poliomyelitis. II. Alterations in calcium and phosphorus metabolism 966
—, and **Shorr, Ephraim.** Metabolic studies in paralytic acute anterior poliomyelitis. III. Metabolic and circulatory effects of the slowly oscillating bed 982
—, and **Shorr, Ephraim.** Metabolic studies in paralytic acute anterior poliomyelitis. IV. Effects of testosterone propionate and estradiol benzoate on calcium, phosphorus, nitrogen, creatine and electrolyte metabolism 995
Wheeler, H. O. See COMBES, PREEDY, WHEELER, HAYS, and BRADLEY 860
Whereat, Arthur F. See KUO and WHEREAT *907
—. See KUO, SCHNABEL, BLAKEMORE, and WHEREAT 1035
White, Abraham G. Water diuresis and antidiuretic mechanisms in diabetes insipidus and hepatic cirrhosis *936
White, Arthur. See KNIGHT and WHITE *906
White, Margaret R., and **Jones, Hardin B.** Radioactivity of human and cattle thyroids associated with fallout *936
Whittenberger, James L. See BORST, BERGLUND, WHITTENBERGER, MEAD, MCGREGOR, and COLLIER 1708
Williams, Robert H. See HOGNESS, LEE, BERG, and WILLIAMS 803
Williams, T. Franklin. See HOLLANDER, WILLIAMS, FORDHAM, and WELT 1059
Winegrad, Albert I. See FROESCH, WINEGRAD, and RENOLD *890
Wintrobe, M. M. See GUBLER, BROWN, MARKOWITZ, CARTWRIGHT, and WINTROBE 1208
Winzler, Richard J. See ROSENTHAL, SAMET, WINZLER, and SHKOLNIK 38
Wolf, J. See KUNKEL, CEPPELLINI, MÜLLER-EBERHARD, and WOLF 1615
Wolf, Stewart. See HAMMARSTEN, CATHEY, REDMOND, and WOLF *897
Wolfe, Stanley J., and **Brin, Myron.** Effect of thiamin deficiency on human erythrocyte metabolism *936
—. See SUMMERSKILL, WOLFE, and DAVIDSON 361
Wolff, J. See AUSTEN, RUBINI, MERONEY, and WOLFF *870
Wollaeger, Eric E. See HIGGINS, LEE, SCHOLER, REITEMEIER, CODE, and WOLLAEGER 265
Wood, Earl H. See WOODWARD, ELLIS, and WOOD *937
Wood, J. Edwin, and **Coffman, Jay D.** Reduction of reactive hyperemia blood flow of the foot by tobacco smoking *937
Wood, John C. See CONN and WOOD *879
Woods, Kenneth R. See ENGLE, WOODS, and PERT *888
Woodward, Edward, Jr., Ellis, F. Henry, Jr., and **Wood, Earl H.** Use of indicator-dilution curves in the diagnosis of valvular insufficiency *937
Wróblewski, Felix, and **Moore, Alice E.** The elaboration by tumor cells of lactic dehydrogenase into the bathing fluids: *In vitro* and *in vivo* studies *937
Wyman, Stanley M. See ATKINSON, KRAMER, WYMAN, and INGELFINGER 581
—. See KRAMER, ATKINSON, WYMAN, and INGELFINGER 589
Wyngaarden, James B. Overproduction of uric acid as the cause of hyperuricemia in primary gout *938
—, **Segal, Stanton,** and **Foley, Joseph B.** Physiological disposition and metabolic fate of infused pentoses in man 1395
—. Overproduction of uric acid as the cause of hyperuricemia in primary gout 1508
—. See PETERSON, PIERCE, WYNGAARDEN, BUNIM, and BRODIE 1301
—. See SEGAL, WYNGAARDEN, and FOLEY 1383

Y

Yalow, A. Aaron. See GROSSMAN, YALOW, and WESTON *896
Yalow, Rosalyn S., and **Berson, Solomon A.** Chemical and biological alterations induced by irradiation of I^{131} labeled human serum albumin 44
—, and **Berson, Solomon A.** Apparent inhibition of liver insulinase activity by serum and serum fractions containing insulin-binding antibody 648
—. See ROTHSCHILD, BAUMAN, YALOW, and BERSON 422
—. See BERSON and YALOW 642
—. See BERSON and YALOW *873
Yearwood-Drayton, V. See ELRICK, ARAI, and YEARWOOD-DRAYTON *887
Yiengst, Marvin J. See SILVERSTONE, BRANDFONBRENER, SHOCK, and YIENGST 504
Young, L. E. See ALTMAN, TABECHIAN, YOUNG, IZZO, MURPHY, and ROBERTS *869
Yü, T. F. See BEARN, YÜ, and GUTMAN 1107

Z

Zak, Solomon J. See GOOD, ZAK, JENSEN, and PAPPENHEIMER *894
Zannoni, Vincent G. See SEEGMILLER, LADU, ZANNONI, and LASTER *928
Zierler, Kenneth L., and **Andres, Reubin.** Movement of potassium into skeletal muscle during spontaneous attack in family periodic paralysis 730
—. Increased permeability of muscle membranes produced by insulin *938
—. See ANDRES, CADER, GOLDMAN, and ZIERLER 723
Zinkham, William H., and **Childs, Barton.** Effect of naphthalene derivatives on glutathione metabolism of erythrocytes from patients with naphthalene hemolytic anemia *938

SUBJECT INDEX

(Page numbers marked with an asterisk refer to abstracts)

A

Acetate, radiolabeled, fatty acid synthesis from, 233–243
Acetazolamide
and bicarbonate excretion, 920–921*
and metabolism
of calcium and citrate, 894–895*
of cerebral ammonium, 934–935*
and potassium excretion, 918*
in pulmonary emphysema, 892*
3-Acetomercuri-2-methoxy-1-hydroxy-propane, 658, 661–662
3-Acetomercuri-2-methoxy-succinyl-propylurea, 658, 660–662
Acetylcholine
and bronchoconstriction, 674
and pulmonary circulation, 271, 671–674, 890*
Acetylkynurenine, 1601–1602
Acetylphenylhydrazine, 618–621, 626–627
Achlorhydria, 1289–1290, 1293
Acid-base balance
in aldosteronism, 923*
and anesthesia, 1121–1128
in hyperventilation, 517, 525, 527
in hypoxia
altitude, 273
right to left shunts, 272–273
Acidity, titratable of urine
and ammonium chloride, 759
in hyperventilation, 517, 520, 527
in respiratory alkalosis, 520, 527
in Wilson's disease, 1111, 1112
Acidosis
and cerebral concentration of phenobarbital, 1223
in congenital heart disease, 273
diabetic, 1588–1592
hydrogen ion distribution, 373–381
in hypoxia, 272–273
and oxygen therapy, 928*
respiratory
and anesthesia, 1127–1128
and extracellular bicarbonate, 374–378, 522–528
hypochloremia, 910*
renal responses, 515–528
of sleep, 924*
in Wilson's disease, 1110–1111
Acromegaly, and adrenal weight-maintenance, 1611, 1613
ACTH. *See* Adrenocorticotropin
Actomyosin, 906*
Acyl glucuronides, in benzoate and salicylate metabolism, 297–302
Addison's disease, plasma ACTH, 1701–1707
Adenine, and erythrocyte lysis, 1503–1506
Adenoma
adrenal, pregnanetriol and pregnanetriolone excretion, 1730, 1731, 1733
chromophobe, of pituitary
concentration of chloride in G. I. tract, 286
concentration of water in G. I. tract, 293
parathyroid, and urinary phosphate, 574
Adenosine
and blood storage, 431–433
and hemoglobin electrophoretic patterns, 228
conversion to inosine, 433
deoxy-, 1502–1506
diphosphate, 1503–1506, 1572
and erythrocyte lysis, 1503–1506
monophosphate, 1572
in nucleotide synthesis pathway, 1572–1577
5′-phosphate, 1503–1506
synthesis in heart muscle, 1572
triphosphate, 1572
and erythrocyte lysis, 1503–1506
protection of glutathione, 623
Adenovirus, and respiratory illness, 1072–1079
Adenylic acid, dephosphorylation, 1575–1577
Adhesions, and common bile duct obstruction, 716–717
Adipose tissue and fatty acid transport, 811–814
Adrenalectomy
and adrenocorticotropin of plasma, 1701–1707
and ascites, 935*
responses to cortisone and DCA after, 1296–1299
and sodium depletion, 911–912*
Adrenal gland
cortex
and ACTH, 548
in adrenal hyperplasia, 1612–1613
and amphenone, 899*, 932*
and cortisol production, 914*
extract in hemorrhagic fever, 102
and gastric secretion, 1171–1181
in hypertension, 1465–1466
in hypoxia and heat stress, 1642–1646
insufficiency
and adrenal steroids, 1703–1705
after cortisone withdrawal, 1610–1611
and protein catabolism, 1316–1317
in liver disease, 920*
and thyroid interrelationships, 1313–1317
tumor, 1609–1610
and urinary pregnanetriol or pregnanetriolone, 1730–1732
mitochondria, 932*
weight at autopsy, epidemic hemorrhagic fever, 127
weight–maintaining activity, in Cushing's syndrome, 1609–1613
Adrenocorticotropin
and adrenal cortical function, 548, 1612–1613
and adrenal weight maintenance, 1609
and albumin synthesis, 896*
blood content, in hypoxia, 1642–1646
and circulating eosinophils, 1172, 1177
effect of cortisol, 72–73
and gastric output, 1173–1181
hydrochloric acid, 1173
hydrogen ion, 1174, 1181
pepsin, 1174, 1181
and heparin-precipitable fraction/fibrinogen ratio, 607–608
and 17-hydroxycorticoids, urinary excretions, 1172, 1177, 1317
in insulin hypoglycycemia, 543–548
and pepsinogen, plasma and urine concentration, 1176, 1180–1181
plasma, after adrenal steroids, 1701–1707
in poliomyelitis, 975
and potassium metabolism, 872–873
Agammaglobulinemia, and delayed allergy, 894*
Age
and cerebral metabolism, 1130–1136
of erythrocytes, 676–679, 903*, 913*
and glucose tolerance, 511–512
and hemodynamics in coarctation of aorta, 1540–1541
and heparin-precipitable fraction levels, 606–616
and insulin binding, 512
and liver findings
at autopsy, 1584
in kwashiorkor, 1581
and lungs
diffusing capacity, 3, 11–16
mechanical behavior, 1680–1687
and myelogenous leukemia, 21
and oxygen utilization, 1133–1136
and renal responses to hypertension, 1461–1463
and sodium intake, 1467
rheumatic child, and streptolysin O, 793–801
and tissue blood flow, 512
Agglutination, erythrocyte
autogenous, 1433
and destruction of sensitive, 1451–1452, 1456–1457
Alanine
and ammonia production, 1647, 1653
plasma concentration
after glutamate infusion, 709
in normal plasma, 1674–1677
after surgery, 1677, 1678
Albumin
cholanic acid affinity for, 540–542
deficiency and hypertriglyceridemia, 703
in epidemic hemorrhagic fever, 113
infusion in shock of, 1694
oliguric phase, 118
shock period, 102

exchangeable
in regional enteritis, 931*
and thyroid therapy, 423–425
in ulcerative colitis, 931*
and heparin
as antilipemic agent, 925*
in nephrosis, 701–704
and hexosamine ratio, total proteins, 56
identification, in sputum, 877*
metabolism, 44–49, 890*
and desiccated thyroid, 422–427
in nephrosis, 701–704, 1336–1342
and plasma lipids, 1559, 1563–1564
renal loss, 704
serum, 539–542
and cholesterol, in obstructive jaundice, 718
hyaline droplets in renal tubule cells due to, 109
and liver insulinase activity, 653
in patients with macroglobulinemia, 459
phenobarbital binding, 1219, 1223
in rheumatoid arthritis, 309–312
splitting of disulfide linkages, 46, 49
synthesis, 417, 896*
in fetus and placenta, 399–403
and thyroid therapy, 423–427
thyroxine binding, 28, 1336–1342

Albuminuria
in epidemic hemmorhagic fever, 1693
in infectious illnesses, 1695
in Wilson's disease, 1108

Alcaptonuria, metabolic defect in, 928*

Alcohol
and hepatic cirrhosis, 362
decompensated, 878*
zinc metabolism, 933*
in hyperuricemic gout, 1509
inhibition of antidiuretic hormone, 1204–1206
and water diuresis maintenance, 1202–1206

Aldosterone
and acid-base metabolism, 923*
biosynthesis, 932*
eosinophil responses, 1172
in fractions of
adrenal vein blood, 691–692
urine extract, 762
and gastric secretions, 1173–1174, 1180
secretion
and air encephalography, 911*
and caval constriction, 689–693
compared with other adrenocortical steroids, 760–761
and hydration state, 390
and pentobarbital, 692–693
and potassium, 383–391, 757–765
and sodium, 383–391, 757–765
urinary excretion, 383–391
in edematous states, 390
of pepsinogen, 1176, 1181

Alginic acid sulfate, anticoagulant properties, 597–598

Alkaline phosphatase. *See* Phosphatase, alkaline

Alkalosis
hypokalemic plasma electrolyte concentrations, 1250–1251
and phenobarbital potency, 1220–1223
species difference, 1220–1221
respiratory
of hepatic coma, 924*
renal response, 515–528

Allergy
delayed, and agammaglobulinemia, 894*
reactions to dextran, 1160–1169

Altitude, and pulmonary ventilation, 270–277

Aluminum gel, and phosphorus metabolism, 569–571

"Alveolar-capillary block" syndrome, 871*

Alveolus, diffusing capacity, 5–8

American Society for Clinical Investigation, proceedings of forty-ninth annual meeting, 866–868

Amino acid. *See also* under specific names
and arteriovenous differences of unesterified fatty acid, 812–813
chromatography
characteristics, 1673
separation in phenylketonuria, 1345–1348
and erythrocyte lysis, 1503, 1504
and hepatic coma, 913*
hippuric, and tryptophan, 1604
metabolic pathway requirements, 1654
oxidase, at autopsy, 1584
and in kwashiorkor, 1581, 1585–1586
plasma, 1672–1679
binding to non-dialyzable molecules, 1674–1676
after surgery, 1677–1678
uremic, 1227–1231
in rheumatic fever, 451–452
toxicity, 1647–1655

o-Amino hippuric acid and tryptophan, 1604

4-Amino-5-imidazolecarboxamide-C, incorporation into uric acid in gout, 908*

Aminophylline, and pulmonary circulation, 672, 673
in emphysema, 892*

Ammonium
arteriovenous difference in hepatic cirrhosis, 888*
peripheral tissues, 362–371
blood levels
and glutamate, 708–711
and toxicity after amino acids, 1647–1655
cerebral, 362, 365–371, 934*
chloride, 367–371
and acidosis, 1110–1111
and bicarbonate reabsorption, 1110–1111
and electrolyte excretion, 759, 764–765
pyruvate concentration in blood after, and nitrogen intolerance, 367
in Wilson's disease, 1110–1111
excretion, and respiratory alkalosis, 517–527
in gastric juice, 874*
in hepatic diseases, 361–371, 934*
coma, 362, 364–365
and amino acids, 913*
metabolism, 361–371
and acetozolamide, 934*
and nitrogenous material in intestine, 364–365
in nucleotide synthesis pathway, 1572
peripheral uptake and release, 362–371
after muscular exercise, 927–928*
in spinal fluid, after thioctic acid, 1211–1212
urinary nitrogen, isotope concentration after N^{15}-1-aspartic acid, 355

Amphenone, and adrenal cortical function, 899*, 932*

Amylase
serum, in kwashiorkor, 1583
synthesis, 417

Amylopectin, and β-lipoprotein, 1364–1366, 1368

Anaphylaxis, 1115–1119

Anastomosis
arteriolar-capillary-venular, 251–253
mediastinal and bronchial channels, 1259
porto-caval and porto-pulmonary, 1257–1264

Androstadiene, 919*

9αF,11βOH-$\Delta^{1,4}$-Androstadiene-3,17-dione, 919*

11βOH-$\Delta^{1,4}$-Androstadiene-3,17-dione, 919*

Δ^4-Androstene-3,17-dione, 919*

11βOH-Δ^4-Androstene-3,17-dione, 919*

Anemia
aplastic, 229, 1440, 1621
blood transaminase levels, 926–927*
electrophoretic patterns of hemoglobin in, 229
hemoglobin
A_2 isolation, 1621
C-disease, 841
hemolytic, 1621
acquired, 229
Cr^{51}-labeled erythrocyte distribution, 1471, 1473, 1477
Fe^{59}-labeled reticulocytes, 1444–1447
macroglobulins, 891*
red cell destruction and survival, 1450, 1456
congenital, 1471–1472, 1475–1477
hexosamine and protein content in, 55
naphthalene, glutathione metabolism of erythrocytes, 938–939*
of hemosiderosis, pulmonary, 1150–1158
of hookworm infection, 1183–1192
in hypersplenism, 871*
hypochromic microcytic, 229, 1157
iron absorption in, 324

Anemia (*cont'd*)
macrocytic
electrophoresis of red cells from, 229
etiology, 915*
pernicious
juvenile, 925*
radiolabeled vitamin B_{12} in, 1552–1553
plasma erythropoietin activity, 896*
in rheumatoid arthritis, 1043–1056
sickle cell, 229
and arterial oxygen unsaturation, 905–906*
auto-splenectomy in adults, 840
irreversible forms, 834
and S hemoglobinopathies, 833–842
and splenectomy, 1440, 1479
of uremia, dialysis, and purine ribosides, 923*
Anesthesia
and acid-base balance, 1121–1128
and mechanical properties of lungs, 1708–1713
Anorexia, after parathyroid therapy, 560
Anoxemia, and metabolic acidosis, 1126
Anoxia, tubulorhexic disruption, 176
Anthranilic acid, 1602
Antibiotics
and arterial ammonia in hepatic coma, 364, 371
and streptococcal infections, 1096–1099
and urea breakdown, 933*
Antibody
agglutinating and sequestration of red cells, 1430–1433
bacterial, and properdin system, 935*
fluorescent technique in lupus serum-nucleoprotein reaction, 890*
in hemolytic anemia, 891*
in immunoreaction model in quinidine purpura, 929*
insulin binding, 873–874*
electrophoretic identification, 643–645
and insulinase activity, 648–655
in paroxysmal hemoglobulinemia, 891*
nocturnal, 900*
precipitins
and systemic reaction to dextran, 1165–1169
and red cell destruction, 1434
response
after adenovirus, 1077
in rheumatic fever, 934*
streptococcal infections, 801, 934*
streptococcal
nephritogenic, 876*
type-specific, 1092–1099
synthesis
by placenta, 403
protein, by homotransplanted lymph nodes, 405–419
typhoid H- and O-
half life, 411–413
rate of synthesis by homotransplanted lymph nodes, 414–415
Antigen
A and B, in epidermis, 749–751
assay in body fluids or tissue, 49
and histamine, serotonin release during anaphylaxis, 1115–1119
immunization in lymph node homotransplant, 408–419
types used, 410–411
interaction with transfer factor from hypersensitive donors, 908–909*
similarity of rabbit-antigamma and macroglobulin, 462–463
streptococcal, in rheumatic children, 793–801
Antihemophilic factor, 485
Antihyaluronidase, 796, 799, 801
Antistreptokinase, 796, 799, 801
Antistreptolysin O
development in streptococcal untreated infections, 1093
response time, 1094
and therapy, 1096
after streptolysin O injection, 794–799
Aorta
coarctation, hemodynamics and splanchnic circulation, 1537–1543
fistula, and Lanatoside C, 336–338
pressure, and coronary blood flow, 1103
red cell and protein concentration, 1451
Appendicitis, heparin-precipitable plasma fractions, 612
Arabinose
and alloxan diabetes, 916*
infusion, 1384
and blood glucose, 1398
and insulin, 1385–1387
metabolism, 1384–1405
pathways, 1404
plasma half-time, 1387
and serum phosphorus, 1399
urinary excretion, 1391–1393, 1398, 1400, 1402, 1405
stereochemical configuration, 1383
Arginine
and blood ammonia, 1648–1652
in hepatic coma and hyperammoniemia, 913*
and nitrogen balance, 1647–1655
and toxicity, of amino acids, 1648–1652
protection, 1648–1652
uremic plasma, 1228–1231
Arterenol. *See* Norepinephrine
Arteriosclerosis, 932*
cerebral content of chloride and water, 286, 293
erythrocyte life span, 676–679
serum and urine content of bile acids, 531
Arthritis
gouty, 55
hexosamine and protein, serum content, 52–53, 55
rheumatoid, 52–53
anemia of, 1043–1056
anti-inflammatory hormone therapy for, 54
cortisol, 1303
and cortisone, 763
plasma half-time, 1303
electrophoretic studies of serum proteins in, 309–313
hypochromia of red cells, 1056
mucopolysaccharide excretion, 1516–1520
and salicylates, 611
Asbestosis, of lungs, 871*
Ascites
aldosterone secretion in, 689–693
in aortic-caval fisula and Lanatoside C, 336–338
and desoxycorticosterone, 692–693
in liver disease
and hepatic coma, 362, 368
post-necrotic cirrhosis, 935*
radiocobalt vitamin B_{12} in study, 18–24
Ascorbic acid in Wilson's disease, 1200
Asparagine, and glutamate, 709
Aspartic acid
and erythrocyte lysis, 1503–1506
hemoglobin content, 1345
in phenylketonuria, 1346–1348
isotopically-labelled, turnover study of myeloma proteins, 352–359
plasma concentration, 1228, 1675–1677
uremic, 1229–1231
Asthma
forearm circulation, 246
pulmonary diffusion and function tests, 13–16
Atrium
in epidemic hemorrhagic fever, 102
at post mortem, 125
gallop rhythm, 910*
and jugular vein pulse, 1037
impulse transmission to ventricle, 883*
pressure
and dextran expansion of plasma, 1234–1238
and epinephrine, 670, 673
and 5-hydroxytryptamine, 671
and nor-epinephrine, 670–671, 673
and pulmonary resistance, 673–674
rubidium^{86} uptake, 479
Atropinase, 903*
Atropine
and blood flow during respiratory cycle, 1569
and cardiac output responses to posture, 1656–1662
psychopharmacological effects, 877–878*

B

BAL. *See* Dimercaprol
Barbital
anesthetic effects, 1223
and sodium bicarbonate, 1221
Behavior
changes in thirsting rats, 435
running activity in mice, satiety responses, 1638–1641
Benadryl®. *See* Diphenhydramine

Benzoate, and acyl glucuronides, 297–302
Bicarbonate
and chloride content of stomach and colon, 285
excretion
after carbon dioxide inhalation, 518, 520, 528
in hyperventilation, 517, 520, 527
plasma concentration
and acetazolamide, 920–921*
and acid metabolism, 374–381, 1127
and arterial oxygen saturation, 271–272
and hydrochloric acid, 374
and shunt hypoxia, 272
after sodium loading, 306
renal filtration, reabsorption and excretion, 518, 523, 526
and respiratory acidosis, 374–378
versus alkalosis, 522, 528
in Wilson's disease, 1110–1111, 1113
Bile
acids
binding by serum proteins, 534, 538–542
dihydroxyl, 533
intestinal concentration, 1531–1532, 1534
serum content, 530–542
urine excretion, in hepatic disease, 530–537
copper concentration in Laennec's cirrhosis, 1212, 1214
excretion
of cortisone metabolites, 1307
of estrogen metabolites, 1267–1275
of tocopherol in liver diseases, 1635
fistula, 1269–1275
hepato-enteric circulation of estrogens in women, 1266–1277
obstruction, 531, 714
lipoprotein spectrum, 716–717
serum bilirubin and cortisone, 1371
tocopherol metabolism, 1627–1636
regurgitation, and trihydroxy/dihydroxy bile acid ratio, 537
Bilirubin
conjugation, 535
metabolism, congenital defects, 927*
serum
after bile obstruction, 1631, 1632
and cortisone, 1370–1373
after erythrocyte and hemoglobin infusion, 1444, 1452
in hemolytic anemia, 1471
in liver disease, 362, 368, 532–536
and glutamate, 707
in Laennec's cirrhosis, 1210
and prednisolone, 1372–1373
urinary, 1370–1373
Bishydroxycoumarin
anticoagulant and antithrombotic effects, 935–936*
and thromboplastin generation test, 489–490, 495
Blood
absorption of radioiron in hemochromatosis, 316–321
adrenocorticotropin
in hypoxia, 1642–1646
in Addison's disease, 1701–1707
aldosterone
in adrenal vein, 691–693
in venous blood, 690
amino acid, forms, 1672
and oxygen tension, 707
ammonia
and glutamate, 707–708
after muscular exercise, 927–928*
anemic, storage of, 228–229
anti-Rh, type specific hemolytic anemia, 1482, 1484
arterial
carbon dioxide content, 1122
gas content, 1132–1136
gas content and quinidine, 844–845
sodium and water absorption in sprue, 267
arterialization of venous and S-type hemoglobin, 896–897*
arteriovenous
age, effect on cerebral oxygen, 1133–1136
age and glucose tolerance, 511
ammonia, in hepatic coma, 363–371
epinephrine, norepinephrine, 892*
coagulability, heparin-precipitable fraction, 599–603
central volume, responses to posture and atropine, 1657–1659
clearance of radioactivity
from labeled estradiol and estrone, 1266–1277
from labeled red cells, 1430–1431
from labeled streptokinase, 888–889*
labeled thyroxine isomers, 31
coagulation
and bishydroxycoumarin, 935–936*
and cholesterol, 915*
congenital Stuart clotting defect, 485–494
genetic aspects, 497–502
in familial hemophilia, and platelet correction, 878–879*
immunological approach to problems, 910–911*
copper
in Laennec's cirrhosis, 1210, 1214
in Wilson's disease, 1200
flow. *See* Blood flow
glucose concentration
age differences, 506
and chlorpromazine, 547
and glucagon, in insulin hypoglycemia, 74–80
in periodic paralysis, 735–736
and tolbutamide potentiation of insulin, 1546–1549
groups A, B, O, and AB absorption by epidermal homogenates, 749–751
iso-osmotic level of freezing point depression, 869–870*
α-ketoglutarate in liver disease and hepatic coma, 363–371
and ammonium chloride, 369
loss. *See also* Hemorrhage
fecal and intestinal, in hookworm infection, 1188–1192
and number of ova, 1191–1192
iron absorption after, 323
oxygen
capillary, 8
in hyperpnea, 271
in polycythemia, 273
retinal venous, 899–900*
pH
and anesthesia, 1121–1128
and cerebral metabolism, 1132–1136
and diffusion capacity in newborn, 1082, 1090
and hemoglobin interaction, 839, 842
and metabolic acidosis during ether, 1127
and oxygen saturation, 273
and phenobarbital concentrations, 1220
and sickling phenomenon, 837
and viscosity, 837, 839, 842
porto-caval shunt
peri-esophageal pathway, 1260
and pulmonary venous pressure, 1263–1264
pressure. *See* Pressure, arterial
pyruvate concentration in liver disease and hepatic coma, 363–364, 367, 370–371
removal and replacement in postural hypotension, 1320
sedimentation rate in anemia of rheumatoid arthritis, 1046
serotonin concentration and anaphylaxis, 1118, 1119
shifts
out of forearm veins after epinephrine and norepinephrine, 1670
and posture, 1660
sickle cell trait, viscosity, 836
and deoxygenation, 838
sludge, in epidemic hemorrhagic fever, 1695, 1698
splanchnic volume and hexamethonium, 861, 863
splenic, and pentobarbital, 1451
storage
in acid-citrate-dextrose, 225–231, 429–431, 433
changes in red cell extracts of, 225–231
osmotic fragility, 227
sugar
effects of glucagon and/or insulin, 76
in malignant disease, 254–263
thromboplastin formation, 495
transaminase levels, in anemia, 926–927*
transfer from systemic to pulmonary circulation, 65–66
transfusions
for epidemic hemorrhagic fever, 102
in hemolytic anemia, 1470–1485
"non-specific" reactions, 877*

Blood (*cont'd*)
urea nitrogen
in epidemic hemorrhagic fever, 99–100, 118, 1693, 1697
venous
oxygen content and coronary blood flow, 1104
portal and pulmonary admixture, 1257
pressure-volume responses, 1663–1671
vessel
flow pattern, 253
support, and oscillation, 992
viscosity, and S hemoglobin concentration, 835–839
volume
in heart disease, 901*
after hexamethonium, 861
intrathoracic, during antigravity suit inflation, 62, 65
peripheral, and venous tone, 65
in splanchnic vasculature, 864
and weight gain from simple overeating, 81–88
Blood flow
adaptation to pulmonary vascular engorgement, 59–66
adrenal, and aldosterone secretion, 691–693
and aortic
caval fistula, 335–339
coarctation, 1541
arm, 245–253, 919–920
in periodic paralysis, 734–736
capillary, in infectious diseases, 1688–1700
and norepinephrine, 1694
and cardiac output, 1144–1148
cerebral, in children, 1130–1136
circulation time, in congestive failure, 919–920*
coronary, 844–846
and hypoxemia, 1101–1106
and myocardial rubidium^{86} uptake, 476–483
and nitroglycerin, 895*
and deficient autonomic reflexes, 1326–1327
and dermal responses to thermal injury, 42
to extremities, and mineral loss, 976
in giraffe, 919*
in glomeruli, 120
hyperemia of foot and smoking, 937*
and hypoxia, 270–277
low pressure, and erythrocyte sequestration, 840
and mechanical behavior of lungs and anesthesia, 1708–1714
in elderly persons, 1680–1687
pattern in blood vessels, 253
peripheral, 106, 844–846
and exercise, 1148
resistance to postures, and atropine, 1657–1658
in poliomyelitis
and oscillating bed, 982–993
reactions to gravity, 987, 991–994
pulmonary, 670, 673, 844–846
and acetylcholine, 671–673, 890*
capillary, in respiratory cycle, 1556–1571
and epinephrine, 670, 673
and exercise, 1141–1148
and norepinephrine, 670, 673
and serotonin, 671, 673
and quinidine, 844–846
renal
in epidemic hemorrhagic fever, 110–111
hemodynamics, and norepinephrine, 89–96
after sodium loading, 303–308
and serotonin, 673
shunt, respiratory adjustment to hypoxia due to, 270–277
splanchnic
in coarctation of aorta, 1537–1543
and hexamethonium, 861, 863, 864
velocity, through glomerulus, 96
Blood pressure. *See* Pressure, arterial
Body
chloride concentration in, 279–287, 343, 1379, 1381
composition and serum sodium concentration and osmolarity, 886–887*
lean mass, electrolyte exchange, 1377–1381
metabolic rate of total and cerebral, 1135–1136
potassium, 1375–1381
and sodium ratio, 436
and water partitioning, 347
size, and lung diffusing capacity, 3–16
water content, 290
Bone
calcium
and magnesium in osteolytic disease, 887*
and phosphorus excretion, 978
and sodium ratio, 345–347
diseases, citric acid metabolism, 909–910*
lesions and anemia, 841–842
magnesium concentration in, 347–348, 887*
marrow
depression in hypersplenism, 871*
deoxyribonucleic acid synthesis by cells, 931*
stimulation, 875*
mineral loss
and circulation, 976
and oscillating bed, 991
in poliomyelitis. *See* Poliomyelitis
and radioactive calcium and strontium, 884–885*
resorption in hyperparathyroidism and in Paget's disease, 893*
Brain
ammonium metabolism
in liver disease, 362, 365–371
and acetazolamide, 934–935*
circulation, and metabolism in childhood, 1130–1136
copper concentration, in Laennec's cirrhosis, 1212, 1214
extract, and prothrombin time, 489
phenobarbital sensitivity, 1223
serotonin levels after 5-hydroxytryptophan, 1595
Breast, carcinoma
glucose tolerance, 256–258
and hypercalcemia, 740, 742
metastatic
liver lipoprotein spectrum, 716–717
and obstructive jaundice, 714
skeletal muscle composition, 1242
Breathing. *See* Respiration
Bromomercuri-, -benzene, -methane, and **-propane,** 658, 665
Bronchiectasis, pulmonary diffusing and function tests in, 13–16
Bronchopneumonia
chloride content of gastrointestinal tract, 286
in epidemic hemorrhagic fever, post mortem, 125–126
water content of gastrointestinal tract, 293
Bronchus, carcinoma, pulmonary diffusion and function tests, 13–16
Buffer
base, and plasma carbon dioxide, 1122–1123
time course of change with respiratory depression, 1125–1126
intracellular, 374
of administered acid, 376, 378, 380
and gastrointestinal juices, 380
and hydrochloric acid, 378
sensitivity to, 877*
in acidosis, 376
Burn
injuries, substances released from skin after, 38–43
respiratory tract pulmonary function, 13–16
Bursitis, forearm circulation, 246

C

Calcification, of traumatized muscle, 825–831
Calcium
balance and aluminium carbonate gel, 571
binding
by chondroitin sulfate, 1718
protein, and hyperventilation, 870*
dietary, 945, 983, 985, 1023–1027
and renal phosphate reabsorption, 552–555
and ethylenediaminetetraacetic acid, 568, 570
and heparin–precipitable fraction in cation-depleted plasma, 599–603
in hypoparathyroidism, 567, 569–571
loss
and magnesium, 887*
and osteoporosis, 968–969, 973
patterns, 967–968
metabolism, 680–687
and acetazolamide, 894–895*
and strontium, 684–685

oxalate, urinary excretion and renal stone formation, 882*
and phosphate
infusion, 552–555
loading, 567–571
metabolism, 573–580
renal reabsorption, 551–555, 580
plasma
and cation depletion, 599–603
and hypoparathyroidism, 550–571
and solubility of heparinized fraction, 602
in poliomyelitis
balance, 968–970, 972, 985–987, 990–993, 1023–1027
and nerve injury, 991
and early ambulation, 978
and estradiol benzoate, 1002
fecal excretion, 1023–1027
and gonadal steroids, 997–1006, 1010
comparison of effects, 1015–1016
and immobilization, 977–979
and oscillating bed, 983–985, 990–994
and testosterone, 1000–1001
serum, 968–970, 974
in breast carcinoma, 740, 742
hypercalcemia, 977
and phosphate excretion, 578–579
ultrafiltrability, 738–747
and pH, 741–742, 745, 747
and temperature, 743–747
and sodium concentration, 434–439
in bone, 346, 348
solubility, 972, 974
in traumatized muscle, 825–831
urinary, 967–970, 979, 983–993, 1023–1027
in hypocalcemia, 437
and parathyroid therapy, 560, 562

Calculus, renal
and immobilization in poliomyelitis, 977, 979
and urinary oxalate excretion, 882*

Cancer
adrenal, and amphenone, 899*
and amino acid toxicity, 1654
and body respiratory quotient, 934
breast. *See* Breast, carcinoma
cell, nucleic acid ribose synthesis, 1408–1414
of cervix, and glucose tolerance, 256–258
common duct, serum lipids, 716–717
gastric, serum lipids, 716–717
glucose metabolism, 254–263
and age, 512
lactic dehydrogenase in, 937–938*
of liver, lipids and lipoproteins, 714, 716–717
of lung, heparin-precipitable serum fraction, 612
metatastic
and heparin-precipitable fractions, 612
and obstructive jaundice, 714
and serum lipoproteins, 716–717
sialic acid test, 452
thyroid hormone-plasma protein complex, 1487

Capillary
arteriole-venule anastomosis, 251
blood
flow during respiratory cycle, 1571
oxygenation, 8
diffusing surface, 3
endothelium, and platelet after transfusion, 881*
in epidemic hemorrhage fever phases, 1695–1697
in lung and cardiovascular diseases, 922*
nail bed, 895–896*
in epidemic hemorrhagic fever, 110, 128
in Q fever, 1688, 1698–1700
injuries, 896*
in renal lesions, 106, 112, 128, 134–137, 144–145
vascular bed, in infectious illnesses, 1688–1700
and norepinephrine, 1689, 1694, 1695

Carbohydrate
dietary intake
lipid and lipoprotein changes, 855–859
and obesity, 81–88
in poliomyelitis, 945
in globulin fractions in disease states, 56, 310–312
intestinal absorption and digestion, 1522–1534
in macroglobulin fraction, 459, 466
metabolism
during familial periodic paralysis, 734–735
and intake, 732, 735
in forearm, 728
as measure of platelet preservation, 878*
in paroxysmal nocturnal hemoglobinuria, 869*
pentoses, 1383–1405
in red cell, 625
myeloma serum and urine content, 357
utilization, plasma nonesterified fatty acids as index, 884*

Carbon dioxide
and ammonium
chloride, 764
excretion, 519, 521, 527
arteriovenous difference
and age, 1133–1136
in familial periodic paralysis, 734
and cerebral circulation, 1133–1136
inhalation
acid-base disturbance, 518, 525, 528
and phenobarbital anesthesia, 1220
renal filtration, reabsorption and excretion of bicarbonate, 523
urinary findings, 518, 521, 525
narcosis, and alkalinization, 928*
pH, and calcium ultrafiltration, 740–742, 745, 747
plasma, 1122
in acidosis, 374, 377, 379
and quinidine, 844–846
and potassium loss from muscle, 728–729
specific activity, after glycine-1-C^{14}, 1511
tension
during anesthesia, 1121–1128
of arterial blood, 1122
and oxygen saturation, 271–272
in newborn, 1082, 1090

Carbon monoxide
diffusing capacity of lung for, 1–16
and erythrocyte glutathione, 620–621
and hemin oxidation, 912*
uptake in newborn, 1082–1092
and diffusing capacity, 1082
and oxygen uptake, 1088–1089
ventilation, 1084–1085

Carbon tetrachloride, and tocopherol metabolism, 1627–1636

Carcinoma. *See* Cancer

Cardiac output
in coarctation of aorta, 1541
and brachial pressure, 1542
ear oximeter for repeated measurement, 894*
in epidemic hemorrhagic fever, 111
and exercise, 6
and systemic resistance, 1144–1145
and hexamethonium, 861
and plasma expansion by dextran, 1234–1238
in pregnancy with heart disease, 880*
and pulmonary
blood flow during respiratory cycle, 1571
pressure changes, 673
and quinidine, 844–846
responses to posture and atropine, 1656–1662

Cardiovascular system
diffusion characteristics of pulmonary membrane, and capillary bed, 922*
and equilibration of
deuterium oxide, 784, 788–791
potassium, 784, 787–788, 791
sodium, 784–786, 788, 791
and isopropylnorepinephrine, 883*
and isotope cation distribution in edema, 786–790

Carditis, heparin-precipitable plasma fraction in, 607–610

Carinamide, and thiosulfate clearance rate, 328–329, 333

Catheterization
cardiac and venous, in chest disorders, 16
esophageal, for swallowing patterns, 930*

Cation
binding by chondroitin sulfate, 1715–1722
counterion defined, 1715
osmotically inactive, 1721
intracellular loss, 376, 379
urinary excretion rates in respiratory acidosis and alkalosis, 519

Cell separation theory, applications, 872*

Cells. *See also* Erythrocytes; Leukocytes
in binding of
mercury, 660–661, 664
thyroxine, 25–36
bone marrow, deoxyribonucleic acid synthesis, 931*
cancer
lactic dehydrogenase *in vitro* and *in vivo*, 937–938*
nucleic acid ribose synthesis, 1408–1414
chloride and sodium concentration in, 343–350
HeLa strain, incorporation of radioactive substrates, 1409–1410
hypersensitive, in mumps virus infection, 893*
Kupffer, iron deposition, 1723–1725
Leydig, chorionic gonadotropin stimulation, 909*
motor nerve, destruction in poliomyelitis, 978
muscle
accumulation of alkali metals, order of preference, 1253, 1255
membrane, sugar transport, 916*
potassium concentration in, 349–350
in renal lesions of epidemic hemorrhagic fever, 160–161
desquamated, 109, 144–145, 186, 202
epithelial, 134–135, 142–143
of ducts of Bellini, 112, 152–153, 220–223
hyperplastic atypical, 158
hyaline droplets in, 108–110
regenerated, nuclei of flattened, 154
vacuolization, 138–141
reticuloendothelial and erythrocyte iron, 875–876*
thiosulfate metabolism in, 322
Ceruloplasmin, in Laennec's cirrhosis, 1210, 1214
Cesium
muscle composition after ingestion, 1251, 1254
plasma concentration in hypokalemic alkalosis, 1250–1251
Chenodeoxycholic acid
binding by albumin, 539
and dihydroxy bile acid, serum ratio, 534–535
Chest
muscle function, in poliomyelitis, 1027
pulmonary diffusing capacity in disorders of, 1–16
Chitin sulfate, precipitation, 597–598, 601
Chloride
ammonium, electrolyte output after, 759, 764–765
binding by chondroitin sulfate, 1716–1719
concentration
arterial, 732, 736
and cortisone, versus desoxycorticosterone acetate, 1296
gastrointestinal, 279–287, 294–295, 343–350
in hypokalemic alkalosis, 1250–1251
in metabolic acidosis, 1126
in muscle, 1242–1247
in tendon, 343
exchangeable, 284–287
with potassium, 1375–1381
excretion
after carbon dioxide inhalation, 519, 521, 528
and ethanol, 1203, 1205
in hyperventilation, 520, 528
after renal artery clamping, 1418–1419, 1423
and sodium, 306
urinary
in poliomyelitis, 1007, 1013, 1016
extracellular, 279
gastrointestinal, 279–287
intraluminal, 294–295
post mortem, 286
loss, in respiratory acidosis, 910*
mercuric, 658–662
sodium
partition, in extracellular volume calculation, 340–350
and renal function, 637
space, in hypocalcemia, 435, 436
Chlormerodrin, structure and diuretic activity, 658–661
p-Chloromercuri-benzoate, 658, 663–665
2-Chloromercuri-1-hydroxy-ethane, 658, 665
2-Chloromercuri-1-methoxy-ethane, 658–665
3-Chloromercuri-2-methoxy-propylurea, 658–659, 661–662
4-Chloro-prednisone, anabolic activities, 919*
Chlorpromazine
and adrenocortical response, 545
to ACTH, 548
insulin hypoglycemia, 543–548
hemolytic properties, 227
and satiety responses in mice, 1639–1641
Chlortetracycline, and urea breakdown, 933*
Cholangiolitis, and liver copper concentration, 1214, 1215
Cholangitis
bile acid content of serum and urine, 531
and obstructive jaundice, 714
Cholanic acid, binding by plasma proteins, 538–542
Cholic acid, binding by plasma proteins, 538–539
Cholecystitis
lipoprotein spectrum, 716–717
and obstructive jaundice, 714
radiochromuim excretion, 1186
Cholelithiasis, lipoprotein spectrum, 715–717
Cholesterol
and blood coagulation, 915*
diet, and stress in coronary disease, 897*
esters, measurement of fatty acid components, 233–243
in hepatic diseases, 531
trihydroxy bile acid, 537
intestinal excretion and plasma levels, 898*
in kwashiorkor, 1582–1583, 1586
metabolism
and formic acid analogues of thyroxine or triiodothyronine, 885*
in lymphoma, 916*
nephrosis, 701–703, 1563–1564
and obesity, 81–88
in obstructive jaundice, 718–719
role of, in fat transport, 81–88
serum content
and bile obstruction, 1631, 1632, 1636
after fat ingestion, 850, 917*
after glucose, 857, 929*
Chondroitin
cation binding, 1715–1722
methyl and sulfate structures, 1716
recovery from plasma, 1329–1330
Chondromucoprotein, sodium binding, 1719
Christmas disease, and thromboplastin generation test, 490
Chromatography
adrenal steroids
dysfunction, and pregnanetriol and pregnanetriolone excretion, 1726–1734
of amino acid in plasma, 1672–1679
of fatty acids of plasma, 237
ion exchange, phenylalanine content of hemoglobin, 1343–1348
of serum acid mucopolysaccharides, 1329–1330
of urinary mucopolysaccharides from rheumatoid arthritis, 1519
Chromium, radioactive
in anemia of hemosiderosis, 1150, 1157–1158
in blood loss with hookworm infection, 1183–1192
Chylomicronemia, and fasting, 859
Chymotrypsin
insulin antagonist, inactivation by, 1589
intestinal concentration, 1529
Circulation. *See* Blood flow
Cirrhosis
and acetazolamide, 934–935*
ascites after post-necrotic, 935*
biliary
electrophoretic serum patterns, 925*
lipoprotein spectrum, 715–717
liver copper content, 1214
pericholangiolitic, 714
secondary to extrahepatic obstruction, 714
carbon tetrachloride-induced and tocopherol metabolism, 1634–1636
forearm circulation in, 246
hemoglobin A_2 isolation, 1621
Laennec's, 716–717
and alcohol
in decompensated, 878*
and hepatic coma, 362

ammonia concentration, 707, 888*
with ascites, 18
bile acid
concentration in plasma, 531–532
conjugation with glycine, 535
body water, 790
copper metabolism in, 1208–1215
cortisone clearance from plasma, 1303
distribution of cobalt labelled vitamin B_{12} in, 18–24
and glutamic acid, 707
hexosamine and protein serum content in, 52–53
seromucoid fractions, 55
α-ketoglutarate of blood after ammonium chloride, 367
lipoprotein spectrum of plasma, 716–717
neuropsychiatric manifestations, 1214, 1216
portal-pulmonary venous anastomoses, 1258–1264
potassium, exchangeable, 787
protein content of seromucoid in, 54
sodium, exchangeable, 785
tocopherol excretion, 1635
varices, esophageal, 1260
vitamin B_{12} serum content in, 22
zinc metabolism, 933*
water diuresis, and antidiuretic mechanism, 936*
xanthomatous, 531, 716–717
Citrate-dextrose, blood storage, 431–433
Citric acid
concentration in blood after glutamate, 708–709, 711
and erythrocyte lysis, 1503–1506
and hyperventilation, 870–871*
metabolism
and acetazolamide, 894–895*
in bone and joint disease, 909–910*
in placenta, 932*
in poliomyelitis
urinary excretion, 968–970
and gonadal steroids, 997–1000, 1013–1015
and oscillating bed, 987, 993
Citrulline, 1673
Coagulation of blood. *See* Blood, coagulation
Colitis, ulcerative, and hypoalbuminemia, 931*
Collagen
affinity for chloride, in extracellular fluid space calculation, 348–349
tendon, water content, 343, 350
thermal degradation of, 41
Colon
intraluminal chloride in, 283–284
water content, 292
Coma
hepatic
blood ammonia and keto-acid, 361–371
copper concentration and thioctic acid, 1211–1214
and hemorrhage, 362, 364–365
and glutamic acid, 707
respiratory alkalosis, 924*
and sodium glutamate, 706–711
insulin
and glucagon, 74–80
plasma 17-hydroxycorticosteroid levels, 545
after intravenous amino acid mixture, 1648, 1649
Compound F. *See* Cortisol
Connective tissue
binding of ions by anionic polysaccharides, 1721
chloride concentration in, 343, 348–350
in renal lesions of epidemic hemorrhagic fever, 150–151, 156–159
Copper
ceruloplasmin and ionic copper in Wilson's disease, 1193–1200
exchange, 927*, 1197–1200
fractionation, in brain, 1213
metabolism
in Laennec's cirrhosis of liver, 1208–1215
and renal function in Wilson's disease, 1107–1113
Coronary artery
circulation
and hypoxemia, 1101–1106
and quinidine, 844–846
and rubidium^{86} uptake, 476–483
disease, serum cholesterol, diet and stress, 897*
Coronary sinus
and hepatic vein differences in unesterified fatty acid, 811
quinidine and blood flow, 844–846
Corticosterone
and circulating eosinophils, 1172
and gastric output
hydrochloric acid, 1173
hydrogen ion concentration, 1174, 1181
pepsin, 1174, 1181
viscosity, 1175, 1180
volume, 1173
and pepsinogen, 1176, 1181
plasma binding, 881–882*
Cortisol
and albumin synthesis, 896*
anabolic activities, 919*
biological half-times after intravenous administration, 67–73, 1303–1304
biosynthesis, 932*
and circulating eosinophils, 1172
and cortisone
conversion to, *in vivo*, 1304–1311
in water diuresis and renal function, 767–773
disappearance rate, 67–73, 1308
urinary excretion, 1307–1311
excretion of radioactive metabolites, 1274
and gastric output, 1173–1175, 1180–1181
and insulin antagonist serum, 1593
metabolism, 67–73
in pregnancy, 1350–1361
in shock, 914*
and pepsinogen, 1176, 1181
and plasma
ACTH in Addison's disease, 1703, 1704, 1706
corticosteroids in Addison's disease, 1705
and potassium metabolism, 872–873*
and triiodothyronine balance studies, 1313–1317
Cortisone
absorption, 1308, 1310
in adrenal cortical dysfunction, 1730
anti-anabolic activities, 919*
biological half-times after intravenous administration, 1303–1304
and calcium metabolism in Paget's disease of bone, 893–894*
versus desoxycorticosterone acetate responses in adrenalectomized rats, 1296–1297
in epidemic hemorrhagic fever, 1694–1697
excretion
biliary, 1307
time factor, after administration, 1306
urinary, 1307–1311
and cortisol
conversion to, 1304–1311
ratio, in plasma, 1308–1310
in water diuresis, and renal function, 767–773
and hyperbilirubinemia, 1370–1373
hypertension induced with, and potassium depletion, 1295–1299
metabolism and disposition, 1301–1311
and myxedema, 891*
and renal function, 767–769
and sodium depletion after adrenalectomy, 911–912*
and water diuresis, 767–769
Creatine
concentration in uremic plasma, 1230
formation rates and conversion to creatinine, 959–961
in poliomyelitis
and gonadal steroids, 997–999, 1016
and phase of disease, 946–949, 951, 954
storage and synthesis, 1011–1012
and testosterone, 995–1012
urinary, 946–949, 952, 1019–1023
and oscillating bed, 986, 987, 993
renal clearance and ethanol, 1203, 1205
Creatinine
clearance
and cortisol, 769–778
and cortisone, 768–769
after diuretic mercury compounds, 662, 665
after norephinephrine, 90–96
ratio to urine osmolatities, 1420
renal, 761
urinary
and exchangeable
chloride, 1380–1381
potassium, 1378, 1380–1381

Creatinine (*cont'd*)
in poliomyelitis, 946–949, 952, 1019–1023
and muscle atrophy, 957, 962, 1027
and oscillating bed, 983, 985–986, 993
reference standard, 1377
Creatinuria, in poliomyelitis, 954, 958–959, 962, 1000–1001, 1011–1012
Cushing's syndrome
adrenal weight-maintaining activity in plasma, 1608–1613
and amphenone, 899*
Cyanmethemoglobin, 620, 626
Cyanocobalamin. *See also* Vitamin B_{12}
in plasma absorption of vitamin B_{12}, 1554–1556
Cystine, and erythrocyte lysis, 1503–1506
Cystitis, urinary protein in, 358
Cytochrome C, in iron deficiency, 874–875*

D

DCA. *See* Desoxycorticosterone acetate
1-Dehydro-17α-methyl-testosterone, 919*
6-Dehydroprednisone, 919*
1-Dehydro-testosterone, 919*
Deoxyadenosine, and erythrocyte lysis, 1502–1506
Deoxycholic acid, protein binding, 538–542
Deoxycytidine, 1503–1506
Deoxyguanosine, 1503–1506
Deoxyinosine, 1503–1506
Deoxypyridoxine, and tryptophan metabolism, 1602, 1606
Deoxyribonucleic acid synthesis by bone marrow cells, 931*
Deoxyribose, 1503–1506
Dermatomyositis, heparin-precipitable plasma fraction in, 611
Desoxycorticosterone acetate
in Addison's disease, 1705
hypertension induced with and potassium depletion, 1295–1299
and potassium metabolism, 872–873*, 1295–1299
and sodium retention, 692
17-Desoxyprednisolone, 919*
Desoxyribonuclease, group A streptococcal, identification of new group, 934*
Deuterium oxide
equilibration, in hydropic subjects, 784, 788–791
and plasma exchange with gastrointestinal water, 289–295
Dextran
allergic reactions and variation in manufacture specifications, 1160–1169
in epidemic hemorrhagic fever, 102
shock, 118
plasma volume expansion hemodynamics, 1233–1238
Diabetes insipidus
and aldosterone activity, 386, 391
and hypernatremia or hyperosmolarity, 885*
and hypotonicity of body fluids, 1204
and Ringer's solution, 885*
water diuresis and antidiuretic mechanism, 936*
Diabetes mellitus
and acidosis, 1126, 1588–1592
alloxan, and sugar transport, 916*
bile acids, in serum and urine, 531
compensated, and skeletal muscle composition, 1242
electrophoretic pattern of spinal fluid and serum protein, 897*
forearm circulation in, 246
glucagon-insulin infusion, 887–888*
and glucose tolerance, 263
and nonesterified fatty acids, 884*
plasma insulin binding in, 395–397, 651, 653
and vitamin B_{12}, 1553
2,6-Diaminopurine, 1503–1506
2,6-Diaminopurine riboside, 1502
Diamox®. *See* Acetazolamide
Dicoumarol®. *See* Bishydroxycoumarin
Diet
and growth in rats, 435
and iron accumulation, 315–324
and obesity, 81–88
potassium and sodium intake and aldosterone activity, 385–387, 390–391
rice and cortisone effects, 768
and serum
cholesterol, 81–88, 917–918*
and stress, 897*
tocopherol levels, 1635
sodium, 385–391
and cortisone, 768
and ACTH, 1296–1299
and cortisol, 769, 776
in hypertension, 1467
Diformyldeoxycholic acid, protein binding, 539
Digitalis, cardio-dynamic responses to, in aortic-caval fistula, 335–339
Dihydrocortisol
biological half-time, 1304
urinary excretion, 1307
Dihydrocortisone
biological half-time, 1304
and cortisone conversion to cortisol, 1309
urinary excretion, 1307
20β-Dihydro-prednisolone, 919*
Dihydroxy bile acid, in hepatic disease
and chenodeoxycholic acid serum content, 535
and serum bilirubin concentration, 536
and trihydroxy bile acid ratios in bile, 530, 532–534
Dilatol®, vascular sensitivity to, individual differences, 1290
Dimercaprol
and copper, urinary excretion, 1211, 1214
hypoglycemic properties, 921*
Diphenhydramine, in epidemic hemorrhagic fever, 1694–1697
Diphosphopyridine nucleotide
dehydrogenase, in liver, 1581, 1584
and erythrocyte glutathione, 623, 626
succinate cytochrome C reductase from heart muscle, 921–922*
Dipyrrylmethene, fecal, anabolic significance, 893*
Diuresis
bicarbonate and acetazolamide, 920–921*
in epidemic hemorrhagic fever, 99–100, 121–127, 130–131
in heart failure, cellular and extracellular alterations, 903*
and heparin-precipitable fraction levels, 609, 613
mannitol, and renal concentrating ability, 631, 635–637
and morphine, 918–919*
and phenobarbital clearance, 1221–1222
poisoning, 1224–1225
phosphate, and parathyroid extract, 564
and vasopressin, 629
water
chloride clearance, 1418–1419, 1423
and cortisol, 769–778
and cortisone, 768–769
in diabetes insipidus and hepatic cirrhosis, 936*
and ethanol, 1202–1206
and reduced renal plasma flow, 1416–1419
after sodium loading, 308, 882*
Diuretics, mercurial, structure and activity, 656–668
Dysarthria, and swallowing dynamics, 590–595
Dysphagia
swallowing mechanics, 589–595
and esophago-gastric sphincter, 930*
Dyspnea
during antigravity suit inflation, 65
in aortic-caval fistula and Lanatoside C, 336
in pulmonary hemosiderosis, 1154

E

Edema
and aldosterone excretion, 388, 390
in epidemic hemorrhagic fever, renal lesions, 106–109
cortical intertubular, 136–139, 144–145, 150–151
retroperitoneal, 102, 106, 128
and equilibration
of deuterium oxide, 784, 788–791
potassium, 784, 787–788, 791
sodium, 784–786, 788, 791
pulmonary, and Lanatoside C, 336–339
of traumatized muscle, 829
EDTA. *See* Ethylenediaminetetraacetic acid
Electrocardiography
apex impulse, in mitral insufficiency, 1036–1037
cellular basis for changes and serum potassium, 897*
in diastolic gallop sounds, 1035–1041

in transmission of atrial impulse to ventricle, 883*
Electroencephalography
with elevated blood ammonia, 913*
in viral myoclonus, 912*
Electrolyte. *See also* specific electrolyte
balance
in aldosteronism, 923*
in epidemic hemorrhagic fever, 99–100
exchange in acidosis, 374, 376, 379
excretion
and ammonium chloride load, 759, 764–765
in arterial hypertension, 1460–1468
in hyperventilation, 520, 528
gastrointestinal, 289–295
in heart failure, 901*, 903*
hypothalamic lesions, and satiety responses in mice, 1638–1641
ionization of synthetic poly-, 1715–1722
metabolism in alkalosis, 522
pancreatic secretion and acetazolamide, 904–905*
urinary excretion
after ammonium chloride, 759, 764–765
after sodium loading, 305–308
and water absorption in sprue, 265–268
Electromyography
in periodic paralysis, improvement with potassium, 731
in viral myoclonus, 912*
Electrophoresis
diffusates from burned skin, 40–43
globulin mobility, 459, 466
of hemoglobin
A_2 separation, 1615–1624
genetic basis of differences, 753–756
after irradiation of iodinated albumin, 45–49
alterations, 49
insulinase activity and plasma proteins, 651–654
insulin-binding antibody identification, 643–645
in isolation of menopausal gonadotrophin, 928–929*
of macroglobulin, 459–460, 466
and nephelometric methods, 1366
of plasma, fetus and placenta, 399–401
plasma fractions
mobility of lipoproteins, 849
nephelometric analysis, 1364
precipitable, 600
in rheumatoid arthritis, 309–313
of serum
alkaline phosphatase activity, 924–925*
in diabetes mellitus, 897*, 1590
hexosamine content of globulins, 52–57
insulin antagonist, 1589–1590
in myeloma, 353–354, 888*
new protein identified, 903*
radioiodinated insulin, 394
sialic acid, 454
in thyroiditis, 780–782
of sputum, in pulmonary carcinomatosis, 877*
of stored erythrocytes in acid-citrate dextrose, 225–231
in thyroxine binding, 28
and pH, 1333–1341
of urinary mucopolysaccharides, 1519
Emphysema
and aminophylline, 892*
and epinephrine, 869*
mechanical behavior of lungs, 1685
diffusing capacity after obstructive, 5, 13–16
respiration regulation, 891–892*
Encephalitis, 612
Encephalomyelitis, and Newcastle disease virus, 912*
Endotoxin
lethal action,
and fibrinoid lesions in Shwartzman reaction, 695–699
and plasma factor, 900*
shock, and cortisol, 914*
Enzyme
cholesterol-esterifying activity, 720
defects in galactosemia, 929*
hydroxylating system, 932*
in Laennec's cirrhosis, 535–537
iron-containing, in iron deficiency, 874*
liver
at autopsy, 1584
in kwashiorkor, 1581–1582
pancreatic juice content, 1529–1530, 1534
sulfhydryl, inhibitors, *in vitro,* and diuretic activity, *in vivo,* 666, 668
time relationship in intestinal content after ingestion, 1529–1560
Eosinopenia, and adrenocorticotropin, 1180
Epidemic hemorrhagic fever
capillary lesions in, 1688–1700
therapeutic agents, 1694
renal lesion in, 99–223, 895–896*
physiological disturbances, 101
See also Kidney
Epinephrine
and blood glucose, 898*
and hypertension, 1325
plasma concentration, 892*
and pressure-volume responses in forearm, 886*, 1663–1671
after phentolamine, 1668–1669
and pulmonary
circulation, 670–673
emphysema, 869*
Erythema
forearm circulation, 246
palmar, in hepatic cirrhosis, 888*
Erythroblastosis fetalis, Cr^{51}-labeled red cells survival, 1439
Erythrocytes
ABO-incompatible, 1430–1433
and aging, 676–679, 903*, 913*
in anemia. *See* Anemia
autogenous, agglutinated, distribution in body tissue, 1433
autohemolysis, 817, 822
carbohydrate metabolism, 625
in paroxysmal nocturnal hemoglobulinuria, 869*
carbon monoxide uptake rate, 8
chloride concentrations, 340–341, 343, 345, 350
and in extracellular fluid, 34
destruction, 833–841
by antibodies, 1428–1457
in hypoagammaglobulinemia, 1455
by isoagglutinins and by isohemolysins, 1431
pathways of, 1456
of sequestrated, 1440
drug-sensitive, and glutathione, 617–627
exchangeable chloride, 281
fragility
osmotic, 227, 819, 822, 1471
and promethazine after inosine, 231
and temperature, 228
fusion to hyaline masses, 136–137
glucose content, 886*
glutathione, destruction mechanism, 617–627
glycolytic pathways and sodium transport, 822
hemoglobin
A_2 separation, 1617
concentration and sickling phenomenon, 833–842
hemolysis
and acetylphenylhydrazine, 623–626
hypotonic, 903*, 913*, 1498–1506
and pH, 1499
paroxysmal nocturnal hemoglobinuria, 900*
reutilization, 1447, 1452
and time of storage, 230
in hereditary spherocytosis, and sodium transport, 816–822
hypochromia, in rheumatoid arthritis, 1056
hypoxanthine/inosine ratio in storage, 430–431
iron
handling by reticulo-endothelial cell, 875–876*
turnover rates, 1049–1050
lysis, 1443, 1452
mass
and exchangeable chloride, or potassium, 1378–1381
reference standard, 1377
metabolism, 938–939*
and thiamin deficiency, 936–937*
non-circulating in epidemic hemorrhagic fever, 129
and plasma
potassium movement, 726
after sodium loading, 306–308
preservation, 429–433
radioactivity in, after radioactive iron, 1046–1049
pulmonary hemosiderosis, 1153, 1156
radiolabeled, 1428–1457, 1470–1485
in age study, 676–679
in hookworm infection, 1183
spleen and liver ratios, 1471–1485
in renal lesions of epidemic hemorrhagic fever, 129, 146–147
riboflavin in kwashiorkor, 1583

Erythrocytes (*cont'd*)
sedimentation rates
in carditis, 607
in heart failure, 607
and heparin-precipitable plasma fraction, 598
in rheumatic fever, 452–454, 607, 610, 613
sequestration
and agglutinating antibody, 1430–1433
non-agglutinating, 1433–1440
Fe^{59}-labeled reticulocytes for evidence, 1443–1447
in hemolytic anemia, 1475
in liver, 840
in lung, 1157
sickling, *in vitro* at oxygen tensions, and pH, 836, 842
size, after exposure to dextrose, 886*
sodium concentration in, 346
splenic trapping, 1470–1485
storage, in acid-citrate-dextrose, 225–231
surface membranes, 816, 822
survival studies, 1043–1056, 1439, 1471–1473
time and methods, 1150, 1153–1154, 1157
thyroxine binding, 28
Erythropoiesis, in pulmonary hemosiderosis, 1150
Erythropoietin, plasma, activity, 896*
Erythrose 4-phosphate
conversion to
ribose, 1410–1412
xylulose-2-C^{14}, 1411–1412
synthesis, 1410
Escherichia coli, radiochromium labeled, in Shwartzman reaction, 695–699
Esophagus
and drinking without swallowing, 586
intraluminal pressures, 582
in dysphagia, 589
pain stimulation, 911*
in swallowing
catheterization for patterns, 930*
propulsion of bolus through, 586–587
Estradiol
metabolism, and hepato-biliary-enteric circulation in women, 1266–1277
in poliomyelitis, 996–1001
radiolabeled, bile excretion, 1267, 1274–1275
in bile fistula, 1269
Estrogen
biliary excretion and metabolism in women, 1274
and hypercupremia, 1214
and lipoprotein concentration, 720
metabolism, possible pathways, 1275
and nitrogen excretion, 1011, 1016
and androgen, 1014, 1015–1016
Estrone, metabolism, and hepato-biliary-enteric circulation in women, 1266–1277
Ethanol. *See also* Alcohol
fractionation of serum, 642–646, 655
Ether
anesthetic effects, and sodium bicarbonate, 1221
metabolic acidosis, 1126
and plasma carbon dioxide content, 1123
and phosphorus metabolism, 898*
Ethylenediaminetetraacetic acid
and heparin-precipitable plasma fraction, 597
plasma and urine responses, to phosphate and calcium, 568–571
Exercise
and blood ammonia, 927–928*
and cardiac output, 6, 1140
ear oximeter for repeated measurement, 894*
and heart rate, 1145
oxygen consumption during, 7–8, 1140, 1146
pulmonary artery pressure responses, 1138–1148
diffusing capacity, 6–16
and splanchnic glucose production, 906*
vascular resistance during, 1141–1144, 1146
Exophthalmos, and myxedema, 891*
Extremity. *See also* Forearm
hyperemia, and smoking, 937*
paralysis, and potassium movement, 731
in poliomyelitis, 953
and gonadal steroids, 1009–1011, 1016
and oscillating bed, 990

F

Fat. *See* Lipids; and **Fatty Acid, unesterified**
Fatigue, and hydration, 631–633
Fatty acid, unesterified
arteriovenous differences
and amino acid, 812–813
from coronary sinus and hepatic vein, 811
after glucose and insulin, 812, 814
saphenous vein samples at cardiac catheterization, 812
and carbohydrate utilization, 884*
metabolism, 890*
transport function, 810–814
Feces, excretion
anabolic significance of dipyrrylmethane and mesobilifuscin, 893*
in bile fistula, 1267–1277
calcium metabolism, 685, 1023–1027
and hypocalcemia, 437
in cholecystitis, 1186
in estrogen metabolism, 1275
gastrointestinal chloride, 284
in hookworm infections, 1183–1192
in iron absorption studies, 316–321
and nitrogen
balance, 571, 1019–1023
multiple myeloma, 355
phosphorus, 1023–1027
and aluminum gel, 571
in poliomyelitis, 1019–1027, 1267, 1275
and strontium metabolism, 682–683, 685
urobilinogen
and cortisone, 1372–1373
in hemolytic anemia, 1471
in hemosiderosis, 1157
in rheumatoid arthritis, 1052, 1055
Fetus
plasma protein synthesis, 398–403
serotonin concentration, and 5-hydroxytryptophan, 1596
Fever
epidemic hemorrhagic, 895–896*
capillary vascular system, 1688–1700
and cortisone, 1694
and diphenhydramine, 1694, 1698
and norepinephrine, 1694, 1695, 1697
renal lesions, 99–223
tetracyclines, 1694, 1697
Q and capillary injury, 896*, 1688, 1698
Fibrinogen
cold-solubility of isolated and heparin, 600–601
and fibrinoid lesions, 615
interference, with β-lipoprotein determinations, 1368
migration rate, electrophoretic, 600
and plasma heparin-precipitable fraction ratio, in diseases, 607–616
synthesis, rate, 417
Fibroadenoma, of breast, and glucose tolerance, 255
Fibroendocarditis, diffusing capacity of lung, 13–16
Fibrosis
and pulmonary diffusing capacity, 13–16
in renal lesions of epidemic hemorrhagic fever, 128–129, 158–159
Fistula
aortic-caval, hemodynamics after Lanatoside C in, 335–339
biliary
and tocopherol metabolism, 1627–1637
urinary excretion of estrogen metabolites in, 1269
broncho-pleuro-cutaneous, 13–16
Fluid
absorption, and dehydration, 630–633
ascitic, 28
electrolyte equilibria in, 786, 788, 790
balance, in epidemic hemorrhagic fever, 99–100
cerebrospinal
ammonia content, and thioctic acid, 1211–1212, 1214
copper content in Laennec's cirrhosis, 1210, 1214
after thioctic acid, 1211
encephalographic volume measurement, 911*
in hepatic coma, 366, 371
and hydration, 631

protein patterns in diabetes, 897*
extracellular, 27, 38
acid-base disturbance, 522
chloride space in, 340–350
hydrogen ion concentration, 381
magnesium concentration, 347–348
in potassium depletion, 764–765
and sodium
depletion, 764–765
excretion, 1461–1463
injection, 435–436
spaces, 340–350
thiosulfate, single injection and infusion/slope methods, 329–333
and thyroid therapy, 423–425
volume, 1461–1463
in acidosis, 374–381
and arterial pressure, 1321
forced drinking, and renal concentrating ability, 630–633
hypotonicity, and diabetes insipidus, 1204
interstitial, chloride content in, 279
intracellular, 423–425
potassium accumulation, 897–898*
in skeletal muscle, 1244
pleural, electrolyte equilibria in, 786, 788, 790
subcutaneous, electrolyte equilibria in, 786, 788, 790
and thyroxine binding, 27–28, 36
transcellular
chloride content, 279
potassium movement, 723–736
and xylose infusion distribution, 1399

Fluorohydrocortisone, in Addison's disease, 1705–1706

Folic acid antagonists, and 6-mercaptopurine in leukemia, 887*

Forearm
circulation in
components of, 245–253
periodic paralysis, 734–736
muscle, potassium movement, 723–729, 731–736
and oxygen consumption, 727–728
venous responses
to epinephrine, 886*
norepinephrine, 1663–1671

Fructose
blood clearance and urinary excretion, 1402
and erythrocyte lysis, 1503–1506

Fructose 6-phosphate
in ribose phosphate production, 1410–1412
synthesis, 1410
in xylulose-2-C^{14} phosphate production, 1411–1412

Fumaric acid, and erythrocyte lysis, 1503–1506

G

Galactosamine
in hexosamine, 1330
mucopolysaccharide, in rheumatoid arthritis, 1518
sulphated-N-acetyl in sodium chondroitin sulfate structure, 1716

Galactose, 929*
and erythrocyte lysis, 1503–1506
metabolism, 1402
accessory pathway, 902*

Galactosemia, enzymatic lesions, 929*

Gallbladder
after meal ingestion and bile acid release, 1531–1532, 1534
and metabolism of phenolic steroids, 1267

Gallop sounds
auricular, 910*
diastolic, 1035–1041
in mitral valve disease, 902*

Gas
alveolar, diffusing capacity test, 4–5
blood content, and cerebral blood flow, 1132–1133
exchange
during spontaneous paralysis, 734
in respiratory cycle, 1556–1571
uptake, measurement in infants, 1081–1082, 1090–1091

Gastrectomy, iron absorption after, 323

Gastric secretions
and adrenal cortex, 1171–1181
composition, 1179–1180
hydrochloric acid, 1173
hydrogen ion concentration, 1174
pepsin, 1174
viscosity, 1175–1176, 1180–1181
volume, 1173

Gastrointestinal tract
absorption
of radiochromium labeled red cell, 1183–1187
of radiolabeled vitamin B_{12}, 1554–1556
from, in sprue, 265–268
from, of tocopherol, 1630–1633
blood and iron loss in hookworm infection, 1188–1192
chloride content, 279–287
in gut, 294–295
intracellular, 343–350
cholesterol excretion, 898*
cortisone absorption, 1310
dietary content and lumen iron, 324
digestion and absorption, 1521–1534
pH of content, 1533–1534
electrolyte, 265–268, 346
and water content, 289–295
hemorrhage, 362, 364–365
intraluminal biopsy, 881*
mercury uptake and binding, 661, 664
motility
and 5-hydroxytryphtophan, 1597–1598
serotonin, 1598
nitrogenous material and ammonia, keto-acids in hepatic coma, 364–365
pain stimulation, 911*
and plasma exchange
acid, 380
chloride, 284–287
and polyethylenglycol absorption, 1521–1534
potassium absorption, 294–295
sodium absorption, 265–268
strontium excretion, 687
water content, 292
absorption from, 265–268

Gelatin, release after thermal injury, 41–43

Giraffe, circulation and respiration, 919*

Globulin
alpha, 54
corticosteroid binding in plasma, 881–882*
hexosamine content, and anti-inflammatory hormone, 53
in rheumatoid arthritis, 309–312
thyroxine-binding in nephrosis, 1336–1342
$alpha_1$, insulin antagonist activity, 1589–1590, 1592
$alpha_2$
mobility, 459, 466
protein content, 54
beta, 459, 466
ratio comparison by electrophoretic and nephelometric methods, 1366
sub-fractions, 402
gamma
antigenic similarity to macroglobulin, 462–463
gamma
electrophoretic mobility, 458–459, 466
of fetus, 403
insulin binding with, 393–397
serum level for lymph node homotransplant, 410
synthesis, rates measured, 417
insulin-binding, 642–646
lipoprotein-containing, deoxycholic acid binding by, 538, 542
migration of denatured albumin with, 45
myeloma serum, Schiff-positive material, 357
plasma, immunological relation, 402–403
serum
hexosamine content of, 51–57
molecular weight, 357
synthesis by placenta, 400
typhoid O-beta$_2$ and H-gamma synthesis, rates, 417

Glomerular filtration rate
and arterial pressure, 1326
and autonomic vasoregulatory reflexes, 1327
in coarctation of aorta, 1540–1541
after cortisol, 770–771
intravenous infusion, 774, 776
after cortisone, 770–771
in diuresis
mercurial compounds, 659–665
phosphate, 564
sodium, 304, 307, 882*
water, and renal artery cuff, 1416–1419
and inulin clearance in hypertension, 1464, 1468

Glomerula filtration rate (*cont'd*)
and morphine, 919*
and norepinephrine, 89–96
and potassium excretion, 882*
and rate of vasopressin infusion, 1067
and renal reabsorption of phosphate, 551–555, 564
in respiratory acidosis and alkalosis, 522
after saline infusion in postural hypotension, 1324–1325
and sodium excretion, 1326
and theophylline, 328
and urine composition in renal disease, 885*
and vasopressin, 630, 633
in Wilson's disease, 1108–1109
Glomerulonephritis
antibody response in, 876*
exchangeable body
deuterium oxide, 790
potassium, 787
sodium, 785
Glomerulosclerosis, diabetic, 785, 787, 790
Glucagon, and insulin, 74–80, 887–888*, 1591, 1593
Glucosamine
in hexosamine, 1330
mucopolysaccharide, in rheumatoid arthritis, 1518
Glucose
arteriovenous difference
in spontaneous paralysis, 734–735
of unesterified fatty acid, 812, 814
blood level
clearance rate, 1402
and glucagon, 74–80
for insulin coma termination, 79
and glutamate, 708–711
and insulin
hypoglycemia, and chlorpromazine, 547
pentose response to, 1383–1393
in periodic paralysis, 734–736
attack induction, 733
and tolbutamide, 889*
dosage, and body size, 510
for epidemic hemorrhagic fever, 102
and erythrocyte glutathione protection, 621, 623, 626
and hemolysis of blood in paroxysmal nocturnal hemoglobulinemia, 869*
intestinal absorption, 1524
and concentration, 1527
lipid concentration in lipoprotein fractions after, 856–859
metabolism
and erythrocyte aging, 913*
in malignant disease, 254–263
of phosphorus during anesthesia, 898–899*
oxidation, 734, 736
and synthesis of cholesterol and fatty acids, 929–930*
radiolabeled, in glycogen formation, 1280–1284
incorporation pattern, 1282
renal function in Wilson's disease, 1109, 1112–1113
splanchnic production and muscular exercise, 906*
stereochemical configuration, 1383
tolerance
age differences, 504–512
in malignancy, 254–263
transport, through kidney, 879*
uptake
by forearm tissue, 728–729
and lactate production in paralysis, 734
urinary, 1402
after renal artery clamping, 1418, 1423
Glucose-6-phosphate
and erythrocytes, 913*, 1503–1506
in ribose phosphate production, 1410–1412
in ribulose-5-phosphate production, 1281
synthesis, 1410
in xylulose-2-C^{14} phosphate production, 1412
Glucose 6-phosphate dehydrogenase, in ribose-1-C^{14} phosphate production, 1411
Glucuronic acid
in chondroitin sulfate structure, 1716
mucopolysaccharide in rheumatoid arthritis, 1518
Glucuronidase
hydrolysis
of cortisone metabolites, 1311
estradiol and estrone, 1272, 1275
after radiolabeled cortisol, 1351, 1353, 1357
after radiolabeled cortisone, 1304
urinary concentration of tetrahydrocortisone versus tetrahydrocortisol, 1310
Glucuronide
anthranilic acid and tryptophan, 1602, 1604
and benzoate, salicylate metabolism, 297–302
bilirubin, biosynthesis, *in vitro*, 927*
urinary excretory patterns, 299–302
Glutamate
content of plasma, 1674–1677
conversion to ketoglutarate, 711
hemoglobin content, 1345
in phenylketonuria, 1346–1348
and hepatic coma, 706–711
and asparagine, 709
and bilirubin concentration, 707
and unesterified fatty acid concentration, 814
Glutamic acid
and erythrocyte lysis, 1503–1506
in hepatic coma and elevated blood ammonia, 913*
incorporation into myeloma proteins, 355–356
plasma, 1228
uremic, 1229–1231
Glutamine
concentration, after glutamate infusion, 708–709
plasma levels, 1674–1676
after surgery, 1677
Glutathione and erythrocyte
destruction mechanism, 617–627
and lysis, 1503–1506
in naphthalene hemolytic anemia, 938–939*
Glyceraldehyde-2-C^{14}, production, 1413
Glyceraldehyde-phosphate
in ribose phosphate production, 1410–1412
synthesis, 1410
in xylulose-2-C^{14} phosphate production, 1411–1412
Glycerides, serum content
after fat ingestion, 850
after glucose, 857
Glycinamide ribotide, in nucleotide synthesis pathway, 1572
Glycine
and ammonia production, 1650–1651
toxicity, 1653
concentration
after glutamate infusion, 709
plasma, 1228, 1674–1676
and serine, 1676
after surgery, 1677
uremic, 1229–1231
and erythrocyte lysis, 1503–1506
isotopically labeled, 1510–1514, 1573
1-C^{14} versus N^{15}, 1512, 1514
and taurine, in bile acid conjugation, 534–535
Glycocholic acid, plasma binding, 538–539
Glycocyamine in poliomyelitis
and estradiol benzoate, 1001
and testosterone, 997–999, 1016
combined, 1004, 1016
Glycodeoxycholic acid, plasma binding, 538–539
Glycogen, formation, 1279–1283
Glycolic acid
and erythrocyte lysis, 1503–1506
oxidase, in liver
at autopsy, 1584, 1585
in kwashiorkor, 1581, 1585
Glycoprotein
liberation, after thermal injury, 42
serum, in rheumatoid arthritis, 309–313
Glycosuria
and adrenal corticoids, 890–891*
and dimercaprol, 921*
and Wilson's disease, 1109, 1112
Goiter
diffuse hyperfunctioning, and thyrotropin, 905*
thiouracil-induced, 885*
thyroid hormone-plasma protein complex, 1487, 1495
Gonadotropin
isolation studies, in menopause, 928–929*
in Klinefelter's syndrome, 909*
in placental metabolism, 932*
Gout
anti-inflammatory hormone therapy, 54
hexosamine and protein serum content in, 52–53, 55

hyperuricemia, 938*
and alcohol, 1509
and uric acid overproduction, 1508–1514
suppression, and 4-amino-5-imidazolecarboxamide in uric acid, 908*
uric acid, 908*
degradation, 1512
overproduction, 1508–1514
Growth hormone
and adrenal weight of hypophysectomized rat, 1612
and insulin antagonist serum, 1591
and cortisol, 1593
metabolic effects, in human and monkey, 873*
preparation from pituitaries, 921*
G suit inflation, responses, 59–66
Guanosine
and acid-citrate-dextrose blood storage in, 431–433
and erythrocyte lysis, 1502
and uric acid excretion, 433
in leucopenic leukemia, 432

H

Haptene, for immunoreaction, 929*
Headache
in epidemic hemorrhagic fever, 102
and hydration, 631
vascular, and dextran, 1234
Heart
beating, isolated, 889*
blood volume in, 901*
copper concentration in Laennec's cirrhosis, 1212, 1215
endotoxin uptake, 696
fetal
protein synthesis, 400–401
and serotonin, 1598
gallop sounds, 902*, 910*, 1035–1041
hemodynamic responses to posture and atropine, 1656–1662
and isopropylnorepinephrine, 883*
mercury uptake and binding, 661, 664
muscle
electron transfer system, 921–922*
nucleotide metabolism, 1572–1577
and norepinephrine, 479–483
plastic surgery, new concept in prosthesis, 892–893*
potassium turnover in regions of, 479–483
pumping capacity and oxygen uptake in mitral stenosis, 915–916*
rate
and atropine, 1657
and peripheral pooling, 1658
and coronary blood flow, 1103
and exercise, 1145
in hypoxia and heat stress, 1643
and Lanatoside C in aortic-caval fistula, 336–338
and norepinephrine, 90–96
and rubidium uptake rate, 473, 476
responses to quinidine, 844–846
spasm, distal segment in, and vestibular sphincter, 930*
stroke volume, 1658–1659
in coarctation of aorta, 1540, 1543
and peripheral pooling, 1658
thyroxine uptake, 29
and vasopressin, 479–483
work
and exercise, 1140–1148
and nitroglycerin, 895*
and plasma expansion by dextran, 1234
Heart disease
and body exchangeable
deuterium oxide, 790
potassium, 787
sodium, 785
congenital, acidosis in, 273
gastrointestinal chloride concentration, 286
and gastrointestinal water concentration, 293
pregnancy in serial cardiac output, 880*
pulmonary and cardiac blood volumes, 901*
radiosodium distribution in transudates and serum, 786
rheumatic, antigen reaction, 795
Heart failure, 390
and aldosterone secretion, 689–693
and edema, 388–389
and serum potassium, 390
anastomosis
injection mass in esophageal and venous beds, 1258
porto-caval and porto-pulmonary, 1257–1264
cellular and extracellular changes in water and electrolytes, 903*
circulation-time measurement, 919–920*
electrolyte and water metabolism, 901*
fibrinogen levels, 607–608, 614
in fistula, aortic-caval, 336–339
and gallop sound
presystolic, 1037
protodiastolic, 1040
right-sided, 1038–1039
and hemodynamics after coarctation of aorta, 1543
and heparin-precipitable plasma fractions, 607–610, 614
and ACTH, 607–608
and Lanatoside C, 338–339
peri-esophageal vein dilation, 1262
in rheumatic fever, 614
and systemic arterial hypertension, 1543
Helium, and lung diffusing capacity, 8
Hemangioma, heparin-precipitable plasma fraction values in, 612
Hematemesis, in epidemic hemorrhagic fever, 129
Hematocrit
in anemia
of rheumatoid arthritis, 1471
sickle cell, and blood viscosity, 836–841
in aorta and spleen, 1451
arterial
after hexamethonium, 861
and quinidine, 844–846
after saline, 1461–1462, 1466
in coarctation of aorta, 1540–1541
and dextran expansion of plasma, 1234, 1235
in epidemic hemorrhagic fever, 99–100, 113, 118
after erythrocyte exposure to dextrose and sodium chloride, 886*
in gout, 1509
in hereditary hemoglobinopathies, 834–843
and infectious illnesses, 1694–1696
iron absorption, 316–324
and plasma corticosteroids temperature responses, 1644
responses to obesity, 84
after sodium load, 306–308, 764
Hematomata, 129
Hematuria, 118
Hemochromatosis
absorption of radioiron in, 314–324
electrophoresis of erythrocytes from, 229
hemoglobin A_2 isolation, 1621
Hemodynamics
cardiac
in aortic-caval fistulas; Lanatoside C, 335–339
and posture; atropine, 1656–1662
in mitral valve disease, 876*, 917*
after plasma expansion by dextran, 1233–1238
pulmonary and serotonin and serotonin antagonists, 924*
renal
and "cell separation theory," 872*
in hypertension, 871–872*
and norepinephrine, 89–96
after parathyroid therapy, 565
and postural hypotension, 1326–1327
in respiratory acidosis and alkalosis, 522, 528
visceral, in coarctation of aorta, 1537–1543
Hemoglobin
A_2 isolation, 1615–1624
comparison of human and primates, animals, 1622–1623
distribution, 1619–1620
properties, 1618
acetylphenylhydrazine-modified and glutathione destruction, 620, 624–627
arterial, and quinidine, 844–846
and cerebral circulation, 1133
concentration
in anemia, 1045–1046, 1471
in hemosiderosis, 1154, 1157–1158
and viscosity of hemoglobin solutions, 835
-creatinine clearance ratio after norepinephrine, 90–96
crystallization of, 230
in erythrocyte extract, 226
Fe^{59}-labeled reutilization, 1446
in gout, hyperuricemic, 1509
hereditary differences, 753–756
species difference, 756

Hemoglobin (*cont'd*)
heterogeneity of, 229
in hookworm infection, 1188–1192
iron absorption, 316–324
oxidation
and carbon monoxide production, 912*
viscosity, 835
phenylalanine content, in phenylketonuria, 1343–1348
plasma levels after radiolabeled red cells, 1430–1432, 1443–1444
in pulmonary capillary bed and diffusing capacity of lungs, 922*
renal
clearance, 89–96
transport, 908*
S-type
hereditary hemoglobininopathies involving, 833–842
peripheral arteriovenous shunt, 896–897*
and sickling, 836, 840–842
uptake of radiochromium, 1186–1188
Hemoglobulinemia, paroxysmal
antibodies, 891*, 900*
nocturnal, 869*, 900*, 1471–1473, 1477–1478
Hemophilia
familial, platelet correction, 878–879*
hemoglobin A_2 isolation, 1621
Hemopoiesis, hemoglobin A_2, per cent prevalence, 1621
Hemorrhage
and hepatic coma
gastrointestinal, and ammonia, 362, 364–365
and glutamic acid, 707
and pulmonary
disposition of erythrocyte iron, 1157
hemosiderosis, 1150
and Stuart clotting defect, 485–495
"female bleeders," 500
genetic aspects, 497–502
Hemosiderin, and serum iron levels in hepatic siderosis, 1723–1725
Hemosiderosis
hepatic, and iron intake, 1723–1725
pulmonary
diffusing capacity, 13–16
idiopathic, 1150–1158
Heparin
and albumin
as anti-lipemic agent, 925*
and plasma cholesterol, 701–703
and calcium binding, 597–598
and cold solubility of isolated fibrinogen, 600
and lipemia clearance in nephrosis, 701–704
plasma precipitable fractions, 596–616
clinical studies, 605–616
isolation and characterization, 596–603
Hepatitis
bile acid, serum and urine content, 531, 533
forearm circulation in, 246
hexosamine and protein, serum content in, 52–53, 55
infectious, 531, 533, 714
fecal excretion of tocopherol, 1635
lipoprotein spectrum, 716–717
and obstructive jaundice, 714–717, 720
serum, and lymph node homotransplantation, 416
Hepatoma
lipoprotein spectrum, 716–717
and obstructive jaundice, 714
Heredity
gene transmission of spherocytosis, 822
of hemoglobin differences, 753–756
of Stuart clotting defect, 497–502
Hexamethonium
hemodynamics after, 860–864
and pulmonary vascular engorgement, 62–63
Hexosamine
content of serum globulins in disease, 51–57
and hormone therapy, 57
and uronic acid molar ratios in protamine precipitates, 1330
Hexose
release, after thermal injury, 41–43
and osmotic lysis of erythrocytes, 1504
Hippuric acid, and benzoate, 302
Histamine
bronchoconstriction, 674
and Dilatol®, 1290
and gastric output
hydrochloric acid, 1173
hydrogen ion, 1174, 1181
pepsin, 1174, 1181
volume, 1173
and promethazine, 1290
and pulmonary circulation, 671–675
release
in anaphylaxis, 1115–1119
after thermal injury, 38–43
temperature responses, 1285–1293
in achlorhydria, 1289–1290, 1293
Histidine
and nitrogen balance, 1647–1655
plasma levels, 1228, 1674–1677
after surgery, 1677
uremic, 1229–1231
Hodgkin's disease
glucose tolerance, 256–258
hemoglobin A_2 isolation, 1621
plasma erythropoietin activity, 896*
plasma heparin-precipitable fraction values in, 612
Homograft, survival, 405–419
Hookworm, intestinal blood loss in infections from, 1183–1192
Hormone. *See also* specific glands; specific hormones
antidiuretic
after alcohol ingestion, 1204–1206
antagonism of cortisone and cortisol, 776–777
and hydration, 629–633
and morphine, 918–919*
and potassium, 918*
rate constant defined, 1067
role in hypertonic urine production, 1425–1426
and sodium excretion after isotonic saline infusion, 1323–1324
and water metabolism, 882–883*
anti-inflammatory and hexosamine content of serum globulins, 51–57
protein, irradiation damage to, 49
Hydration
in adrenalectomized rats and cortisone versus desoxycorticosterone acetate, 1299
and isotope equilibration of electrolytes, 790
and renal concentrating ability, 629–633
and sodium depletion, 1299
Hydrochloric acid
gastric output, and adrenal cortical steroid infusion, 1173
metabolism, and hydrogen ion distribution, 373–381
Hydrocortisone. *See* Cortisol
Hydrogen ion
concentration
and albumin binding of cholanic acid, 540
in gastric juice, 1174, 1181
distribution, and degree of metabolic acidosis, 373–381
excretion, in respiratory alkalosis, 517, 520, 527
Hydronephrosis, urine composition, 885*
Hydrosulphite, and erythrocyte glutathione, 620–621
11 β-Hydroxyandrostenedione, from cortisol, 1274
3-Hydroxyanthranilic acid, 1602
17-Hydroxycorticosteroids
and aldosterone output, 911*
in hypoxia, and heat stress, 1643–1645
plasma, in poliomyelitis, 956
urinary excretion, 760–761, 763
and ACTH, 1172, 1177, 1180, 1317
after cortisol and triiodothyronine, 1314–1316
5-Hydroxyindoleacetic acid, urinary excretion, 1596
3-Hydroxykynurenine, and tryptophan, 1601–1602, 1604
Hydroxylamine, and acyl glucuronides, 302
3-Hydroxymercuri-2-methoxy-1-propylcarbamyl-0-phenoxyacetate, 658, 662
Hydroxyproline, release after thermal injury, 41–43
5-Hydroxytryptamine. *See* Serotonin
5-Hydroxytryptophan, metabolism, and pharmacological effects, 1594–1598
Hyperadrenocorticism, and amphenone, 899*, 932*
Hyperbilirubinemia
and cortisone, 1370–1373
and prednisolone, 1372–1373
Hypercalcemia
after hypervitaminosis D and milk-alkali syndrome, 899*

in osteolytic disease, 887*
after parathyroid therapy, 560, 565
in poliomyelitis, 977–978
Hypercalciuria
in osteolytic disease, 887*
in poliomyelitis, 966–981
Hypercholesteremia
in nephrosis, 703, 1563
pathogenesis, 1564
trihydroxy bile acid concentration, 537
Triton-induced, 1563
Hypercupremia, in Laennec's cirrhosis, and estrogen, 1214
Hyperemia
blood flow of foot and smoking, 937*
in epidemic hemorrhagic fever, 104
splanchnic, in coarctation of aorta, 1543
Hyperglobulinemia
Cr^{51}-labeled red cell destruction in, 1441
Hyperkalemia
in acidosis, 381
after adrenal tumor removal, 923*
and sodium depletion, 384
and urinary aldosterone, 391
Hyperlipemia
albumin-heparin as anti-lipemic agent, 925*
bile acids, in serum and urine, 531
after fat ingestion, 849–850
in nephrosis, 701–704, 873*, 1563–1564
pituitary function in, 872*
Hypernatremia
and diabetes insipidus, 885*
and hypocalcemia, 434–439
Hyperparathyroidism
and Paget's disease of bone calcium studies, 893–894*
after parathyroid therapy, 560
Hyperphagia, and satiety responses in mice, 1638–1641
Hyperphosphatemia, after muscle trauma, 831
Hyperplasia
adrenal
and amphenone, 899*
in Cushing's syndrome, 1608–1609
pregnanetriol and pregnanetriolone excretion, 1730–1734
of epithelial cells, in epidemic hemorrhagic fever, 220–223
Hyperpnea, of high altitude dweller, 271
Hypertension
circulation in forearm, 246
in coarctation of aorta, 1537, 1542
desoxycorticosterone acetate and cortisone induced, 1295–1299
electrolyte and water excretion in, 1460–1468
in epidemic hemorrhagic fever, 99–100, 1695–1696
natriuresis in essential, 871–872*
personality, behavior, and vasopressor mechanisms, 918*
plasma radioactivity, after radiolabeled vitamin B_{12}, 1553
portal, and anastomosis, 1259
pulmonary, and acetylcholine, 890*
renal and splanchnic vascular resistance, 1542–1543
after splanchnicectomy, 1462–1468
Hyperthyroidism
and non-thyroxine iodine release, 930*
radioiodinated, hormone disappearance, 1488, 1494–1495
Hyperuricemia, in primary gout and uric acid production, 1508–1514
Hyperventilation
bicarbonate, 523, 527
calcium and citric acid complex, 870–871*
and diffusing capacity of the lung, 11
and electrolyte excretion, 520, 527–528
and pH of urine, 517, 520, 525
renal hemodynamics in, 522–527
and titratable acidity, 520, 527
Hypervitaminosis D, and milk-alkali syndrome, 899*
Hypoalbuminemia
and hyperlipemia in nephrosis, 703
in ulcerative colitis and regional enteritis, 931*
Hypocalcemia
in hypernatremic states, 434–439
and phosphate infusion after muscle trauma, 831
and urinary excretion of phosphorus, 901*
Hypochloremia, in respiratory acidosis, 910*
Hypogammaglobulinemia
erythrocyte, type B, destruction in type A patient, 1455
lymph node homotransplant for, 405–419
Hypoglycemia
adrenal cortical response and chlorpromazine, 543–548
after dimercaprol, 921*
insulin, 1389
and ACTH, 543–548
and chlorpromazine, 547
and glucagon, 74–80
after sulfonylureas, mechanism of response, 889–890*, 922*
Hypokalemia, potassium chloride for and aldosterone activity, 388, 391
Hyponatremia, and sodium depletion, 387, 391
Hypoparathyroidism
calcium, and phosphate metabolism, 550–580
and parathyroid therapy, 557–565
and renal function, 550–561
Hypoproconvertinemia, Stuart factor in, 485–494
Hypoproteinemia, hemoglobin A_2 isolation, 1621
Hypoprothrombinemia, hereditary study, 497–502
Hypotension
in epidemic hemorrhagic fever, 99–100
and capillary changes, 1691–1697
shock, 128
postural
arterial pressure after removal and replacement of blood, 1320
chloride excretion, 1325
glomerular filtration rate, 1324–1325
sodium excretion and methyl fluorohydrocortisone, 1324
after quinidine, 846
Hypothalamus, electrolytic lesions, and satiety responses in mice, 1638–1641
Hypothyroidism, and phosphate, 567
See also Myxedema
Hypoxanthine
and erythrocyte lysis, 1503–1506
in nucleotide synthesis pathway, 1572
oxidation *in vivo*, to uric acid, 433
and stored blood, 430
inosine ratio, 430–433
Hypoxia
blood ACTH and plasma corticosteroids, 1642–1646
respiratory adjustments, to altitude and shunt, 270–277

I

Immunology
and blood coagulation problems, 910*
interaction of lymph node homotransplant and recipient, 410–411
in macroglobulin study, 456–466
model for reaction in quinidine purpura, 929*
pyrogenic and leukopenic effects of hemolysis, 904*
techniques in macroglobulin study, 457–458, 466
tuberculin, in lymph node homotransplant, 408, 410–411
hypersensitivity, 411, 416
Infant
dehydration, hypernatremic, 438
plasma heparin-precipitable fraction values, 614
pulmonary ventilation and diffusion, 1081–1091
radioactivity elimination rate after cortisol-4-C^{14}, 1352–1353, 1356, 1360–1361
respiration, measurement of mechanics, 440–448
in neonatal distress, 443–444
Infection
fever in, 99
and capillary changes, 1688–1700
hookworm, intestinal blood loss with, 1183–1192
plasma heparin-precipitable fraction values, 612
streptococcal
antibody levels in rheumatic children after, 791
chlortetracycline and penicillin in treatment, 1096–1099
viral, susceptibility to, and stress, 922*

Injury
hepato-cellular, trihydroxy/dihydroxy bile acid ratio and intensity, 537
thermal, substances released from skin, 38–43
Inosine, and erythrocytes
lysis, 1500–1502
glutathione protection, 623, 626
in stored blood, 226–231
hypoxanthine ratio, 430–433
phosphorolytic cleavage, 430
Inosinic acid
and erythrocyte lysis, 1500–1506
in nucleotide synthesis pathway, 1572
Insulin
age differences, in responses, 504–512
and alloxan diabetes, 916*
and arteriovenous differences of unesterified fatty acid, 812
binding, 873–874*
electrophoretic identification of antibody, 642–646
species specificity, 395–396
and blood levels of pentoses, infused, 1383–1393
and glucagon, 74–80, 887–888*
for coma termination, 76
and glucose, periodic paralysis, attack induction, 733
and hypoglycemia, 1389
and ACTH, 543–548
chlorpromazine, 547
iodinated, for kinetics of insulinase activity, 648–655
membrane transport, 1393
and sugar, 916*
molecular weight, 395
and permeability of muscle membranes, 938*
resistance, 648–655, 1592
gamma globulin for binding in, 393–397
and tolbutamide
in depancreatized dogs, 1546–1549
hepatic action, 922*
Intestine. *See* Gastrointestinal tract
Inulin
clearance
and chloride, 1325
after cortisone and cortisol, 770–771
in hypertension, 1461–1466
in hypoparathyroidism, 559, 564
in mannitol diuresis, 631
and dietary protein, 635–637, 640
and phosphate, 567
in postural hypotension, 1325
ratio to urine osmolalities, 1421
after renal artery cuff inflation and water diuresis, 1416–1419
and vasopressin, 1422
and renal reabsorption of phosphate, 551–555
and sodium, 1466
in Wilson's disease, 1108–1109, 1112
and probenecid, 1110, 1113
distribution relative to chloride and sodium, 344–350
macrophage sequestration of, 345, 348
Iodide, binding by diaphragm, 807
3-Iodomercuri-2-hydroxy-propane, 658, 664–665
Iron
absorption and accumulation in hemochromatosis, 314–324
"mucosal block," 324
deficiency
after ferrous sulfate therapy, 838
hemoglobin A_2 separation, 1621
in hookworm infection, 1188
iron-containing enzymes in, 874*
in pulmonary hemosiderosis, 1150
erythrocyte, handling by reticuloendothelial cell, 875–876*
metabolism, in anemia of rheumatoid arthritis, 1043–1056
plasma, utilization, and nitrogen mustards, 874*
release from sensitized red cells, 1456
serum concentration
and half time of plasma clearance, 1048
and intake in siderosis, 1723–1725
and rate of red cell uptake, 1048
Isoleucine
and nitrogen balance, 1647–1655
plasma content, 1228, 1673–1677
after surgery, 1677
uremic, 1229–1231
Isoniazid
inhibition of kynurenine transaminase, 1606
and pulmonary tuberculosis, 926*
and tryptophan metabolism, 1600–1606
Isopropylnorepinephrine, cardiovascular effects, 883*

J

Jaundice
and liver copper concentration, 1214
obstructive
bile acid content of serum and urine, 533
and cholangitis, 714
cholesterol levels, 718
lipoprotein spectrum, 713–720
post-hepatic, and cortisone, 1370–1371
serum, 533
bilirubin, 1370–1371
dihydroxy bile acid, 537
Joint
diseases, citric acid metabolism, 909–910*
fluid, thyroxine-binding by, 28

K

Keratoconjunctivitis, epidemic, 905*
Keratoconus, albumin metabolism and thyroid, 423
Keto acid, metabolism, 361–371
Ketocholanic acids, plasma binding, 539
Ketoglutarate, and glutamic acid, 709–711
Ketone acid, and ammonia metabolism in liver disease, 361–371
Ketone bodies, and metabolic acidosis, 1126
17-Ketosteroids
and adrenal dysfunction, 1732–1733
in poliomyelitis, 949
and gonadal steroids, 997–1000, 1006, 1013, 1015
urinary, 760–763, 765, 949
in stress, 956
Kidney
artery clamp and diuresis, 1423–1425
clearance
and acid conjugation, 537
and ethanol, 1203, 1205
of pepsinogen, 1177, 1180
of phenobarbital, and urine flow, 1221–1224
in coarctation of aorta
and plasma flow, 1542
vascular resistance, 1539
concentration
and dietary protein, 630, 635–640
of mercury compounds, 660–668
process, 629–640
copper concentration in Laennec's cirrhosis, 1212, 1215
damage
in osteolytic disease, 887*
and protein turnover rates, 358
disease
arterial occlusive, 885*
in pregnancy and pre-eclampsia, 920*
and renal transport of hemoglobin, 908*
and urine composition, 885*
endotoxin uptake, 696–699
excretion
of concentrated urine
after arterial occlusion, 1419–1420
in thirsting rats, 436
of radiostrontium, 685
failure, 99
acute, 132
casts, 148–149
fibrinoid deposits, 608
glomerular, 697
fluid balance maintenance, 127
and hydration, 629–633
function, 1112–1113
and calcium infusion, 576
and di-sodium ethylenediaminetetraacetic acid, 570
in hypertension, 1460–1468
induction of disease for study, 876*
and mercury compounds, diuretic properties, 656–668
and necrosis, 914–915*
after parathyroid therapy, 560–571
and sodium, 303–308, 1460–1468
and tubular necrosis, 914–915*
and urine composition, 885*
in Wilson's disease, 1107–1113
and probenecid, 1110, 1113
hemodynamic responses to norepinephrine, 89–96
ischemia, and coarctation of aorta, 1543

iso-osmotic level of freezing point depression in boiled tissue, 869–870*
lesions in epidemic hemorrhagic fever, 99–223
anoxia, 120, 176
Bowman's space, 148–149, 154–155, 192
circulatory collapse, 110–112, 128–129
convolution
distal, 148–149, 172–173, 188–191, 198–201, 218–219
proximal, 138–143, 146–149, 153–159, 164–183, 192–195, 202–205, 216
cortex, 120, 138–159, 206
dilatation, 134–135, 154–155
epithelium, 156–157
gram positive droplets, 142–143
hemorrhage, 146–147
surface scarring, 160–161
ducts of Bellini, 148–149, 152–153, 220–223
renal failure casts of Addis, 144–145, 220
lobule, 104, 105, 115
of loop of Henle, 168–180, 184–185
in medulla, 134–135
fibrosis, 158–161
hemorrhage, 150–151, 156–157, 160–161
necrosis, 154–155
nephron, 103–104, 111–112, 119, 127, 162–172
dilatation, 120, 126, 148–151, 158–159, 192–197, 216–217
papilla, 144–145, 148–149, 152–153
phases
convalescence, 99, 126–127
diuretic, 99, 121–127, 129, 154–161
febrile, 100–102, 110–111
hypotensive, 104–117, 140–142
shock, 99, 102, 106–108, 134–143, 174–175
transition, 99, 108, 112–117, 129–130, 140–141, 144–149
oliguric, 99, 117–121, 129–132, 148–155
prehemmorhage, 101–102
and pulmonary edema, 107–108, 140–142
resumé of findings, 128–132
tubules, 111–114, 121, 124, 127–129, 148, 152, 156, 176–187, 192–193
cellular patterns, 206–211
collecting, 114, 123, 127, 128, 188–191, 206–214, 220–221
degeneration, 146–147
edema, 136–137
fibrosis, 126, 156–161
necrosis, 99–100, 114, 122, 128, 148–155, 186
proliferation, 122–123, 154–155, 160–161
thickening of basement membrane, 156–157
perfusion of blood, *in vivo*, 812
plasma albumin clearance in proteinuria, 426
reabsorption
of norepinephrine, 94, 96
of phosphate, 550–555
after sodium loading, 307–308
in respiratory acidosis or alkalosis, 517–528
sensitivity, to antidiuretic hormone, 776, 1425–1426
serial biopsy in toxemia of pregnancy, 920*
serotonin levels, after 5-hydroxytyptophan, 1595
sodium
and aldosterone, 693
excretion, 1462–1468
stone formation and urinary oxalate excretion, 882*
transport
of glucose, 879*
hemoglobin, 908*
tubules, 914–915*
and vasopressin activity, 1067
Kimmelstiel-Wilson disease, bile acid in serum and urine, 531
Klinefelter's syndrome, and chorionic gonadotropin, 909*
Kwashiorkor, liver, biochemical changes, 1579–1586
Kynurenic acid, and tryptophan, 1601–1604
Kynurenine
conversion to anthranilic and kynurenic acids, 1602
and tryptophan, 1601–1604
Kyphoscoliosis, and pulmonary diffusing capacity, 13–16

L

Lactate
blood levels
after pentose infusion, 1398–1399
in periodic paralysis, 734–735
and metabolic acidosis, 1126
muscle production in forearm, 728
and D-xylose, 1399
Lactonase, in ribose-1-C^{14} phosphate production, 1411
Lactose
absorption, by intestine, 1526, 1534
dietary, intolerance in galactosemia, 929*
Laennec's cirrhosis. *See* Cirrhosis
Lanatoside C, in aortic-caval fistula, 335–339
Leishmaniasis, radiochromium excretion, 1186
Lergigan®. *See* Promethazine
Leucine
and nitrogen balance, 1647–1655
plasma levels, 1228, 1674–1677
after surgery, 1677
uremic, 1229–1231
and unesterified fatty acid concentration, 814
Leukemia
aleukemia, plasma erythropoietin activity, 896*
erythrocyte survival, 1471, 1473
glucose tolerance, 254–263
hemoglobin A_2 isolation, 1621
heparin-precipitable plasma fraction values in, 612
leukopenic, guanosine infusion, 432
lymphocytic, 18–24, 229, 256–258, 1471, 1473
and splenectomy, 1479
methotrexate sensitivity in 6-mercaptopurine sensitivity, 887*
myeloblastic, 229
myelogenous, 256–258
vitamin B_{12}, serum activity, 18, 904*, 915*
psychological factors, 895*
vitamin B_{12} metabolism, 18–24
Leukocytes
during anaphylaxis, 1118
endotoxin-laden, in necrotic areas, 698
hypersensitivity, in homotransplant recipient, 411, 416, 419
labeling with radioactive diisopropylfluorophosphate, 870*
levels and destruction in immune hemolysis, 904*
and red cell breakdown in spleen, 1456
transfer of sensitivity factor to nonsensitive recipient, 908–909*
Leukopenia, and immune hemolysis, 904*
Levophed®. *See* Norepinephrine
Levulinic acid, and erythrocyte lysis, 1503–1506
Linoleic acid, 242
Lipase, in intestinal content, 1530
Lipemia
clearance
after antikidney serum, 701–702
in nephrosis, 700–704
production of alimentary, meal composition for, 849
Lipid. *See also* Fatty acid, unesterified
chromatographic separation, fatty acids, 233–243
fatty acids biosynthesis, 233–243
and glucose oxidation, 929*
in non-phospholipid fat in intestine, 1527–1528
and lipoprotein transport, 848–859
plasma, 233–243
in arteriosclerotic plaques, 932*
of sterol esters, separation of, 238
unsaturated, and serum cholesterol, 917*
liver, in kwashiorkor, 1582
muscle content, 1242–1247
comparison, in literature, 1246
after trauma, 827–831
plasma concentration
in lipoprotein fractions after carbohydrate, 855–859
in nephrosis, 700–704, 1560, 1561
in obstructive jaundice
recovery from Cohn fractions, 720
ultracentrifugation patterns, 715, 718, 720
serum concentrations, 715–720
and fat ingestion, 848–859
synthesis, and glucose oxidation, 929–930*

Lipid (*cont'd*)
triglyceride
absorption, 1524
clearing, in pathogenesis of nephrotic hyperlipemia and hypercholesteremia, 1564
dietary intake
lipid and lipoprotein responses, 848–859
and obesity, 81–88
in poliomyelitis, 945
fatty acid components of, 233–243
in weight gain, 81–88
Lipoprotein, plasma
"alpha" levels, in metatastic carcinoma, 720
beta, comparison of methods, 1363–1368
concentration
and biliary obstruction, 714–720
and esterified cholesterol, 713–720
and weight gain, 86
fractions
after fat ingestion, 850–852
after glucose, 856–859
mobility, 849
nomenclature, 849
Sf 5–20, and nephelometric method, 1368
spectrum in obstructive jaundice, 713–720
synthesis, by liver, 720
ultracentrifugation, 713–720, 849–859
Lithocholic acid, plasma binding, 539
Liver
albumin production and thyroid therapy, 426
biliary and enteric circulation of estrogens in women, 1260–1277
blood flow rate, in coarctation of aorta, 1540–1541
carbohydrate retention and tolbutamide, 922*
carcinoma
lipoprotein spectrum, 716–717
chloride, intracellular in, 343, 350
cholesterol
esterification, 720
and thyroxine and triiodothyronine analogues, 885*
chromium^{51} trapping
in hemolytic anemia, 1470–1485
cirrhosis. *See* Cirrhosis
copper concentration, 1212–1215
and cortisone
conversion to cortisol, 1309
disappearance rate, 1308
disease
adrenal cortical function, 920*
and ammonia
metabolism, 361–371
production, 1654
uptake and release, 362–371
keto-acid metabolism, 361–371
obstructive, bile acid conjugation with glycine and taurine, 534–535
plasma fibrinogen levels, 614
and D-ribose, 899*
serum bile acid content, 530–537
endotoxin uptake, 696–699
fetal, synthesis of plasma protein by, 398–403
function, in obstructive jaundice, 716–717, 720
glucose release, age differences, 512
glycogen formation, 1279–1283
and incompatible erythrocytes, 1430–1433, 1456–1457
injury due to drug toxicity, bile acid content of serum, 533
insufficiency, and metabolic acidosis, 1126
insulinase inhibition and insulin-binding antibody, 648–655
inulin and sodium space in, 348
iso-osmotic level of freezing point depression in boiled tissues, 869–870*
in kwashiorkor, 1579–1586
autopsy findings, 1584
mercury uptake and binding, 661, 664
protein synthesis, rates measured, 417
rubidium^{86} trapping and norepinephrine or vasopressin, 482–483
serotonin levels after 5-hydroxytryptophan, 1595
siderosis and iron intake, 1723–1725
temperature response to histamine, 1286–1293
and Dilatol® or promethazine, 1290
tocopherol metabolism in carbon tetrachloride damage, 1627–1637
vitamin B_{12} uptake, compared to plasma, 1554–1556
Lung
asbestosis, 871*
blood volume in heart disease, 901*
carcinoma
glucose tolerance, 256–258
carcinomatosis, electrophoretic and gel diffusion of sputum, 877*
circulation
and acetylcholine, 671–672, 674
and epinephrine, 670, 673, 674
and histamine, 671
and 5-hydroxytryptamine, 671
and norepinephrine, 670–671, 673–674
compliance, 1680–1686
and arm immersion in ice water, 63–64
after G suit inflation, 61
and hexamethonium, 62
in infant, 444
and left atrial pressure, 1710–1713
in neonatal respiratory distress, 447–448
and norepinephrine, 63
and type of breathing, 1684
after vascular engorgement, 60–62
congestion, and air-flow resistance, 1713
diffusing capacity, 922*
and carbon monoxide, 1–16
in chest disorders, 13–16
in newborn, 1081–1090
and position of body, 6–11
endotoxin uptake, 696, 698
hemosiderosis, 1150–1158
heparin-precipitable plasma fraction values in conditions of, 612
in hypoxia, 1566–1571
iron uptake in pulmonary hemosiderosis, 1150–1158
mechanical behavior
and anesthesia, 1708–1714
in elderly persons, 1680–1687
mercury uptake and binding, 661, 664
in respiratory cycle, 1566–1571
rubidium^{86} uptake, 482–483
stiffening of, in congestive heart failure, 59
transpulmonary pressure, 1680–1687, 1709–1712
and elastic properties of thorax, 1685
vascular resistance and left atrial pressure, 673
vasomotor responses to drugs, 669–674
vital capacity, 1682–1686
and oscillating bed, 990, 993
volume
in chest disorders, 13–16
effects of variation on diffusing capacity, 6
and pressure relation, 1682–1683
work, in newborn infants, 442–448
Lupus erythematosus
disseminated
and cortisone, 611
erythrocytes life span in, 1471–1473, 1481
serum hexosamine and protein content, 52–55
serum nucleoprotein reaction, 890*
Lymph
after lymph node homotransplantation, 409
thyroxine binding, 28
Lymph nodes
homotransplanted, antibody protein synthesis by, 405–419
biopsy findings, 408–409, 414, 416
Lymphocytosis, atypical, after lymph node homotransplant, 409
Lymphoma
cholesterol metabolism, 916*
glucose tolerance in, 754–763
heparin-precipitable plasma fractions, 612
hepatic, ammonia metabolism, 362
psychological factors, 895*
Lymphosarcoma
electrophoresis of red cells, 229
glucose tolerance, 256–258
Lysine
and nitrogen balance, 1647–1655
plasma concentration, 1228, 1674–1677
after surgery, 1677
uremic, 1229–1231

Lyxose
and blood glucose, 1398
and insulin, 1386
metabolism, 1384–1405
pathways, 1404
space calculation, 1392
stereochemical configuration, 1383

M

Macroglobulinemia, physio-chemical and immunologic studies, 456–466
Macroglobulins, 458–466
in hemolytic anemia, 891*
Magnesium
concentration
in muscle, 1242–1247
comparison of literature, 1246
in osteolytic disease, 887*
flame-spectrometric method in renal failure, 933*
and plasma
calcium, 831
cation-depleted, 599–603
heparinized fractions, 602
Malaria, vivax, acute, capillary studies, 1689
Malic acid, and erythrocyte lysis, 1503–1506
Malignancy. *See* Cancer
Mannitol diuresis
and dietary protein, 636–640
and hydration, 631
Mannose, 1402
Mastoiditis, heparin-precipitable plasma fraction values in, 612
Measles, heparin-precipitable plasma fraction values in, 612
Melena, in epidemic hemorrhagic fever, 129
Meningitis
heparin-precipitable plasma fraction in, 612
tuberculous, sialic acid tests, 452
Menorrhagia, and Stuart factor level, 500
Meperidine, and acid-base balance, 1123, 1128
Meralluride
in heart failure, 388–389
structure and activity, 658
Mercaptomerin, and renal clearance of phenobarbital, 1221
6-Mercaptopurine, sensitivity to, 887*
Mercury, diuretic activity and structure of compounds, 656–668
Mersalyl, structure and synthesis, 658, 662
Mesobilifuscin, fecal, anabolic significance, 893*
Metaplasia, myeloid
radiocobalt-labeled vitamin B_{12}, 18–24
uric acid degradation, 1512
Methionine
and erythrocyte lysis, 1503–1506
and nitrogen balance, 1647–1655
plasma concentrations, 1228, 1674–1677
after surgery, 1677
uremic, 1229–1231
Methotrexate, sensitivity to, in 6-mercaptopurine sensitivity, 887*
Methyl fluorohydrocortisone
and blood pressure in acute hypervolemia, 1322
and sodium excretion in orthostatic hypotension, 1324
Milk-alkali syndrome, and hypercalcemia, 899*
Mitochondria, adrenal 11-β-hydroxylase, 932*
Mitral valve
disease
gallop rhythm, 902*, 1036–1037
hemodynamics, 876*, 917*
insufficiency, 876*, 1036–1037
antigen reaction, 795
indicator-dilution curve in diagnosis, 937*
stenosis
and cardiac pumping capacity, 915–916*
and pulmonary diffusion, 13–16
Moniliasis, after lymph node homotransplant, 409
Mononucleosis, infectious
and capillary
injury, 896*
studies, 1689
Morphine, and urine flow rate, 918–919*
Mucopolysaccharides
serum acid, 875*, 1329–1331
uronic acid, 875*
in rheumatoid arthritis, 1516–1520
Mucoprotein
plasma
in nephrotic syndrome and after diuresis, 609, 613
in rheumatic fever, 610, 613
serum, colorimetric procedure for, 452–454
and sulfuric acid reagent, 451–452
Mumps
cellular damage, 893*
heparin-precipitable plasma fractions, 612
Muscle
analysis of components, 1239–1247
in diseases, 1242
cation accumulation, 346, 350, 1249–1255
order of preference, 1253–1255
cesium, rubidium, and potassium ratios, 1253–1255
and dietary cesium, 1251, 1254
chloride, intracellular, 343, 350
glycogen formation, 1279–1283
heart extracts, nucleotide metabolism, 1572–1577
injury, calcification after, 825–831
and hydrochloric acid, 830
and parathyroid, 830
and phosphate, 829, 831
and sodium bicarbonate, 830
membrane permeability and insulin, 938*
in periodic family paralysis, 730–736
pharyngeal constrictor in swallowing, 591–595
potassium movement, 723–736, 879–880*
potassium rubidium and cesium ratios, 1253–1255
psoas, copper concentration, in Laennec's cirrhosis, 1212, 1215
rubidium, cesium and potassium ratios, 1253–1255
rubidium^{86} uptake, 482–483
sodium, intracellular, 346, 350
strength, 953–962. *See also* Poliomyelitis
thyroxine and triiodothyronine binding, 803–808
tongue, in dysphagia, 595
uterine, serotonin content, 1598
Myasthenia gravis, and swallowing dynamics, 590–595
Mycobacteriophage, and mycobacteria, *in vivo,* 906–907*
Myelofibrosis
radiolabeled erythrocyte distribution, 1471–1472, 1477
and splenectomy, 1479
Myeloma, 888*, 1441
erythrocytes
destruction, 1441
electrophoretic pattern, 229
hemoglobin A_2 separation, 1621
serum and urine proteins, 352–359, 888*
Myocarditis
idiopathic, plasma hexosamine and protein content in, 55
and right-sided summation gallop, 1038–1039
Myocardium
and adipose tissue fatty acid transport, 811–814
metabolism, and nitroglycerin, 895*
oxygen consumption and coronary blood flow, 1101–1106
and plasma potassium exchange, 476
rubidium^{86} uptake, 468–477
Myoclonus, viral, 912*
Myxedema. *See also* Hypothyroidism
ground substance, 891*
plasma clearance of corticosteroids, 1303
and thyroid therapy, 426
thyroxine degradation, 31, 931*

N

Naphthalene, and glutathione metabolism of erythrocytes, 938–939*
Narcosis, carbon dioxide, prevention by alkalinization, 928*
Necrosis
aseptic, of head of femur in sickle cell anemia, 841
renal and tubular function, 914–915*
epidemic hemorrhagic fever, 99–100, 114, 117–122, 128, 148–155, 186, 212–215
and radioendotoxin uptake, 697–698
Neoplasm. *See* Cancer
Nephrectomy
calcium of plasma after, 826–827
inulin space after, in rat, 348

Nephritis, hemoglobin A_2 separation, 1621
Nephrosclerosis, arteriolar
erythrocyte life span, 676–679
renal function and urine composition, 885*
Nephrosis
albumin
and lipemia clearance, 700–704
turnover study, 358
heparin-precipitable plasma fractions, 609, 613
hyperlipidemia, 873*
pituitary function, 872*
plasma lipid changes, 1558–1564
thyroxine binding in, 28, 1333–1341
Nervous system
autonomic
hexamethonium blockade, 864
sodium and water excretion, 1319–1327
central, and venous tone, 65–66
Neuroblastoma, heparin-precipitable plasma fraction values in, 612
Neutropenia
and antibody utilization, 416
after lymph node homotransplant, 409
Newcastle disease, and encephalomyelitis, 912*
Nicotinamide, and erythrocyte
hemolysates, 623, 626
lysis, 1503–1506
Nicotinic acid, tryptophan metabolic pathway to, 1602
Nilevar®. *See* Norethandrolone
Nitrogen
α-amino plasma, and renal reabsorption in Wilson's disease, 1108, 1113
balance
and arginine, 1653–1654
after cortisol and triiodothyronine, 1314–1317
in hypoparathyroidism, 569–571
and intravenous synthetic amino acid mixture, 1648–1649
and blood ammonia in cirrhotics, 707
content, of tissue slices, 29
cortisone versus DCA effect in adrenalectomized rats, 1297–1299
dietary intake, 945–951, 954–961
and renal concentrating ability, 635–640
incorporation into myeloma protein, 355, 358
intolerance, after portacaval anastomosis, 367
mucopolysaccharides in rheumatoid arthritis, 1518
in muscle composition, 1242–1247
after trauma, 826–831
poliomyelitis balance, 942–962, 1019–1023
and combined steroid therapy, 1015–1016
and estradiol, 997–999, 1001
fecal, 1019–1023
and intake, 945–951, 954–961, 1019–1023
and oscillating bed, 983–987
and sulphur ratios, 950, 957–958, 962
and testosterone, 996–1000, 1010–1011
urinary, 982–983, 986, 1000, 1001, 1019–1023
tendon content, 343
urea, 355
in epidemic hemorrhagic fever, 99–100, 118
in uremic plasma, 1230
after water deprivation, 436, 926*
Nitroglycerin
and coronary circulation, 895*
and hypotension, 1325
and myocardial metabolism, 895*
3-Nitromercuri-2, 3-dehydro-1-hydroxy-propane, 658, 662
Nitrous oxide, and acid-base balance, 1123, 1128
Nonesterified fatty acids. *See* Fatty acid, unesterified
Norepinephrine, 102, 116
and capillary responses
to epidemic hemorrhagic fever, 1694–1698
to infectious illness, 1689
cardiac responses, 90–96
and coronary blood flow, 472–477, 479–483
and hemoglobin excretion, 89–96
and myocardial uptake of radiolabeled rubidium, 468–483
plasma concentration, 892*
pressure-volume after, in forearm, 1663, 1667–1670
and pulmonary circulation, 670, 673–674
and vasodepressor response, 63–65
Norethandrolone, anabolic effects, 907*
Nucleoprotein, and lupus serum reaction, 890*
Nucleosides
and osmotic resistance of erythrocytes, and age of cell, 903*
phosphorylase, 430
phosphorylation, 1572
Nucleotides
pyridine, in liver autopsy findings, 1584–1585
synthesis of purine, in heart muscle extracts, 1572–1577
Nutrition
and amino acid plasma concentration after surgery, 1677
in hepatic siderosis, 1723
in poliomyelitis, 945, 983, 985
satiation, and responses in mice, 1638–1641
and serum cholesterol, 81–88
and tocopherol tolerance, 1629, 1635

O

Obesity
development of, 81–88
and satiety responses in mice, 1638–1641
Oophorectomy, and satiety responses in mice, 1638–1641
Orinase®. *See* Tolbutamide
Ornithine
and blood ammonia, 1650, 1652
plasma concentration, 1674–1677
Oscillating bed, in poliomyelitis, 982–993
Osteitis deformans
calcium metabolism, 578–580
and hyperparathyroidism, 893–894*
serum electrophoretic pattern, 925*
strontium metabolism, 681
Osteomalacia
in Wilson's disease, 1108, 1113
Osteoporosis
and calcium loss, 968–969, 973
developmental evidence, 971, 976–977
strontium metabolism, 681
Oxygen
arterial, 271–274, 734, 844–846
unsaturation, and sickle cell anemia, 905–906*
arteriovenous difference
and age, 1133–1136
after hexamethonium, 861
and blood ammonia in cirrhotics, 707
clearance of cyanosis after alkalinization by gastrodialysis, 928*
consumption
and cardiac capacity in mitral stenosis, 915–916*
in coarctation of aorta, 1540–1541
and coronary blood flow, 1103–1106
during exercise, 7–8, 1140–1148
and oscillating bed, 990
and potassium loss from muscle, 727–728
and quinidine, 844–846
in spontaneous paralysis, 734, 736
after tetraiodothyroformic acid, 885*
and erythrocyte glutathione, 620–621, 626
retinal venous blood estimation by photographic means, 899–900*
in anesthetized patients, 1123
tension
and pulmonary diffusing capacity, 7–10
and viscosity
of sickle cells, 836, 842
of whole blood, 837, 842
uptake
by newborn, and pulmonary diffusing capacity for carbon monoxide, 1083–1092
Oxyhemoglobin, and erythrocyte glutathione, 620, 624, 626
Oxythiamine, and erythrocyte lysis, 1503–1506
Oxytocin and hypotension, 1325

P

Paget's Disease. *See* Osteitis deformans
Palmitic acid, turnover rates of, 242
Pancreas
carcinoma
and lipoprotein pattern, 716–718

protein synthesis rates measured, 417
removal, and tolbutamide potentiation of insulin, in dogs, 1546–1549
vitamin B_{12} uptake by, 22
Pancreatitis
electrolyte secretion and acetazolamide, 904–905*
and glutamic acid, 707
Para-aminohippurate clearance
after cortisone and cortisol, 770
in hypertension, 1461–1468
and sodium excretion, 1466
in hypoparathyroidism and parathyroid extract, 559, 564
after norepinephrine, 90–96
and phosphate, 551–555, 557
after renal artery obstruction and water diuresis, 1416–1419, 1423
in Wilson's disease, 1108–1109, 1112
Paralysis. *See also* Poliomyelitis
familial periodic and potassium transcellular movement, 730–736
of pharyngeal constrictor muscle, 595
Parathyroid, in hypoparathyroidism, and renal function, 557–571
Penicillin
resistant staphylococci mediation by penicillinase, 879*
and type 14 streptococcal infections, responses
antibody, 1097
antistreptolysin O, 1096–1097
Penicillinase, and penicillin resistant staphylococci, 879*
Pentobarbital, and aldosterone secretion, 692–693
Pentose
disappearance rate from plasma, 1386
and insulin, 889*
disposition and metabolic fate of infused, 1395–1405
phosphate pathway in ribose metabolism, 899*, 1408–1414
Pepsin, gastric output, 1174, 1178–1181
Pepsinogen synthesis, 932*
after ACTH and adrenocortical steroids, 1176–1181
Pericholangitis, lipoprotein spectrum, 716–717
Peristalsis, and functional dysphagia, 930*
Pharyngitis
erythrocyte sedimentation rate, 609
heparin-precipitable plasma fractions, 609, 612
after lymph node homotransplant, 409
Pharynx, dynamics of swallowing, 581–595
in dysphagia, 589–595
Phenergan®. *See* Promethazine
Phenobarbital, distribution and excretion, 1217–1225
Phenolic steroids. *See* Estrogens
Phenothiazine. *See* Promethazine
Phentolamine, and venous pressure-volume responses after epinephrine, 1668–1669
Phenylalanine
hemoglobin content, in phenylketonuria, 1343–1348
and nitrogen balance, 1647–1655
plasma concentrations, 1228, 1674–1677
after surgery, 1677
uremic, 1229–1231
Phenylketonuria, amino acid pattern in hemoglobin, 1346–1348
Phlebotomy, iron absorption after, 324
Phlorhidzin, and sugar transport across muscle cell membrane, 916*
Phosphatase, alkaline
electrophoretic studies, 924–925*
plasma in obstructive jaundice, 716
plasma in poliomyelitis, 968–970, 978
and gonadal steroids, 997–999
Phosphate
excretion, 558, 560, 576, 578
after carbon dioxide inhalation, 519, 521, 527
in hyperventilation, 518, 520, 527
glomerular filtration rate in diuresis, 564
hypotonic buffer, pH and hemolysis in, 1499
infusion, after muscle trauma, 829, 831
and iron absorption, 323–324
metabolism, and calcium, 573–580
in nucleotide synthesis pathway, 1572
plasma concentrations, 576, 580
after muscle trauma, 826–831
renal reabsorption
in hypothyroidism, 550–571
in parathyroid disease, 550–580
and parathyroid therapy, 557–571
serum concentration, 436–437
in malignant disease, 261–263
in Wilson's disease, 1109, 1113
Phosphaturia, after parathyroid therapy, 565
6-Phosphogluconate, oxidation to 2-keto-6-phosphogluconate, 624, 626
6-Phosphogluconic dehydrogenases, and erythrocyte aging, 913*
3-Phosphoglyceric acid
and erythrocyte lysis, 1503–1506
in nucleotide synthesis pathway, 1572
Phosphoketopentoepimerase, in pentose phosphate pathway, 1412
Phospholipid
concentration
intestinal, 1531–1534
in obstructive jaundice, 718–719
fatty acid components of, 233–243
plasma, and total cholesterol in nephrosis, 1562–1564
serum content
after fat ingestion, 850–853
after glucose, 857
5-Phosphoribosylamine, in nucleotide synthesis pathway, 1572
5-Phosphoribosylpyrophosphate
in nucleotide synthesis pathway, 1572
reaction with adenine, 1574–1575
Phosphorus
aluminum gel and absorption, 571
concentration
in bone, 348
in muscle, 1242–1247
dietary, 945, 983
and phosphate reabsorption, 552–555
in hypoparathyroidism, and parathyroid extract, 562, 569–571
metabolism alterations during anesthesia, 898*
in poliomyelitis
balance, 968–970, 979, 1023–1027
dietary intake, 945, 1023–1027
excretion, 978, 1023–1027
and gonadal steroids, 997–999, 1001–1002, 1006, 1015
and oscillating bed, 983
urinary excretion, 562, 1023–1027
and aluminum gel, 569–571
after ethylenediaminetetraacetic acid, 568
and hypocalcemia, 901*
Pitressin®. *See* Vasopressin
Placebo, pharmacology of, 907–908*
Placenta
electrophoretic identification of proteins, 403
perfusion studies, 932*
Plasma
absorption of vitamin B_{12}, 18–24, 1554–1556
dual mechanism, 884*
ACTH, after adrenal steroids, 1701–1707
adrenal weight-maintaining activity in Cushing's syndrome, 1608–1613
amino acid concentration unbound, 1672–1679
ceruloplasmin copper release, reversibility, 1200
cholesterol levels and intestinal excretion, 898*
citrated, and chondroitin sulfate, 598
constituents, 1122
and acetazolamide, 920–921*
in acidosis, 374–381, 1127
and aldosterone excretion, 758–760, 764–765
and cation depletion, 599–603
in hypokalemic alkalosis, 1250–1251
in hypoparathyroidism, 550–571
in myelogenous leukemia, 22–23
and norepinephrine, 472, 476, 479
and skeletal muscle uptake, 723–731
after sodium loading, 306–308
of uremic, 1228–1231
corticosteroid responses, 881–882*
to ACTH, 1612
chlorpromazine, 545
and cortisol, 67–73, 1351, 1353
and cortisone, 1302–1303, 1310

Plasma (*cont'd*)
endotoxin uptake, 696
factor in lethality, 900*
erythropoietin activity, 896*
estradiol or estrone, 1271
and gastrointestinal exchange
acid, 380
chloride, 284–287
deuterium oxide, 292–295
glucuronidates, 1272, 1275, 1351, 1359
hematocrit, after red cell exposure to dextrose, 886*
hemoglobin
after anti-D sensitized red cell injection, 1442–1443
after norephinephrine, 90–96
heparin-precipitable fractions, 596–616
histamine and serotonin release
after amine injection, 1118
after egg albumin and horse serum, 1116–1117
hypoxanthine/inosine ratio of stored blood, 430–431
and insulin binding, 512, 652–653
iron
in pulmonary hemosiderosis, 1152–1155
in rheumatoid arthritis, 1044–1048
utilization, 874*
lipids
and antikidney serum, 701–703
fatty acid separation, 233–243
maternal, and umbilical, 1353–1354
cortisol content, 1351, 1359
mercury concentration and diuretic responses, 659–668
osmolality, after renal artery occlusion and water diuresis, 1416–1419
pepsinogen, and gastric secretion, 1176, 1180
pH, 374, 377, 379
and arterial oxygen saturation, 271–272
and phenobarbital, 1220, 1222, 1224
phosphate, 575–580
infusion, 552–555
after muscle trauma, 831
and urinary excretion, 571
protein
and aorta, spleen and vena cava erythrocytes, 1451
and cholanic acid, 538–542
ethanol fractionation, 642–646, 655
and liver insulinase activity, 651–655
synthesis, rates measured, 417
in fetus and placenta, 398–403
and thyroid therapy, 423–427
thyroxine binding, 25–36
renal flow, 551–555
in coarctation of aorta, 1540–1541
in hypertension, 1461–1468
after norepinephrine, 90–96
and sodium excretion, 1461–1463, 1468
in Wilson's disease, 1108–1109, 1113
and probenecid, 1110
"skimming"
in epidemic hemorrhagic fever, 1694, 1697
in infectious diseases, 1694, 1697
steroid concentration, time factor, after administration, 67–73, 1306
storage of extracts, 225–231
streptokinase level and fibrinolytic effect, 889*
thyroid hormone complex, 1487
tocopherol, in hepatic diseases, 1634
unesterified fatty acid, 810–814, 890*
volume, 304, 307, 1541
dextran expansion, 1160–1168
and obesity, 84
in postural hypotension, 1321
Platelets
in anaphylaxis, 1118–1119
correction, in familial hemophilia, 878–879*
in epidemic hemorrhagic fever, 99–100, 118
immunoreaction model in quinidine purpura, 929*
preservation, carbohydrate metabolism as measure, 878*
transfused, radiosulfur in study of hemostatic activity, 881*
Pneumonia
forearm circulation in, 246
hexosamine and protein serum content in, 52–53, 55
lobar
ammonia metabolism, 362
capillary studies, 1689
Poisoning
carbon tetrachloride, ammonia metabolism in hepatic coma, 362
lead, hemoglobin A_2 isolation, 1621
phenobarbital, 1224–1225
Poliomyelitis
albumin metabolism in, 423
dysphagia, and swallowing, 589–595
paralytic acute anterior
ambulation, 961, 978
atrophy, 957–958, 962
circulatory derangements, 987–992
denervation, influence, 975
disease phases
acute, 943, 946, 967–974, 983
chronic, 943, 954–955, 974, 983–989, 1002, 1005
convalescent, 943, 946, 949–954, 967–974, 983, 989–990, 1001–1004
convalescent early, 987–988, 997–999
and dietary intakes, 944–945
stress periods, and ACTH, 975
and gonadal steroids, 995–1016
combined, 1002–1005, 1015–1016
immobilization, 975–977
Lovett method examination, 1027
metabolic studies, 941–1033
basal rate, 990, 992, 1008, 1014, 1016
calcium, 966–979, 995–1016
creatine, 941–962, 995–1016
phosphorus, 966–979, 995–1016
nitrogen, 941–962, 995–1016
and oscillating bed, 982–994
Polyarthritis, heparin-precipitable plasma fractions, 608–611
Polycythemia
and hypoxia, 273
and pulmonary diffusing capacity, 13–16
splenic trapping of red cells, 1472, 1477–1478, 1480–1481
Polydipsia, after parathyroid therapy, 560
Polysaccharides
of connective tissue, counterion binding by anionic, 1721
protein ratio, in rheumatoid arthritis, 310–312
Posture
cardiac output responses and atropine, 1656–1662
circulatory reactions in poliomyelitis, 987–992
effect on swallowing, 586
hypotension, and renal responses to sodium chloride, 1322–1327
and lung diffusing capacity, 6–11
Potassium
absorption, intestinal, 732
in acidosis, 376–381
and aldosterone, 384–391, 757–765
balance
after cortisol and triiodothyronine, 1314–1317
in hydropic patients, 784–791
and hypertension, 1295, 1298–1299, 1461–1465
in hypocalcemia, 435–437
and intracellular fluid, 1251–1252
in poliomyelitis
and gonadal steroids, 1007, 1013, 1016
and intake, 945, 983, 1008
binding by mucoprotein of cartilage, 1721
chloride
and chondroitin sulfate, 1717
and methyl chondroitin, 1720
depletion, 757–765
exchangeable, correlation and reference standards, 1375–1381
excretion, 397, 1461–1465
and cortisol, 769–778
and cortisone, 768–769
and ethanol, 1203, 1205
maintenance during sodium diuresis, 882*
in respiratory acidosis or alkalosis, 517–518, 520–521, 525–528
in water diuresis and renal artery occlusion, 1423
in gastrointestinal contents, 294–295
and hyperkalemia, 384, 387, 391
and hypotonic urine, 918*
intake, 384–391, 945, 983
and growth, 435
iodide, and thyroid, 912–913*
metabolism and adrenal cortical steroids, 872–873*

movement, 879–880*
in basal state and during night, 723–736
and calcium deficiency, 880*
and carbon dioxide, 728–729
and glucose, 728–729
and lactate, 728
and oxygen, 727–728
muscle
composition, 723–729, 1242–1247, 1251–1254
forearm, 723–736
replacement by rubidium or cesium, 1253–1255
transfer *in vivo*, 879–880*
myocardial turnover rate, 472–473, 476
after l-norepinephrine, and vasopressin, 475
in periodic paralysis attack after glucose and insulin, 733
in acidosis, 374, 376, 379, 381
in hypokalemic alkalosis, 1250–1251
after muscle trauma, 826–831
plasma concentration, 758
and renal reabsorption of phosphate, 551–555
serum
and cellular basis for electrocardiographic changes, 897*
in malignancy, 261–263
response to cortisone versus desoxycorticosterone acetate, 1296
and urinary salt-retaining activity, 388–391
sodium and water partitioning, 347
thiocyanate, metabolism, 912–913*
Prednisolone
anabolic activities, 919*
eosinophil responses, 1172
and gastric secretion, 1173–1175, 1181
and plasma pepsinogen, 1176, 1181
and hyperbilirubinemia, 1370–1373
Prednisone
in Addison's disease, 1705
anabolic activities, 919*
Pregnancy
adrenal weight-maintaining activity in plasma, 1611, 1613
and corticosteroid metabolism, 1350–1361
and heart disease, serial cardiac output study, 880*
phenolic steroids, 1267
plasma heparin-precipitable fractions in, 613–614
toxemia of serial renal biopsies, 920*
Pregnane-3α, 17α, 20α-triol, excretion in adrenal cortical dysfunction, 1726–1735
Pregnane-3α, 17α, 20α-triol-11-one, excretion in adrenocortical dysfunction, 1726–1735
Pressure
aortic
-caval fistula, 336–339
and coronary blood flow, 1103
arterial
and arm immersion in ice water, 63–64
and blood replacement in postural hypotension, 1320
in coarctation of aorta, 1540–1541
flow relationship, 1542
and coronary blood flow, 1103–1106
and cortisone versus desoxycorticosterone acetate, 1296–1299
and dextran expansion of plasma, 1234–1238
diastolic, 336–339
and stress, 918*
in dystrophia myotonica, 593–595
in epidemic hemorrhagic fever, 99–100, 111, 113, 128
deforming effect, 150–151
and pressor drugs, 113, 1694
and epinephrine, 670, 673
and exercise, 1141–1148
femoral, in coarctation of aorta, 1540–1541
and hexamethonium, 62, 861–862
in hypervolemia, 1326
and methyl fluorohydrocortisone, 1321–1322
in hypoxia and heat stress, 1643
and norepinephrine, 63, 90–96
and oscillating bed, 992
postural responses, and atropine, 1657–1661
pulse, 1540, 1543
and quinidine, 844–846
and renal response to sodium chloride, 1464–1468
atrial
and hexamethonium, 862
and 5-hydroxytryptamine, 671
and gallop sounds, 1038–1043
and posture, 1660
and pulmonary
vascular resistance, 673
volume-pressure ratios, 1710–1713
in cardiospasm, 930*
carotid pulse, 336
central venous
after arm immersion in ice water, 63
after G suit inflation, 61, 64
and hexamethonium, 62
and norepinephrine, 63
after vascular engorgement, 60–62
cerebrospinal fluid and hydration, 631
diastolic-systolic in isolated beating heart, 889*
in drinking without swallowing, 586
esophageal
and swallowing, 582–595
in Valsalva maneuver, 5–6
forearm vein, 1663–1671
and epinephrine, 886*
inspiratory, and pulmonary response to age, 1681
jugular vein and atrial gallop sound, 1037
peripheral venous
and aldosterone secretion, 691–693
and dextran plasma expansion, 1234–1235
and hexamethonium, 65
pharyngeal, and swallowing, 582–583, 587, 590–595
after prostigmine, 593
plethysmographic and esophageal, and nitrous oxide breathing, 1568
pulmonary. *See also* Pulmonary artery
and anesthesia, 1708–1714
capillary and left-sided gallop, 1037
in coarctation of aorta, 1540–1541
and epinephrine, 670, 673
and exercise, 1138–1148
flow resistance, 1680
and norepinephrine, 670, 673
and porto-pulmonary shunt, 1263–1264
and serotonin, 670, 671
wedge, and gallop sounds, 1037, 1041
pulse
and oscillating bed, 992, 993
in right heart failure, 1037
splenic venous, and hexamethonium, 862
in swallowing, 583–588
thoracic, in Valsalva maneuver, 5
and vascular engorgement, 59–66
ventricular
in aortic-caval fistula, 336–338
and gallop sounds, 1038–1043
volume
in neonatal respiratory distress, 444–445
for pulmonary work determination, 446–448
wedged hepatic venous and hexamethonium, 862
Primaquine, red cell sensitivity after acetylphenylhydrazine, 618–621, 626–627
Probenecid
tubular response in Wilson's disease, 1110
and uric acid in gout, 1509
urinary excretion of acyl glucuronides after, 297–302
Proconvertin, activity, in congenital deficiency, 492, 495
Progesterone, in Addison's disease, 1705
Proline
plasma, 1228, 1674–1677
after surgery, 1677
uremic, 1229–1231
Promethazine
and erythrocyte lysis, 1503–1506
and hemoglobin electrophoresis of stored blood, 227
and histaminic action, 1290
and pulmonary vascular response to serotonin, 924*
Properdin system
antibody to, and erythrocyte hemolysis, 900*
inhibition of bactericidal activity, 935*
Prosthesis, in plastic cardiac surgery, new concept, 892–893*

Prostigmine, dysphagia relieved by, and swallowing dynamics, 590–595
Protein
binding
of bile acid, 538, 542
insulin, 396
of phenobarbital, 1219, 1222–1223
thyroxine, 25–36, 923–924*, 1333
in tissue slice, 29
and cholanic acid, 538–542
C-reactive
and ACTH, 608
in rheumatic fever, 453, 613
degradation, after radioactive albumin, 46
denaturation, during iodination procedure, 49
and dermal responses to thermal injury, 38–43
dietary intake
and blood ammonia concentration, 364, 371
in poliomyelitis, 945
and renal concentrating process, 630, 635–640
and serum cholesterol, 917–918*
fractions
ethanol procedure, 642–646, 655
heparin-precipitable, in diseases, 609–611
fibrinogen-like, 603
sedimentation pattern, 600
and insulin, 651–655, 1589–1590
perchloric acid soluble, 54
solubility of, 596–603
hydroxyproline in, after thermal injury, 41
intestinal absorption and digestion, 1522–1534
lactalbumin and running-activity levels in mice, 1639
leakage of into Bowman's space, 138–139
in myeloma
electrophoresis, 353–354, 888*
and ultracentrifugation, 353–354
isotopic turnover study, 352–359
in liver in kwashiorkor, 1581–1586
plasma
after fat ingestion, 849, 853
and liver insulinase activity, 651–655
in potassium and sodium depletion, 764
radiothyroxine distribution in, 30
after sodium loading, 306–308
synthesis in fetus and placenta, 398–403
in poliomyelitis
and gonadal steroids sparing action, 1010–1011
serum, 951–953
storage after testosterone, 1011
serum
bile acid interaction with, 534
characteristics of previously unidentified, 902–903*
in diabetes, 897*
in epidemic hemorrhagic fever, 99–100
and globulin ratio in obstructive jaundice, 717
half-life, 359
hexosamine ratio, 53
insulin, 396, 651–653
in kwashiorkor, 1583
in nephrosis, 1333
precipitation with trichloracetic acid, 453
in rheumatoid arthritis, 309
in seromucoid in gouty arthritis, 55
after sodium injection, 436
of thyroiditis, 781
and thyroxine, 923–924*
synthesis, 398–403
antibody, by homotransplanted lymph nodes, 405–419
rates, measured, 417
urine
half-life, 359
molecular weight, 357
withdrawal therapy and arterial ammonia levels, 364–365, 371
Proteinuria
in epidemic hemorrhagic fever, 99–100, 110, 118, 128
and serum albumin concentration, 426
Prothrombin
and Russell's viper venom, 488–489
serum conversion accelerator congenital deficiency, 492, 495
time, and oscillating bed, 990
two-stage assay, thrombin evolution, 487
Psoriasis, albumin metabolism and thyroid, 423
Pulmonary artery
carbon dioxide content and quinidine, 844–846
circulation and acetylcholine, 890*
congestion in mitral insufficiency, 917*
disease, and diffusing capacity, 13–16
pressure
and dextran expansion of plasma, 1234–1238
and epinephrine, 670, 673
and exercise, 1138–1148
and left atrial pressure, 672, 673
and norepinephrine, 670–671, 673
wedge, 1234, 1238
responses to coarctation of aorta, 1540–1541
Pulmonary function. *See* Lung
Pulsus bisferiens, genesis of, 907*
Purpura
quinidine, model for immunoreaction, 929*
thrombopenic, hemoglobin A_2 isolation, 1621
Pyelonephritis
in epidemic hemorrhagic fever, 128
in gout, hyperuricemic, 1509
renal function, and urine composition, 885*
Pyridone, excretion after tryptophan ingestion, 1602
Pyridoxine
hydrochloride excretion, 1601–1602
and tryptophan, 1605–1606
Pyrogen, endogenous, in immune hemolysis, 904*
Pyrophosphates, in nucleotide synthesis pathway, 1572
Pyruvate, blood concentration
after ammonium chloride
in hepatic coma, 366, 371
in liver diseases, 367–371
after glutamate infusion, 708–709, 711
and nitrogen intolerance after portacaval anastomosis, 367
after pentose infusion, 1398–1399

Q

Quinidine
hemodynamic effects, 844–846
purpura, immunoreaction model, 929*

R

Rectum
chloride content, 284
metastatic carcinoma liver lipoprotein spectrum, 716–717
temperature response to histamine, 1286–1293
and Dilatol® or promethazine, 1290
Red cell. *See* Erythrocytes
Reserpine, and satiety responses in mice, 1638–1641
Respiration
and acidosis, 515–528
and alkalosis, 515–528
and anesthesia, 1121–1128, 1708–1714
and cellular metabolism, 32
after chemical burn of tract, 13–16
in chest disorders, 13–16
cycle, pulmonary capillary flow and gas exchange, 1566–1571
and exercise, 1140–1148
in giraffe, 919*
and G suit inflation, 61–66
in hepatic coma and sleep, 924*
in hypoxia
altitude and shunt, 270–277
and heat stress, 1643
in poliomyelitis, 944
in pulmonary emphysema, 891–892*
pulmonary mechanics, 440–448
and aging, 1680–1687
diffusing capacity, 2–16, 1081–1091
and neonatal distress, 443–444, 448
resistance, and
emphysema, 1680–1687
vascular engorgement, 61
volume, and quinidine, 844–846
Respiratory quotient
in malignant disease, 934*
and quinidine, 844–846
Respiratory tract
chemical burn, 13–16
chloride, intracellular, 344, 350
infection
after adenovirus, in volunteers, 1072–1079
after lymph node homotransplant, 410

Reticulocytes
Fe^{59}-labeled, 1445–1447
reutilization, 1447–1448
in hemolytic anemia, 1471
Retina, venous blood oxygen estimation by photographic means, 899–900*
Rheumatic fever
antibody response, 934*
anti-inflammatory hormone therapy for, 54
hexosamine and protein serum content in, 52–53
plasma heparin-precipitable fraction values, 597, 610, 613
fibrinogen ratio, 607–608
sialic acid test, 452–454
and streptolysin O, 793–801
Rhinitis, allergic, and cortisone, 768
Riboflavin
liver content
at autopsy, 1584
in kwashiorkor, 1581, 1585
and tryptophan, 1601–1602
Ribose
and erythrocyte lysis, 1503–1506
glutathione protection, 623
metabolism
in carcinoma cell, 1408–1414
and pentose phosphate pathway, 899*
phosphate, production from hexose-2-C^{14} and erythrose phosphates, 1412
Ribose-1-phosphate, enzymatic phosphorolysis, 430–433
Ribose-5-phosphate
in pathway for purine nucleotide synthesis, 1572
in ribose-1-C^{14} phosphate production, 1411
Riboside
benzimidazole, and erythrocyte lysis, 1503–1506
purine, and dialysis in anemia of uremia, 923*
Ribulose-5-phosphate
conversion from glucose-6-phosphate, 1281
in ribose-1-C^{14} phosphate production, 1411
Rocky Mountain spotted fever, and capillary injury, 896*, 1688–1700
Rubidium
dietary, muscle composition after, 1251–1252, 1254
myocardial uptake, 468–477
plasma concentration in hypokalemic alkalosis, 1250–1251

S

Salicylates
in rheumatoid arthritis, 611
and mucopolysaccharide excretion, 1517, 1519–1520
and thyroid function, 870*
urinary excretion of acyl glucuronides after, 297–302
Salicylurate, excretory patterns, 300–302
Saliva
and dehydration, 629
and hypertrophied glands in kwashiorkor, 1583
Sarcoidosis
hepatic, bile acid content of serum and urine, 531
pulmonary diffusing and function tests in, 13–16
Sarcoma
and glucose tolerance, 256–258
heparin-precipitable plasma fractions, 612
Scarlet fever
antibody response, 934*
heparin-precipitable fraction plasma values in, 612
Schonlein-Henoch purpura, heparin-precipitable plasma fraction in, 611
Scleroderma
heparin-precipitable plasma fraction in, 611
pulmonary diffusing and function tests in, 13–16
Sedoheptulose 7-phosphate, synthesis, 1410–1412
Septicemia, heparin-precipitable plasma fraction values in, 612
Serine
plasma content, 1228, 1674–1677
after surgery, 1677
uremic, 1229–1231
Serotonin
and 5-hydroxytryptophan, 1594–1598
and pulmonary
circulation, 671, 673
vascular responses, 671, 673, 924*
release, in anaphylaxis, 1115–119
Serum
calcium and phosphorus in poliomyelitis, 973–974
cholesterol and obesity, 81–88
copper and thioctic acid, 1211
lipoprotein fat-transport system in, 86
uric acid in gout, 1509
Shock
endotoxin, and cortisol, 914*
epidemic hemorrhagic fever, 99, 102, 106–108, 128, 134–143, 174–175, 1688, 1691–1694
hemorrhagic, and metabolic acidosis, 1126
Shunt, circulatory, and pulmonary ventilation, 270–277
Shwartzman reaction
endotoxin uptake in, 695–699
fibrinoid lesions, and endotoxin lethal action, 695–699
Sialic acids
release, after thermal injury, 41–43
serum measurement, 449–454
specific reactions, 451–452
Siderosis, levels and iron intake, 1723–1725
Sinus
arrhythmia, and atropine, 1571
coronary, oxygen content and blood flow, 1103–1104
pyriform, 595
Skeleton, metabolic state and urinary strontium excretion, 686–687
Skin
A and B antigens, 749–751
in epidemic hemorrhagic fever, 106, 110, 128
mercury uptake and binding, 661, 664
metachromatic material in myxedematous, 891*
release of substances after thermal injury, 38–43
sensitivity, and allergic reaction to dextran, 1160–1169
temperature
and histamine, 1285–1293
in poliomyelitis
and gonadal steroids, 1009
and oscillating bed, 988–990
Smoking, and reactive hyperemia blood flow of foot, 937*
Sodium
absorption, in sprue, 265–268
acetate, and erythrocyte lysis, 1503–1506
and aldosterone secretion mechanism, 383–391
balance
after cortisol and triiodothyronine, 1314–1317
in hydropic subjects, 784–786, 788, 791
in poliomyelitis and gonadal steroids, 1007, 1012–1013, 1016
and serum calcium content, 434–439
bicarbonate, and phenobarbital, 1220, 1225
chloride
and erythrocyte lysis, 1502–1506
and plasma heparin-precipitable fraction, 599–603
and renal responses
to hypertension, 1464–1465
postural hypotension, 1322–1327
chondroitin sulfate and ion binding, 1716
citrate and plasma heparin-precipitable fraction, 597–598
concentration
in acidosis, 374–376, 379
and body electrolyte composition, 886–887*
and cortisone versus desoxycorticosterone acetate, 1296
and dehydration, 631
gastrointestinal, 294–295
in hypokalemic alkalosis, 1250–1251
muscle, 1242–1247
and potassium deficiency, 1251–1251
after trauma, 826–831
and renal function, 885*
depletion
after adrenalectomy, 911–912*
and aldosterone output, 757–765
and body weight, 758
diuresis
and potassium excretion, 882*
responses, 659–660

Sodium (*cont'd*)
exchange
in acidosis, 376, 379
in edema, 785
excretion
and carbon dioxide inhalation, 519, 521, 527–528
in congestive failure, 901*
and cortisol, 769–778
and cortisone, 768–769
and ethanol, 1203, 1205
in hypertension, 1460–1468
in hypotension, 1322–1323
in mercurial diuresis, 659
after renal artery clamp, 1423
extracellular fluid after hypertonic sodium injection, 435
intake
and ACTH versus cortisone, 1296–1299
and aldosterone activity, 385–391
in hypertension, 1467
in poliomyelitis, 945
intracellular, 1251–1252
exchange for potassium, 1299
space, 340–350
iodide-I^{131}, binding by diaphragm, versus thyroxine-I^{131}, 807
lactate, and erythrocyte lysis, 1503–1506
loading and renal function, 303–308
and pepsin secretion, 1180
pyruvate, and erythrocyte lysis, 1503–1506
retention and desoxycorticosterone, 692
serum concentration, osmolarity, and body composition, 886–887*
sulfate, and renal phenobarbital clearance, 1221
transport, in hereditary spherocytosis, 816–822
Somatotropin. *See* Growth hormone
Spinal cord
copper concentration in Laennec's cirrhosis, 1212, 1215
demyelinization and chloride and water content, 286, 293
Splanchnicectomy
effect on electrolyte metabolism, 1460–1469
residual hypertension, 1462–1468
Spleen
copper concentration in Laennec's cirrhosis, 1212, 1215
enlargement in hemolytic anemia, 1471–1472, 1477–1480
in red cell destruction, 1430–1457
uptake
of endotoxin, 696–697
erythrocytes in hemolytic anemia, 1470–1485
mercury, 661–664
vitamin B_{12} in myelogenous leukemia, 22
Splenectomy
hemolytic process after, 1477–1481
and red cell destruction, 1440, 1445
in hereditary spherocytosis, sodium transport after, 822
for thrombocytopenia, 410
tuberculin reactivity after, 408
Sprue
hemoglobin A_2 isolation, 1621
sodium absorption from small bowel, 265–268
urinary strontium excretion, 686
Staphylococcus, penicillin resistant and penicillinase, 879*
Steroids
adrenal cortical
biosynthesis, 932*
and electrolyte depletion, 760–763
and glucosuria, 890–891*
and heparin-precipitable plasma fraction in rheumatoid arthris, 611
plasma ACTH after, 1701–1707
and potassium metabolism, 872–873*
responses to intravenous infusion of, 1171–1181
sodium-retaining, and sodium excretion in postural hypotension, 1324
and water metabolism, 882–883*
anabolic and anti-anabolic activities, 919*
gonadal, in poliomyelitis, 995–1017
phenolic, metabolism, 1266–1277
See also Estrogen
therapy
in adrenal hyperplasia, 1730
See also specific steroid
Stomach. *See also* Gastrointestinal tract
carcinoma of
electrophoresis of red cells from, 229
lipoprotein spectrum, 716–717
intraluminal chloride in, 283
radioactivity of cobalt labelled vitamin B_{12}, 22
temperature response
to histamine, 1286–1293
in achlorhydria, 1289–1290
and Dilatol® or promethazine, 1290
water content, 292
Stomatitis, after lymph node homotransplant, 409
Streptococcus
group A, identification of new group, 934*
type-specific antibody
and antistreptolysin O, 1092–1099
to M-protein, nephritogenic, 876*
Streptolysin O, and rheumatic fever, 793–801
Stress
adrenal cortical hyperfunction, 975
and albumin synthesis, 896*
in coronary disease and serum cholesterol, 897*
and diastolic pressure in hypertension, 918*
heat, and hypoxia, plasma ACTH and corticosteroids, 1642–1646
nitrogen loss, 956–957, 961
psychophysiologic, and susceptibility to viral infection, 922*
Strontium, and calcium metabolism, 680–687, 884–885*
Stuart clotting defect
genetic aspects, 497–502
in hypoproconvertinemia, 485–494
Succinic acid, and erythrocyte lysis, 1503–1506
Succinylsulfathiazole, and urea breakdown, 933*
Sucrose
and erythrocyte lysis, 1503–1506
volume of distribution, 329–333
Sulfate
plasma steroid ester fraction, after radioestradiol and estrone, 1272–1273, 1275
sodium, and renal clearance of phenobarbital, 1221
Sulfhydryl
blockade, and diuresis, 666
reactive groups, after irradiation, 46, 49
Sulfonylurea
hypoglycemic response, 889–890*
and insulin, 1549
Sulfuric acid
mucopolysaccharide in rheumatoid arthritis, 1518
reagent tests in rheumatic fever, 451–452
Sulphur
urinary excretion in poliomyelitis, 946–949
and nitrogen ratios, 950, 957–958, 962
Surgery
amino acid plasma concentration, and nutrition, 1677
cardiovascular plastic, new concept in prosthesis, 892–893*
Swallowing, dynamics of, 581–595

T

Tachycardia
after quinidine, 845–846
response to posture and atropine, 1660, 1661
Taurine
bile acid conjugation, 534–535
plasma concentration, 1674–1677
Taurocholic acid, plasma binding, 539
Taurodeoxycholic acid, plasma binding, 539
Temperature
and blood stored in acid-citrate dextrose, 228
and calcium ultrafiltrability, 743–747
and heparin-precipitable plasma fraction, 601–602
and plasma corticosteroids in hypoxia, 1643–1644
in poliomyelitis, 988–989, 993–994, 1285–1293
responses to
in achlorhydria, 1289–1290, 1293
dermal, 38–43
and histamine, 1285–1293
Testosterone
derivatives, anabolic effects of 9α F, 11β OH, 17α-methyl, 919*
methyl and propionate, 1011
other gonadal steroids, 1274
in poliomyelitis, 995–1017
Tetany, and calcium chloride in hypoparathyroidism, 569–571

Tetracycline, in epidemic hemorrhagic fever, 1694, 1697
Tetraiodothyroformic acid, 885*
Thalassemia
hemoglobin A_2 isolation in blood, 1615–1624
iron absorption in, 324
Theophylline, and thiosulfate clearance rate, 328–329, 333
Thiamin
deficiency, and erythrocyte metabolism, 936–937*
excretion, after tryptophan ingestion, 1601–1602
Thioctic acid
blood ammonia, 1211, 1214
serum copper, 1211, 1214
Thiopental
and acid-base balance, 1123
and phosphorus metabolism, 898*
Thiosulfate, metabolism, 327–333
Thiouracil, radiosulfur labeled, uptake and metabolism, 912–913*
Thorax
blood flow, during respiratory cycle, 1571
elastic properties, 1685–1686
and facial flush in epidemic hemorrhagic fever, 1694
plasma distribution, after G suit inflation, 61–62, 65
vena caval constriction and aldosterone secretion, 689–693
Threonine
and nitrogen balance, 1647–1655
plasma concentration, 1228, 1674–1677
after glutamate infusion, 709
after surgery, 1677
uremic, 1229–1231
Thrombin, evolution from plasma prothrombin, 487
Thrombocytopenia, after lymph node homotransplant, 410
Thromboplastin
generation tests, 489
in hereditary hypoprothrombinemia, 501
platelet correction in familial hemophilia, 878–879*
Thrombosis, and bishydroxycoumarin, 935–936*
Thymidine, and erythrocyte lysis, 1503–1506
Thyroid
and adrenal cortical interrelations, 1313–1317
and albumin metabolism, 422–427
disease and thyroxine degradation rate, 931*
function
and hormone-plasma protein complex, 1486–1495
and salicylates, 870*
iodide metabolism, 912–913*
and myxedema, 891*
non-thyroxine iodine release, 930*
radioactivity fallout in human and cattle, 936*
Thyroiditis, serum proteins, 780–782
Thyrotoxicosis
albumin catabolism, 426
corticosteroids, 1303, 1308
Thyrotropin, and diffuse hyperfunctioning goiter, 905*
Thyroxine
binding
and concentration, 803–808
of extracellular, in tissue slices, 25–36
in nephrosis, 1336–1342
by serum proteins, 923–924*
and thyroid function, 1486–1495
and cholesterol metabolism, 885*
protein complex in sera ultracentrifugation, 1336, 1339
in thyroid disease, degradation rate, 931*
Tissue
adipose, fatty acid transport, 811–814
cation accumulation, 1249–1255
copper concentration in Laennec's cirrhosis, 1212, 1215
erythrocyte destruction in, 1428–1457
hydration, and renal concentrating process, 629–631
iron distribution in pulmonary hemosiderosis, 1152–1156
magnesium, and plasma calcium, 831
phenobarbital, plasma ratio, 1220
strontium absorption, 687
thyroxine binding *in vitro,* 25–36
Tocopherol
metabolism in hepatobiliary disease, 1627–1637
after tocopheryl acetate and carbon tetrachloride intoxication, 1634–1636
Tolbutamide
and blood glucose concentration, 889*
and hypoglycemia, 922*
and insulin, exogenous in depancreatized dogs, 1546–1549
and pentose, 889*
Toxemia of pregnancy, serial renal biopsies, 920*
Toxicity
after amino acid administration, and l-arginine, 1647–1655
ammonia, and arginine, glutamic acid, 913*
of amphenone, 899*
copper, in Wilson's disease, 1200
phenylalanine, in phenylketonuria, 1348
Transaminase
glutamic-oxaloacetic blood levels, in anemia, 926–927*
liver findings
at autopsy, 1584
in kwashiorkor, 1582, 1586
Transplant, lymph node, 409–410
Tricarboxylic acid, and erythrocyte lysis, 1503–1506
Triformylcholic acid, plasma binding, 539
Triglycerides. *See* Lipids
Trihydroxy bile acid
and dihydroxy ratios, 532
serum content, 534
Triiodothyroformic acid, 885*
Triiodothyronine
binding phenomenon in rat diaphragm, *in vitro,* 803–808
and cholesterol metabolism, 885*
and cortisol balance studies, 1313–1317
and myxedema, 891*
Triphosphopyridine nucleotide, and erythrocyte glutathione, 623–627
Triton, and plasma lipids in nephrosis, 1560, 1563–1564
Trypsin
concentration
intestinal, 1529
time relationship, 1530
and insulin antagonist in serum, 1589
Tryptophan
binding, 1674–1676
and pH, 1678
metabolism, 1600–1606
pathway to nicotinic acid, 1602
and nitrogen balance, 1647–1655
plasma concentration, 1674–1677
after surgery, 1677
in serum proteins and sialic acid measurement, 449, 452
Tuberculosis
fibrocavernous, and pulmonary diffusing capacity, 13–16
hemoglobin A_2 isolation, 1621
isoniazid, and deoxypyridoxine in urinary excretion of tryptophan, 1606
pulmonary, chemotherapy, 926*
sialic acid test, 452
Tumor
adrenal cortical
and Cushing's syndrome, 1609–1610
hypoaldosteronism after, 923*
pregnanetriol and pregnanetriolone excretion, 1731–1733
pituitary
gastrointestinal chloride content, 286
gastrointestinal water content, 293
Typhoid
H- and O-antibody
half life, 411–413
rate of synthesis by homotransplanted lymph nodes, 414–415
O-agglutinin, titration of sera, 418–419
Typhus, scrub, and capillary injury, 896*, 1690–1699
Tyrosine
hemoglobin content, 1345
in phenylketonuria, 1346–1348
plasma concentration, 1674–1677
after surgery, 1677

U

Ulcer, peptic, hemoglobin A_2 isolation, 1621
Urea
breakdown rate, 933*
clearance
in mannitol diuresis, 631
and dietary protein, 636–640
excretion
and cortisol, 769–778
and cortisone, 768–769
and intake, 638–639
and vasopressin, 631–632

Urea (*cont'd*)
after water deprivation, 436, 926*
after xylose, 1402
tubular reabsorption
in water diuresis, 777
in Wilson's disease, 1110, 1113
Uremia
amino acid levels of plasma, 1227–1231
anemia of, dialysis and purine ribosides, 923*
and calcium levels, 827
flame-spectrometric method for magnesium, 933*
hemoglobin A_2 isolation, 1621
Urethane, and protein turnover rates, 358
Uric acid
degradation, 1512
in gout, 938*, 1508–1514
serum and urine levels after guanosine or inosine infusion, 432–433
Uridine, and erythrocyte lysis, 1503–1506
Uridine triphosphate, and pentose metabolism, 1404
Urine
alkaline, and phenobarbital, 1224
bilirubin
and cortisone, 1371–1373
and prednisolone, 1373
concentration
alcohol, and diuresis, 1202–1206
and aluminum gel, 571
bile acid in hepatic disease, 531, 536–537
copper in Laennec's cirrhosis, 1210–1214
gastric acid, 380
and sodium, 307–308, 758–765
tetrahydrocortisone glucuronide and tetrahydrocortisol, 1310
excretion in
of acyl glucuronides after benzoate, 297–302
aldosterone, 383–391, 692–693, 1176
extract bioassay, 762
D-arabinose, 1391–1393, 1398–1405
calcium, 685, 887*, 978
and ethylenediamine tetraacetic acid, 568
in osteolytic disease, 887*
in parathyroid therapy, 562
cortisol, 1317
and vasopressin, 629–633
creatinine
and exchangeable chloride, 1380–1381
and exchangeable potassium, 1378, 1381
reference standard, 1377
electrolytes after ammonium chloride, 759, 764–765
electrolytes in hyperventilation, 517, 520, 525
hemoglobin, after norepinephrine, 89–96
17-hydroxysteroids
after ACTH, 1172, 1177, 1180, 1317
after cortisol and triiodothyronine, 1314–1317
5-hydroxytryptophan, 1595
magnesium, in osteolytic disease, 887*
of pentoses, 1391–1393, 1398, 1400
pepsinogen after ACTH and adrenal cortical steroids, 1176–1177, 1180–1181
phosphate, and parathyroid therapy, 558, 562, 568, 576
and sodium intake, 305–308, 384–391
strontium, 681–685
of tryptophan, 1606
in Wilson's disease, 1110–1113
flow
in acidosis, 374, 376, 379
in chlormerodrin diuresis, 659
and cortisol, 769–778
and cortisone, 768–769
and diuresis
mannitol, 631–637
mercury compounds, 658–660
water, 1202–1206, 1416–1419
in epidemic hemorrhagic fever, 99–100, 111, 128, 130–131
after ethanol, 1202–1206
and glomerular filtration rate, 885*
in hypertension, 1461–1468
and vasopressin, 1465–1466
in hyperventilation, 522, 525
in hypoparathyroidism and parathyroid extract, 564
and kidney clearance of phenobarbital, 1221–1222
plasma ratio, 1222, 1224
rate and morphine, 918–919*
after sodium chloride in orthostatic hypotension, 1325
and sodium phosphate, 567
and water deprivation, 436, 629–633
in gout, hyperuricemic, 1509
hypertonic, in absence of antidiuretic hormone, 1416–1426
hypotonic
and potassium, 918*
after isotonic saline in postural hypotension, 1322
mucopolysaccharides in rheumatoid arthritis, 1516–1520
nephrotic, thyroxine-binding by, 28
nitrogen balance and aluminum gel, 571
osmolality, 1203
and cortisol, 770
and cortisone, 769–770
and creatinine clearance ratio, 1420–1421
after high-protein feeding, 926*
after renal artery occlusion and water diuresis, 1416–1419
in thirsting rats, 436
and vasopressin, 629–631, 880*, 1422
infusion rate, 1060–1063
pH
and bicarbonate diuresis, 923*
after carbon dioxide inhalation, 518, 521, 525
and renal clearance of phenobarbital, 1221–1225
in respiratory alkalosis, 517, 520, 525, 527
and testosterone, 1014
in Wilson's disease, 1109–1113
in poliomyelitis, 946–949, 952, 957, 962
calcium, 967–970, 1023–1027
and ambulation, 978
chloride, 1007, 1013, 1016
citric acid, 968–970, 1023–1027
creatine and creatinine, 946–949, 952, 1012, 1014–1016, 1019–1023, 1027
glycocyamine, 997–999, 1001, 1016
and gonadal steroids, 997–999, 1001, 1007, 1013–1014, 1016
nitrogen, 950, 957–962, 1019–1023
and oscillating bed, 983–986, 993
phosphorus, 966–981, 1023–1027
sulphur, 946–949, 957–958, 962, 1019–1023
and urinary tract calculus, 977, 979
in potassium and sodium depletion, 758–765
pregnanetriol and pregnanetriolone excretion in adrenal dysfunction, 1726–1735
proteins
in multiple myeloma, 352–359, 888*
in proteinuria, 426
sequestration, 358
D-xylose, and insulin, 1388
Urobilinogen, fecal excretion
in hemolytic anemia, 1471
in hemosiderosis, 1157
Urolithiasis, and acetazolamide, 894*
Uronic acid
hexosamine molar ratios in protamine precipitates, 1330
mucopolysaccharides, 875*, 1331
Urticaria
capillary studies, 1693, 1698
and penicillin, 1693
forearm circulation in, 246
Uterus
gravid, neurogenic stimuli and preeclampsia, 920*
serotonin concentration and 5-hydroxytryptophan, 1596

V

Vaccine, live adenovirus and respiratory illness, 1079
Valine
and nitrogen balance, 1647–1655
plasma concentration, 1228, 1673–1677
after surgery, 1677
uremic, 1229–1231
Vascular system
capillary, in epidemic hemorrhagic fever, 1688–1700
cerebral, and age, 1136
coronary
and nitroglycerin, 895*
and quinidine, 844–846
pulmonary
engorgement, 59–66
and 5-hydroxytryptamine, 924*
reactivity, in hypertension, 918*
renal, in epidemic hemorrhagic fever, 99–100, 104, 106, 128
resistance
cerebral, 1136
in coarctation of aorta, 1539, 1542–1543

coronary, and quinidine, 844–846
and hexamethonium, 861, 863
Vasoconstriction
congestion and circulation in forearm, 252
intrarenal, and norepinephrine, 96
pulmonary
and epinephrine, 670, 673
and 5-hydroxytryptamine, 671, 673
and norepinephrine, 670, 673
renal, and norepinephrine, 96
Vasodilation
capillary
in infectious diseases, 1690, 1693, 1695, 1696
and cortisone, 1697
and circulation, forearm, 252
coronary, in hypoxemia, 1106
in epidemic hemorrhagic fever, 103, 105, 128, 134–135, 148–151
and histamine, promethazine or Dilatol®, 1290, 1292–1293
peripheral arteriolar, 863
pulmonary, and acetylcholine or aminophylline, 673
Vasopressin. *See also* Hormone, antidiuretic
antidiuretic response
and cortisone, 776
and pressor activity, 1066–1071
and coronary blood flow, 472–477, 479–483
and hypertension, 1325
and myocardial uptake of rubidium^{86}, 468–477
plasma clearance, 475–483
and osmolality of urine, 1422
pyrogenic reaction, 1067
renal response
in epidemic hemorrhagic fever, 102
in hypertension, 1465–1466
and water reabsorption, 1059–1071
serum potassium and aldosterone excretion in dogs, 389
urinary content
in hydration, 630–631
osmolar, 880*, 926*
and renal artery clamp, 1422–1423
and water excretion, solute-free, in postural hypotension, 1323
Vena cava
erythrocyte and protein concentration, 1451
inferior, thoracic constriction, and aldosterone secretion, 689–693
superior, and portal venous bed anastomosis, 1257–1264
Venous pressure-volume curve
and epinephrine, 886*
and norepinephrine, 1663–1671
Ventilation
alveolar, acclimatization to altitudes, 270–277
and exercise, 1140–1148
in poliomyelitis, and oscillating bed, 990, 992
and quinidine, 844–846
Ventricle
atrial impulse transmission mechanism, 883*
left
in aortic-caval fistula, and Lanatoside C, 336–338
work and quinidine, 844–846
potassium concentration, 479
right, work, and quinidine, 844–846
weight, and vasopressin, or norepinephrine, 475–476
Virus
adenovirus types 3, 4, and 7 respiratory illness in volunteers, 1072–1079
mumps, delayed hypersensitivity in and cellular damage, 893*
myoclonus due to, 912*
Viscera
hemodynamics, in coarctation of aorta, 1537–1543
intracellular chloride, sodium, 343–349
transport of fatty acids to adipose tissue, 811–814
Vitamin B_{12}
activity, in leukemic sera and tissues, 904*
binding, in myelogenous leukemia, 18–24, 915*
dual plasma absorption, 884*, 1551–1556

W

Water
body, partitioning from potassium and sodium, 347
clearance
after isotonic saline, in postural hypotension, 1322–1323
and rate of vasopressin infusion, 1064–1066
concentration
of electrolytes, 3
in muscle, 1242–1247
and vasopressin, 880*
deprivation and renal concentrating ability, 629–633
diuresis, 776–777
and cortisol, 769–773
in diabetes insipidus, 1206
and hepatic cirrhosis, 936*
and ethanol, 1202–1206
and phenobarbital clearance, 1221–1222
and renal artery cuff inflation, 1416–1419
excretion
in heart failure, 901*
in hypertension, 1460–1468
and sodium, 305–308
extracellular, thiosulfate single injection method for, 327–333
gastrointestinal content, 289–295
absorption from, in sprue, 265–268
intracellular
and age, 512
in heart failure, 903*
and potassium deficiency, 1251, 1252
metabolism
and adrenal steroids, 882–883*
in heart failure, 901*
muscle content after trauma, 827–831
in poliomyelitis, balance and gonadal steroids, 1007, 1013, 1016
renal excretion, 1202–1206
and morphine, 918–919*
renal tubular reabsorption
and antidiuretic hormone, 1059–1071
and cortisol or cortisone, 777–778
requirement for urine isosmotic state, 629
retention and hyponatremia, 388
swallowing dynamics, 586
tendon content, 343
Weight
anabolic effect of norethandrolone, 907*
and cortisol, 769–778
and cortisone, 768–769
and desoxycorticosterone acetate, 1296
and diffusing capacity of the lung, 3, 11–14
and exchangeable
chloride, 1379
potassium, 1377
gain in aortic-caval fistula and Lanatoside C, 336–338
from simple overeating, 81–88
and glucagon dosage, 77
in newborn infants, in ventilation and diffusion, 1082–1084
and pentose disappearance from blood, 1398
in poliomyelitis, 946–949, 952–955, 1019–1023
and oscillating bed, 986
and testosterone, 997–999
and potassium depletion, 758
and pulmonary diffusing capacity, 13–16
reference standard, 1377
and sodium
depletion, 758
excretion in hypertension, 1467
intake, 306, 307
and water deprivation, 436
Wilson's disease
ceruloplasmin copper exchange with ionic, 927*, 1193, 1197–1200
and hepatic coma, ammonia metabolism, 362
and renal function, 1107–1112
and probenecid, 1110, 1113

X

Xanthine oxidase, in liver
at autopsy, 1584
in kwashiorkor, 1581, 1585–1586
Xanthomatosis, liver copper content, 1214
Xanthosine, in erythrocytes, osmotic lysis, 1502
Xanthurenic acid, excretion, after tryptophan ingestion, 1601–1602
D-Xylose
metabolism, 1395–1405
and glucose, 1389
and insulin, 1385–1388
stereochemical configuration, 1383
Xylulose 5-phosphate, in xylulose-2-C^{14} phosphate production, 1411

Z

Zinc, metabolism in post-alcoholic cirrhosis, 933*

THE JOURNAL

OF

CLINICAL INVESTIGATION

VOLUME XXXVI

1957

PUBLISHED BY

THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION

PHILIP K. BONDY, *Editor-in-Chief*

Associate Editors

FRANKLIN H. EPSTEIN

ALLAN V. N. GOODYER

EDITORIAL COMMITTEE

THOMAS P. ALMY
ROBERT W. BERLINER
FRANCIS P. CHINARD
GEORGE L. CURRAN
LEWIS DEXTER
LEONARD P. ELIEL
WARD S. FOWLER
ROBERT A. GOOD
JOHN B. HICKAM
EDWARD C. REIFENSTEIN, JR.
ARNOLD S. RELMAN
I. HERBERT SCHEINBERG
JOHN V. TAGGART
RICHARD W. VILTER
LAWRENCE E. YOUNG

CONTENTS

NUMBER 1, PART I, JANUARY, 1957

A Standardized Breath Holding Technique for the Clinical Measurement of the Diffusing Capacity of the Lung for Carbon Monoxide. C. M. OGILVIE, R. E. FORSTER, W. S. BLAKEMORE, AND J. W. MORTON 1

The Plasma Disappearance, Excretion, and Tissue Distribution of Cobalt^{60} Labelled Vitamin B_{12} in Normal Subjects and Patients with Chronic Myelogenous Leukemia. AARON MILLER, HOWARD F. CORBUS, AND JOHN F. SULLIVAN 18

The Influence of Extracellular Thyroxine-Binding Protein upon the Accumulation of Thyroxine by Tissue Slices. NORBERT FREINKEL, SIDNEY H. INGBAR, AND J. THOMAS DOWLING 25

Substances Released from the Skin Following Thermal Injury. I. Histamine and Proteins. SOL ROY ROSENTHAL, CHARLES SAMET, RICHARD J. WINZLER, AND SELWYN SHKOLNIK .. 38

Chemical and Biological Alterations Induced by Irradiation of I^{131} Labeled Human Serum Albumin. ROSALYN S. YALOW AND SOLOMON A. BERSON 44

The Hexosamine Content of the Serum Globulins in Normal and Pathological Sera. ALFRED JAY BOLLET 51

Pulmonary and Circulatory Effects of Acute Pulmonary Vascular Engorgement in Normal Subjects. STUART BONDURANT, JOHN B. HICKAM, AND JOSEPH K. ISLEY 59

The Effect of Intravenous Cortisol Injections on the Plasma Cortisol Concentration in Man. JAMES SCHEUER AND PHILIP K. BONDY 67

The Effect of Glucagon on the Blood Glucose Level and the Clinical State in the Presence of Marked Insulin Hypoglycemia. JEROME L. SCHULMAN AND STANLEY E. GREBEN 74

Weight Gain from Simple Overeating. II. Serum Lipids and Blood Volume. JOSEPH T. ANDERSON, ADRIAN LAWLER, AND ANCEL KEYS 81

Urinary Hemoglobin Excretion and Renal Circulatory Dynamics: A Study of the Effect of L-Norepinephrine in the Dog. WILLOUGHBY LATHEM AND ALVIN D. BENJAMIN 89

NUMBER 1, PART II, JANUARY, 1957

The Renal Lesion in Epidemic Hemorrhagic Fever. JEAN OLIVER AND MURIEL MACDOWELL. 99

NUMBER 2, FEBRUARY, 1957

Electrophoretic Studies of Red Cell Extracts of Stored Blood. EDWARD R. BERRY AND ALFRED CHANUTIN 225

The Biosynthesis of the Fatty Acids of the Plasma of Man. I. The Formation of Certain Chromatographically Separated Higher Fatty Acids of the Major Lipide Complexes from Acetate–1–C^{14}. S. R. LIPSKY, A. HAAVIK, C. L. HOPPER, AND R. W. MCDIVITT 233

Rapid and Slow Components of the Circulation in the Human Forearm. EDWARD D. FREIS, HAROLD W. SCHNAPER, AND LAWRENCE S. LILIENFIELD 245

The Glucose Metabolism of Patients with Malignant Disease and of Normal Subjects as Studied by Means of an Intravenous Glucose Tolerance Test. PAUL A. MARKS AND JONATHAN S. BISHOP 254

Absorption of Water and Sodium from the Small Intestine of Patients with Nontropical Sprue. JOHN A. HIGGINS, PHILIP R. LEE, JOHN F. SCHOLER, RICHARD J. REITEMEIER, CHARLES F. CODE, AND ERIC E. WOLLAEGER 265

Adaptive Value of Respiratory Adjustments to Shunt Hypoxia and to Altitude Hypoxia. GEORGE HUSSON AND A. B. OTIS 270

Gastrointestinal Water and Electrolytes. III. The Equilibration of Radiobromide in Gastrointestinal Contents and the Proportion of Exchangeable Chloride (Cl_e) in the Gastrointestinal Tract. N. J. SWEET, J. NADELL, AND I. S. EDELMAN 279
Gastrointestinal Water and Electrolytes. IV. The Equilibration of Deuterium Oxide (D_2O) in Gastrointestinal Contents and the Proportion of Total Body Water (T.B.W.) in the Gastrointestinal Tract. F. GOTCH, J. NADELL, AND I. S. EDELMAN 289
The Chemical Estimation of Acyl Glucuronides and Its Application to Studies on the Metabolism of Benzoate and Salicylate in Man. DAVID SCHACHTER 297
Oral Sodium Loading in Normal Individuals. KEHL MARKLEY, MANUEL BOCANEGRA, GUILLERMO MORALES, AND MIGUEL CHIAPPORI 303
Objective Evaluation of Patients with Rheumatic Diseases. II. Paper Electrophoretic Studies of Serum Glycoprotein and Protein from Patients with Rheumatoid Arthritis. GEORGE STIDWORTHY, R. W. PAYNE, CLARA L. SHETLAR, AND M. R. SHETLAR 309
The Absorption of Radioiron Labeled Foods and Iron Salts in Normal and Iron-Deficient Subjects and in Idiopathic Hemochromatosis. ROBERT B. CHODOS, JOSEPH F. ROSS, LEONARD APT, MYRON POLLYCOVE, AND JAMES A. E. HALKETT 314
An Evaluation of the Single Injection Thiosulfate Method for the Measurement of Extracellular Water. LEON C. CHESLEY AND ABRAHAM LENOBEL 327
The Hemodynamic Response to Lanatoside C of Dogs with Experimental Aortic-Caval Fistulas. OSCAR W. SHADLE, THOMAS B. FERGUSON, DAVID C. SABISTON, JR., AND DONALD E. GREGG 335
The Distribution of Sodium and Chloride and the Extracellular Fluid Volume in the Rat. DONALD B. CHEEK, CLARK D. WEST, AND CATHERINE CARTER GOLDEN 340
Incorporation of N^{15}-L-Aspartic Acid into the Abnormal Serum and Urine Proteins of Multiple Myeloma (Studies of the Inter-Relationship of these Proteins). ELLIOTT F. OSSERMAN, ADA GRAFF, MARGARET MARSHALL, DOLORES LAWLOR, AND SAMUEL GRAFF 352

NUMBER 3, MARCH, 1957

The Metabolism of Ammonia and α-Keto-Acids in Liver Disease and Hepatic Coma. W. H. J. SUMMERSKILL, STANLEY J. WOLFE, AND CHARLES S. DAVIDSON 361
The Internal Distribution of Hydrogen Ions with Varying Degrees of Metabolic Acidosis. WILLIAM B. SCHWARTZ, KARL J. ØRNING, AND RICHARD PORTER 373
A Study of the Mechanism of Secretion of the Sodium-Retaining Hormone (Aldosterone). JOHN H. LARAGH AND HERBERT C. STOERK 383
Physical Binding of Insulin by Gamma Globulins of Insulin-Resistant Subjects. BELTON A. BURROWS, THEODORE PETERS, AND FRANCIS C. LOWELL 393
Plasma Protein Synthesis in the Human Fetus and Placenta. JOSEPH DANCIS, NANCY BRAVERMAN, AND JOHN LIND 398
Antibody Protein Synthesis by Lymph Nodes Homotransplanted to a Hypogammaglobulinemic Adult. CHRISTOPHER M. MARTIN, JOHN B. WAITE, AND NORMAN B. MCCULLOUGH 405
The Effect of Large Doses of Desiccated Thyroid on the Distribution and Metabolism of Albumin-I^{131} in Euthyroid Subjects. MARCUS A. ROTHSCHILD, ARTHUR BAUMAN, ROSALYN S. YALOW, AND SOLOMON A. BERSON 422
Erythrocyte Preservation. VIII. Metabolic Degradation of Nucleosides *In Vitro* and *In Vivo*. MARION HENNESSEY, CLEMENT A. FINCH, AND BEVERLY WESCOTT GABRIO 429
Experimental Studies of the Mechanisms Producing Hypocalcemia in Hypernatremic States. LAURENCE FINBERG 434
Studies of Respiratory Physiology in the Newborn Infant. III. Measurements of Mechanics of Respiration. C. D. COOK, J. M. SUTHERLAND, S. SEGAL, R. B. CHERRY, J. MEAD, M. B. MCILROY, AND C. A. SMITH 440

A New Method for Measuring Sialic Acid Levels in Serum and Its Application to Rheumatic Fever. EUGENE L. HESS, ALVIN F. COBURN, RICHARD C. BATES, AND PRISCILLA MURPHY 449
Physico-Chemical and Immunologic Studies on Macroglobulins. A. H. SEHON, L. GYENES, J. GORDON, M. RICHTER, AND B. ROSE 456
A Study in Dogs of Methods Suitable for Estimating the Rate of Myocardial Uptake of Rb^{86} in Man, and the Effect of L-Norepinephrine and Pitressin® on Rb^{86} Uptake. W. D. LOVE AND G. E. BURCH 468
Differences in the Rate of Rb^{86} Uptake by Several Regions of the Myocardium of Control Dogs and Dogs Receiving L-Norepinephrine or Pitressin®. W. D. LOVE AND G. E. BURCH ... 479
Stuart Clotting Defect. I. Segregation of an Hereditary Hemorrhagic State from the Heterogeneous Group Heretofore Called "Stable Factor" (SPCA, Proconvertin, Factor VII) Deficiency. CECIL HOUGIE, EMILY M. BARROW, AND JOHN B. GRAHAM 485
Stuart Clotting Defect. II. Genetic Aspects of a 'New' Hemorrhagic State. JOHN B. GRAHAM, EMILY M. BARROW, AND CECIL HOUGIE 497
Age Differences in the Intravenous Glucose Tolerance Tests and the Response to Insulin. FELIX A. SILVERSTONE, MARTIN BRANDFONBRENER, NATHAN W. SHOCK, AND MARVIN J. YIENGST 504

NUMBER 4, APRIL, 1957

The Renal Response in Man to Acute Experimental Respiratory Alkalosis and Acidosis. E. S. BARKER, R. B. SINGER, J. R. ELKINTON, AND J. K. CLARK 515
Bile Acid Content of Human Serum. I. Serum Bile Acids in Patients with Hepatic Disease. DANIEL RUDMAN AND FORREST E. KENDALL 530
Bile Acid Content of Human Serum. II. The Binding of Cholanic Acids by Human Plasma Proteins. DANIEL RUDMAN AND FORREST E. KENDALL 538
Inhibitory Effect of Chlorpromazine upon the Adrenal Cortical Response to Insulin Hypoglycemia in Man. NICHOLAS P. CHRISTY, DONALD LONGSON, WILLIAM A. HORWITZ, AND MARY M. KNIGHT 543
Renal Reabsorption of Phosphate in Normal Human Subjects and in Patients with Parathyroid Disease. DAVID D. THOMPSON AND HOWARD H. HIATT 550
The Effects of Parathyroid Extract on Renal Function in Man. HOWARD H. HIATT AND DAVID D. THOMPSON 557
Effects of Phosphate Loading and Depletion on the Renal Excretion and Reabsorption of Inorganic Phosphate. DAVID D. THOMPSON AND HOWARD H. HIATT 566
Some Effects of Intravenously Administered Calcium on Inorganic Phosphate Metabolism. HOWARD H. HIATT AND DAVID D. THOMPSON 573
The Dynamics of Swallowing. I. Normal Pharyngeal Mechanisms. MICHAEL ATKINSON, PHILIP KRAMER, STANLEY M. WYMAN, AND FRANZ J. INGELFINGER 581
The Dynamics of Swallowing. II. Neuromuscular Dysphagia of Pharynx. PHILIP KRAMER, MICHAEL ATKINSON, STANLEY M. WYMAN, AND FRANZ J. INGELFINGER 589
A Heparin-Precipitable Fraction of Human Plasma. I. Isolation and Characterization of the Fraction. RICHARD T. SMITH AND RICHARD W. VON KORFF 596
A Heparin-Precipitable Fraction of Human Plasma. II. Occurrence and Significance of the Fraction in Normal Individuals and in Various Disease States. RICHARD T. SMITH 605
The Mechanism of Glutathione Destruction and Protection in Drug-Sensitive and Non-Sensitive Erythrocytes. *In Vitro* Studies. ERNEST BEUTLER, MELBA ROBSON, AND ELLEN BUTTENWIESER 617

NUMBER 5, MAY, 1957

The Influence of Bodily Hydration on the Renal Concentrating Process. FRANKLIN H. EPSTEIN, CHARLES R. KLEEMAN, AND ACHIEL HENDRIKX 629
The Effect of Feeding Protein and Urea on the Renal Concentrating Process. FRANKLIN H. EPSTEIN, CHARLES R. KLEEMAN, STEWART PURSEL, AND ACHIEL HENDRIKX 635
Ethanol Fractionation of Plasma and Electrophoretic Identification of Insulin-Binding Antibody. SOLOMON A. BERSON AND ROSALYN S. YALOW 642
Apparent Inhibition of Liver Insulinase Activity by Serum and Some Fractions Containing Insulin-Binding Antibody. ROSALYN S. YALOW AND SOLOMON A. BERSON 648
Studies on Structure Diuretic Activity Relationships of Organic Compounds of Mercury. R. H. KESSLER, R. LOZANO, AND R. F. PITTS 656
The Effects of Pharmacologic Agents on the Pulmonary Circulation in the Dog. Studies on Epinephrine, Nor-Epinephrine, 5-Hydroxytryptamine, Acetylcholine, Histamine, and Aminophylline. HANS G. BORST, ERIK BERGLUND, AND MAURICE MCGREGOR 669
The Distribution of Fe^{59} Tagged Human Erythrocytes in Centrifuged Specimens as a Function of Cell Age. E. RAYMOND BORUN, WILLIAM G. FIGUEROA, AND SEYMOUR M. PERRY 676
Strontium^{85} and Calcium^{45} Metabolism in Man. HERTA SPENCER, DANIEL LASZLO, AND MILTON BROTHERS 680
Increased Aldosterone Secretion in Dogs with Right-Sided Congestive Heart Failure and in Dogs with Thoracic Inferior Vena Cava Constriction. JAMES O. DAVIS, MAURICE M. PECHET, WILMOT C. BALL, JR., AND M. JAY GOODKIND 689
The Distribution of Cr^{51} Labeled *E. Coli* Endotoxin in the Generalized Shwartzman Reaction. RICHARD T. SMITH, ABRAHAM I. BRAUDE, AND FRANCIS J. CAREY 695
In Vivo Studies of the Role of Albumin in Endogenous and Heparin-Activated Lipemia-Clearing in Nephrotic Rats. RAY H. ROSENMAN AND MEYER FRIEDMAN 700
Biochemical Observations on the Use of L-Glutamic Acid in the Treatment of Hepatic Coma. FRANK L. IBER AND THOMAS C. CHALMERS 706
Ultracentrifugal Characterization of the Lipoprotein Spectrum in Obstructive Jaundice: Studies of Serum Lipid Relationships in Intra- and Extrahepatic Biliary Obstruction. ROBERT H. FURMAN AND LOYAL L. CONRAD 713
Net Potassium Movement Between Resting Muscle and Plasma in Man in the Basal State and During the Night. REUBIN ANDRES, GORDON CADER, PETER GOLDMAN, AND KENNETH L. ZIERLER 723
Movement of Potassium into Skeletal Muscle During Spontaneous Attack in Family Periodic Paralysis. KENNETH L. ZIERLER AND REUBIN ANDRES 730
The Ultrafiltrable Calcium of Human Serum. I. Ultrafiltration Methods and Normal Values. T. Y. TORIBARA, A. RAYMOND TEREPKA, AND PRISCILLA A. DEWEY 738
A and B Antigens in the Human Epidermis. D. NELKEN, J. GUREVITCH, AND Z. NEUMAN 749

NUMBER 6, PART I, JUNE, 1957

The Hereditary Transmission of Hemoglobin Differences in Mice. SALOME GLUECKSOHN-WAELSCH, HELEN M. RANNEY, AND BETTY F. SISKEN 753
Aldosterone Excretion in Normal Subjects Depleted of Sodium and Potassium. BEN B. JOHNSON, AMOS H. LIEBERMAN, AND PATRICK J. MULROW 757
The Effects of Cortisone and Hydrocortisone on Water Diuresis and Renal Function in Man. LAWRENCE G. RAISZ, WILLIAM F. MCNEELY, LAWRENCE SAXON, AND JACK D. ROSENBAUM 767
An Electrophoretic Study of Serum Proteins in Thyroiditis. NORMAN WEISSMAN AND MARTIN PERLMUTTER 780

The Equilibration of Radiosodium (Na^{24}), Radiopotassium (K^{42}), and Deuterium Oxide (D_2O) in Hydropic Human Subjects. M. P. O'Meara, L. W. Birkenfeld, F. A. Gotch, and I. S. Edelman 784
The Response of Rheumatic and Non-Rheumatic Children to Streptolysin O Concentrate. Robert W. Quinn 793
The Concentration and Binding of Thyroxine and Triiodothyronine by Rat Diaphragm. John R. Hogness, Norman D. Lee, Margaret K. Berg, and Robert H. Williams 803
Unesterified Fatty Acid in Human Blood Plasma. II. The Transport Function of Unesterified Fatty Acid. Robert S. Gordon, Jr. 810
Sodium Transport Across the Surface Membrane of Red Blood Cells in Hereditary Spherocytosis. John F. Bertles 816
The Acute Calcification of Traumatized Muscle, with Particular Reference to Acute Post-Traumatic Renal Insufficiency. William H. Meroney, Glen K. Arney, William E. Segar, and Henry H. Balch 825
Studies on the Destruction of Red Blood Cells. XII. Factors Influencing the Role of S Hemoglobin in the Pathologic Physiology of Sickle Cell Anemia and Related Disorders. Mortimer S. Greenberg, Edward H. Kass, and William B. Castle 833
Hemodynamic Effects of Quinidine: Including Studies of Cardiac Work and Coronary Blood Flow. George C. Rowe, Dean A. Emanuel, George M. Maxwell, John F. Brown, Cesar Castillo, Benjamin Schuster, Q. R. Murphy, and Charles W. Crumpton 844
Early Effects of Fat Ingestion on Lipids and Lipoproteins of Serum in Man. Richard J. Havel 848
Early Effects of Fasting and of Carbohydrate Ingestion on Lipids and Lipoproteins of Serum in Man. Richard J. Havel 855
The Hemodynamic Effects of Hexamethonium Bromide in the Dog, with Special Reference to "Splanchnic Pooling." B. Combes, J. R. K. Preedy, H. O. Wheeler, R. M. Hays, and S. E. Bradley 860
Proceedings of the Forty-Ninth Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N. J., May 6, 1957 866

Number 6, Part II, June, 1957

Metabolic Studies in Paralytic Acute Anterior Poliomyelitis. I. Alterations in Nitrogen and Creatine Metabolism. G. Donald Whedon and Ephraim Shorr 942
Metabolic Studies in Paralytic Acute Anterior Poliomyelitis. II. Alterations in Calcium and Phosphorus Metabolism. G. Donald Whedon and Ephraim Shorr 966
Metabolic Studies in Paralytic Acute Anterior Poliomyelitis. III. Metabolic and Circulatory Effects of the Slowly Oscillating Bed. G. Donald Whedon and Ephraim Shorr 982
Metabolic Studies in Paralytic Acute Anterior Poliomyelitis. IV. Effects of Testosterone Propionate and Estradiol Benzoate on Calcium, Phosphorus, Nitrogen, Creatine and Electrolyte Metabolism. G. Donald Whedon and Ephraim Shorr 995

Number 7, July, 1957

Diastolic Gallop Sounds, the Mechanism of Production. Peter T. Kuo, Truman G. Schnabel, Jr., William S. Blakemore, and Arthur F. Whereat 1035
Radioactive Iron Metabolism and Erythrocyte Survival Studies of the Mechanism of the Anemia Associated with Rheumatoid Arthritis. Emil J. Freireich, Joseph F. Ross, Theodore B. Bayles, Charles P. Emerson, and Stuart C. Finch 1043
A Study of the Quantitative Relationship Between Antidiuretic Hormone (Vasopressin) and the Renal Tubular Reabsorption of Water. Walter Hollander, Jr., T. Franklin Williams, Christopher C. Fordham, III, and Louis G. Welt 1059

Acute Respiratory Illness in Volunteers Following Intramuscular Administration of Live Adenovirus. M. R. HILLEMAN, R. E. HODGES, M. S. WARFIELD, AND S. A. ANDERSON.. 1072
Pulmonary Ventilation and Diffusion in the Human Newborn Infant. MILDRED T. STAHLMAN.... 1081
Type-Specific Streptococcal Antibody. FLOYD W. DENNY, JR., WILLIAM D. PERRY, AND LEWIS W. WANNAMAKER.... 1092
Hypoxemia and Coronary Blood Flow. ROBERT M. BERNE, JOHN R. BLACKMON, AND THOMAS H. GARDNER.... 1101
Renal Function in Wilson's Disease. A. G. BEARN, T. F. YÜ, AND A. B. GUTMAN..... 1107
Serotonin and Histamine Release During Anaphylaxis in the Rabbit. T. P. WAALKES, H. WEISSBACH, J. BOZICEVICH, AND S. UDENFRIEND.... 1115
The Immediate Effects of Respiratory Depression on Acid-Base Balance in Anesthetized Man. DUNCAN A. HOLADAY, DOROTHY MA, AND E. M. PAPPER.... 1121
An Adaptation of the Nitrous Oxide Method to the Study of the Cerebral Circulation in Children; Normal Values for Cerebral Blood Flow and Cerebral Metabolic Rate in Childhood. CHARLES KENNEDY AND LOUIS SOKOLOFF.... 1130
Response of Pulmonary Artery Pressure and Total Pulmonary Resistance of Untrained, Convalescent Man to Prolonged Mild Steady State Exercise. SALVATORE M. SANCETTA AND LOUIS RAKITA.... 1138
Idiopathic Pulmonary Hemosiderosis. A Study of the Anemia and Iron Distribution Using Radioiron and Radiochromium. LEONARD APT, MYRON POLLYCOVE, AND JOSEPH F. ROSS.... 1150
Studies on the Immunochemical Basis of Allergic Reactions to Dextran in Man. ELVIN A. KABAT, GERARD M. TURINO, ARTHUR B. TARROW, AND PAUL H. MAURER.... 1160
Effects of Eight-Hour Intravenous Infusions of ACTH and the Adrenocortical Steroids in Normal Man. I. Basal Gastric Secretion, and Plasma and Urinary Pepsinogen. B. I. HIRSCHOWITZ, D. H. P. STREETEN, J. A. LONDON, AND H. M. POLLARD.... 1171
Study of Urinary and Fecal Excretion of Radioactive Chromium Cr^{51} in Man. Its Use in the Measurement of Intestinal Blood Loss Associated with Hookworm Infection. MARCEL ROCHE, MARIA ENRIQUETA PEREZ-GIMENEZ, MIGUEL LAYRISSE, AND ESTELA DI PRISCO. 1183

NUMBER 8, AUGUST, 1957

Exchange of Ceruloplasmin Copper With Ionic CU^{64} With Reference to Wilson's Disease. I. HERBERT SCHEINBERG AND ANATOL G. MORELL.... 1193
The Influence of Ethanol Upon Maintained Water Diuresis in Man. JACK D. ROSENBAUM, SOLOMON PAPPER, HENRY W. COHEN, AND REGINA MCLEAN.... 1202
Studies on Copper Metabolism. XXIII. Portal (Laennec's) Cirrhosis of the Liver. C. J. GUBLER, H. BROWN, H. MARKOWITZ, G. E. CARTWRIGHT, AND M. M. WINTROBE..... 1208
The Distribution and Excretion of Phenobarbital. WILLIAM J. WADDELL AND THOMAS C. BUTLER.... 1217
Apparent Free Amino Acids in Deproteinized Plasma of Normal and Uremic Persons. PETER F. SALISBURY, MAX S. DUNN, AND EDWARD A. MURPHY.... 1227
Further Observations on the Hemodynamic Effect of Plasma Volume Expansion by Dextran. J. W. FLEMING AND W. L. BLOOM.... 1233
Skeletal Muscle Analyses in Health and in Certain Metabolic Disorders. I. The Method of Analysis and the Values in Normal Muscle. BENJAMIN A. BARNES, ESTHER B. GORDON, AND OLIVER COPE.... 1239
Cation Accumulation by Muscle Tissue: The Displacement of Potassium by Rubidium and Cesium in the Living Animal. ARNOLD S. RELMAN, ANNE T. LAMBIE, BELTON A. BURROWS, AND ARLENE M. ROY.... 1249

Porto-Caval and Porto-Pulmonary Anastomoses in Laennec's Cirrhosis and in Heart Failure. PAUL CALABRESI AND WALTER H. ABELMANN 1257
Studies on Phenolic Steroids in Human Subjects. II. The Metabolic Fate and Hepato-Biliary-Enteric Circulation of C^{14}-Estrone and C^{14}-Estradiol in Women. AVERY A. SANDBERG AND W. ROY SLAUNWHITE, JR. 1266
Pathways of Glycogen Formation in Liver and Skeletal Muscle in Fed and Fasted Rats. PAUL A. MARKS AND PHILIP FEIGELSON 1279
The Effect of Histamine on Skin and Deep Temperatures in Man With Particular Reference to Liver Temperature. W. GRAF 1285

NUMBER 9, SEPTEMBER, 1957

Depletion of Carcass Potassium in Rats Made Hypertensive With Desoxycorticosterone Acetate (DCA) and With Cortisone. ABBIE I. KNOWLTON AND EMILY N. LOEB 1295
The Physiological Disposition and Metabolic Fate of Cortisone in Man. RALPH E. PETERSON, CHARLES E. PIERCE, JAMES B. WYNGAARDEN, JOSEPH J. BUNIM, AND BERNARD B. BRODIE 1301
Thyroid-Adrenocortical Interrelations: Failure to Demonstrate Antagonism Between Triiodothyronine and Hydrocortisone in Man. KENNETH FREMONT-SMITH, FRANK L. IBER, AND IRVIN C. PLOUGH 1313
The Influence of Autonomic Vasoregulatory Reflexes on the Rate of Sodium and Water Excretion in Man. HENRY N. WAGNER, JR. 1319
Acid Mucopolysaccharides in Normal Serum. ALFRED JAY BOLLET, MARIA W. SERAYDARIAN, AND WILLIAM F. SIMPSON 1328
Thyroxine-Binding by Serum and Urine Proteins in Nephrosis. Qualitative Aspects. JACOB ROBBINS, J. E. RALL, AND MARY L. PETERMANN 1333
A Comparison of the Phenylalanine Content of the Hemoglobin of Normal and Phenylketonuric Individuals: Determination by Ion Exchange Chromatography. DAVID W. ALLEN AND W. A. SCHROEDER 1343
Physiological Disposition of 4-C^{14}-Cortisol During Late Pregnancy. CLAUDE J. MIGEON, JEAN BERTRAND, AND PATRICIA E. WALL 1350
A Simple Nephelometric Method for the Determination of Human Serum Beta-Lipoprotein. PETER BERNFELD, MORDECAI E. BERKOWITZ, AND VIRGINIA M. DONAHUE 1363
Influence of Cortisone and Prednisolone in Hyperbilirubinemia. RICARDO KATZ, HÉCTOR DUCCI, AND HERNÁN ALESSANDRI 1370
The Relationship of Total Exchangeable Potassium and Chloride to Lean Body Mass, Red Cell Mass and Creatinine Excretion in Man. F. P. MULDOWNEY, J. CROOKS, AND M. M. BLUHM 1375

NUMBER 10, OCTOBER, 1957

The Effect of Insulin on Blood Levels of Infused Pentoses in Man. STANTON SEGAL, JAMES B. WYNGAARDEN, AND JOSEPH FOLEY 1383
Physiological Disposition and Metabolic Fate of Infused Pentoses in Man. JAMES B. WYNGAARDEN, STANTON SEGAL, AND JOSEPH B. FOLEY 1395
Studies of Ribose Metabolism. I. The Pathway of Nucleic Acid Ribose Synthesis in a Human Carcinoma Cell in Tissue Culture. HOWARD H. HIATT 1408
Production of Hypertonic Urine in the Absence of Pituitary Antidiuretic Hormone. ROBERT W. BERLINER AND DOUGLAS G. DAVIDSON 1416
The Destruction of Red Cells by Antibodies in Man. I. Observations on the Sequestration and Lysis of Red Cells Altered by Immune Mechanisms. JAMES H. JANDL, A. RICHARDSON JONES, AND WILLIAM B. CASTLE 1428

Electrolyte and Water Excretion in Arterial Hypertension. I. Studies in Non-Medically Treated Subjects with Essential Hypertension. WILLIAM HOLLANDER AND WALTER E. JUDSON 1460
Radioactivity Over the Spleen and Liver Following the Transfusion of Chromium^{51}-Labelled Erythrocytes in Hemolytic Anemia. LEE L. SCHLOESSER, DONALD R. KORST, DALLAS V. CLATANOFF, AND ROBERT F. SCHILLING 1470
The Thyroid Hormone-Plasma Protein Complex in Man. I. Differences in Different States of Thyroid Function. MILTON W. HAMOLSKY, HASKELL E. ELLISON, AND A. STONE FREEDBERG 1486
The Effects of Nucleosides on the Resistance of Normal Human Erythrocytes to Osmotic Lysis. ERNST R. JAFFÉ, BERTRAM A. LOWY, GRACE A. VANDERHOFF, PHILIP A. AISEN, AND IRVING M. LONDON 1498
Overproduction of Uric Acid as the Cause of Hyperuricemia in Primary Gout. JAMES B. WYNGAARDEN 1508
Urinary Excretion of Acid Mucopolysaccharides by Patients with Rheumatoid Arthritis. NICOLA DI FERRANTE 1516
Studies of Intestinal Digestion and Absorption in the Human. B. BORGSTRÖM, A. DAHLQVIST, G. LUNDH, AND J. SJÖVALL 1521

NUMBER 11, NOVEMBER, 1957

General Hemodynamics and Splanchnic Circulation in Patients with Coarctation of the Aorta. JAMES W. CULBERTSON, JOHN W. ECKSTEIN, WALTER M. KIRKENDALL, AND GEORGE N. BEDELL 1537
The Potentiation of Exogenous Insulin by Tolbutamide in Depancreatized Dogs. RAYMOND CAREN AND LUCILLE CORBO 1546
A Dual Mechanism of Vitamin B_{12} Plasma Absorption. ALFRED DOSCHERHOLMEN AND PAUL S. HAGEN 1551
Plasma Lipid Interrelationships in Experimental Nephrosis. RAY H. ROSENMAN, SANFORD O. BYERS, AND MEYER FRIEDMAN 1558
Measurements of Pulmonary Capillary Blood Flow and Gas Exchange Throughout the Respiratory Cycle in Man. ARTHUR B. DUBOIS AND ROBERT MARSHALL 1566
Mechanisms of Synthesis of Purine Nucleotides in Heart Muscle Extracts. DAVID A. GOLDTHWAIT 1572
Biochemical Changes in Liver Associated with Kwashiorkor. HELEN B. BURCH, GUILLERMO ARROYAVE, RUTH SCHWARTZ, ANA MARIA PADILLA, MOISÉS BÉHAR, FERNANDO VITERI, AND NEVIN S. SCRIMSHAW 1579
Further Characterization of an Insulin Antagonist in the Serum of Patients in Diabetic Acidosis. JAMES B. FIELD, FRANK TIETZE, AND DEWITT STETTEN, JR. 1588
Studies with the Serotonin Precursor, 5-Hydroxytryptophan, in Experimental Animals and Man. J. DAVIDSON, A. SJOERDSMA, L. N. LOOMIS, AND S. UDENFRIEND 1594
Quantitative Studies on Human Urinary Metabolites of Tryptophan as Affected by Isoniazid and Deoxypyridoxine. J. M. PRICE, R. R. BROWN, AND FRANK C. LARSON 1600
Studies in Cushing's Syndrome. II. Adrenal Weight-Maintaining Activity in the Plasma of Patients with Cushing's Syndrome. JOSEPH W. JAILER, DONALD LONGSON, AND NICHOLAS P. CHRISTY 1608
Observations on the Minor Basic Hemoglobin Component in the Blood of Normal Individuals and Patients with Thalassemia. H. G. KUNKEL, R. CEPPELLINI, U. MÜLLER-EBERHARD, AND J. WOLF 1615

NUMBER 12, DECEMBER, 1957

The Effects of Experimental Hepatobiliary Disease on Certain Aspects of Tocopherol Metabolism in the Rat. GERALD KLATSKIN AND WILLIAM ALLAN TISDALE 1627
Studies of the Satiety Response in Mice. GUY HOLLIFIELD AND WILLIAM PARSON 1638
Blood Adrenocorticotrophic Hormone and Plasma Corticosteroids in Men Exposed to Adverse Environmental Conditions. HENRY B. HALE, GEORGE SAYERS, KATHERINE L. SYDNOR, MAX L. SWEAT, AND DONALD D. VAN FOSSAN 1642
Toxicity and Blood Ammonia Rise Resulting from Intravenous Amino Acid Administration in MAN: The Protective Effect of L-Arginine. JOHN L. FAHEY 1647
Effects of Posture and Atropine on the Cardiac Output. ARNOLD M. WEISSLER, JAMES J. LEONARD, AND JAMES V. WARREN 1656
The Pressure-Volume Responses of Human Forearm Veins During Epinephrine and Nor-Epinephrine Infusions. JOHN W. ECKSTEIN AND WILLIAM K. HAMILTON 1663
Unbound Amino Acid Concentrations in Human Blood Plasmas. RAPIER H. MCMENAMY, CHARLES C. LUND, AND J. LAWRENCE ONCLEY 1672
The Mechanical Behavior of the Lungs in Healthy Elderly Persons. N. R. FRANK, J. MEAD, AND B. G. FERRIS, JR. 1680
Capillary Observations in Patients with Hemorrhagic Fever and Other Infectious Illnesses. SHELDON E. GREISMAN 1688
Plasma Adrenocorticotrophic Hormone in Addison's Disease and its Modification by the Administration of Adrenal Steroids. JOHN E. BETHUNE, DON H. NELSON, AND GEORGE W. THORN 1701
The Effect of Pulmonary Vascular Pressures on the Mechanical Properties of the Lungs of Anesthetized Dogs. HANS G. BORST, ERIK BERGLUND, JAMES L. WHITTENBERGER, JERE MEAD, MAURICE MCGREGOR, AND CLARENCE COLLIER 1708
The Binding of Cations by Chondroitin Sulfate. SAUL J. FARBER AND MAXWELL SCHUBERT. 1715
Serum Iron Levels in Siderosis Due to Habitually Excessive Iron Intake. J. HIGGINSON, K. J. KEELEY, M. ANDERSSON, AND A. R. P. WALKER 1723
Pregnane-3α, 17α, 20α-Triol and Pregnane-3α, 17α, 20α-Triol-11-One Excretion by Patients with Adrenocortical Dysfunction. R. I. COX AND M. FINKELSTEIN 1726
Author Index to Volume XXXVI 1736
Subject Index to Volume XXXVI 1754